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CHAPTER 1.1 
Parkinson's disease: piedng together a genetic jigsaw 
Abstract 
The mie of genetics in the pathogenesis of Parkinson's disease (IP'O) has been 
subject to debate for decades. In recent years, the discovery of five genes and 
several more loci has provided important insight into its molecular aetiology. 
Some PD genes possibly cause PO by protein aggregation. The presence of Lewy 
bodies in carriers of mutations in one gene anel their absence iin carriers of 
another, however, still point towards a complex pathogenie network with PO as a 
common clinical end point. The recent identification of the fourth and fifth PO 
genes SlJlggl~sts multiple pathways: an impaired oxidative-stress defense for 
mutations in OJ-1, and a defect in another signaliing patlhway for mutations in 
NR4A2. Despite knowledge of geneties in famili~11 PD, uur knowledge of the 
common, Ilate-onset form of PO remains limited. In non-j'amilial PO, gen es and 
environmentprobably interact to give rise to tlhe disease. We review advances in 
the genetics of PD, focusing on the monogellic forms ,and theil' clinical and 
populatioll-genetic consequences. 
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Introduction 
Parkinson's disease (PO) is a movement disorder and an important cause of 
morbidity anel mortality in later life (prevalence 1.6 percent in the elderiy) I. PO is 
c1inically characterised by lhe 'cardinal signs': resting tremor, rigidity and 
braelykinesia. In some stuelies, postural instability is considered a fourth cardinal 
sign.2 Asymmetric onset of symptoms anel a gooel, prolongeel response to levoelopa 
endorse the clinical eliagnosis. Neuropathological examination show~, degeneration 
of the substantia nigra anel various other regions of basal ganglia, brain stem, 
autonomic nervous system anel cerebral cortex. The dopaminergic tract is 
predominantly affected in PO, but the cholinergic, noradrenergic anel serotinergic 
systems are also involveel, albeit to alesser degree.3 Lewy bodies, intracytoplasmatic 
protein aggregates considered to be the neuropathological hallmark of PO, are 
founel throughout the brain. Although in a specialist setting the clinical eliagnosis of 
PO could be neuropathologically confirmed in up to 90 percent, this level of 
agreement elsewhere is usually less than 80 percent.4,5 Yet Lewy bodies are not 
sufficient to establish the neuropathological diagnosis of PO. 6 Furtherrnore, recent 
developments in genetics indicate that some monogenic forms of parkinsonism are 
not always associated with Lewy bodies. 7•B The term parkinsonism embodies all 
clinical syndromes in which clinical features are similar to PO, regardless of 
pathology or concomitant symptoms. Parkinsonism occurs in other primary 
neurodegenerative diseases such as multiple system atrophy. progressive 
supranuclear palsy, and in vascular disease, major depression and dementia. 
Exogenous factors (such as neuroleptic medication and l-methyl-4-phenyl-l,2,3,6-
tetrahydropyridine, or MPTP)9 leading to secondary parkinsonism have long 
supported the view thaI: PO was likely to be a non-genetic disorder. From the recent 
developments in genetics, however, the role for genetic components in at least a 
proportion of PO becomes evident. 
Pathogenesis of PO 
A consistent risk factor for PO is age. 1 The list of putative environmental risk factors 
is long, but few studies have shown a consistent association. Exposure to pesticides 
is one of the most establ ished environmental risk factors for PO. lO The debate about 
the role of genes in typical, idiopathic PO is ongoing. The estimated proportion of 
patients in the general population who have at least one relative with PO varies 
from 6.4 to 10.3 percent, whereas studies using hospital-based patient series report 
frequencies of up to 33 percent. 11 -14 The increased frequencies in clinic-based 
populations could trui)! be due to a more frequent family history amongst clinic-
based patients, yet such patients mayalso have a recollection bias for PO in 
relatives. A large study in twins suggested strong inheritance in PO with onset 
before the age of 50 years. Beyonel this onset age, however, only weak evidence for 
a genetic aetiology was found. 15 Another twin study using PET neuroimaging 
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revealed, however, (preclinieal) disease concordanc:e in twins regardless of onset 
age. 16 
From d genetic perspective, several modes of inheritance for PO have been 
postulated,. ranging from autosomal dominant inheritance with variabie penetrance 
to mitochondrial inheritance. 17,18 Most studies of recent date indicate a complex, 
multifactorial mode of inheritance, with several genes interacting with 
environmental risk factors. An incident possibly illustrating a combination of 
environmental and genetic factors in PO is the smal! epidemic of parkinsonism in 
MPTP users. 9 MPTP was a component of a party drug, giving rise to parkinsonism 
clinically indistinguishable from idiopathic PD in relatively young individuals. Not 
all those exposed to MPTP, however, developed parkinsonism, Regardless of the 
dose, a certain genetic make-up may therefore have made certain people more 
vulnerable to the effe cts of MPTP, or have protected others. 
Vet there are a number of families in which PD segregates in an 
unambiguously mendelian fashion. Since 1997, I inkage to eleven genes and loci 
has been reported.8,19.28 Six of these are implicated in PO with an autosomal 
domi nant pattern of i nheritance, 8, 19,21·23,28 four in that with autosomal recessive 
inheritance,W.24'26 and one in late-onset, seemingly sporadic PD,27 
Table 1: GenE's for familial Parkinson's disease 
Gene/locus Location Inheritance Onset Distinetil'e clinical features LB 
parkin 6q25 AR early- frequent dyskinesialdystonia; noa 
juvenile slow progression 
DH 1p36 AR early foc:al dyston i a; n,a 
slow progression; 
psychiatrie symptoms 
PARI<6 1 p35-36 AR early slow progression n.a 
PARI<9 1p36 AR juvenile spastieity; n.a. 
dementia; 
supranuclear ophthalmoparesis 
alpha- 4q21 AD late lower prevalenee tremor; yes 
synuclein more rapid progression 
UCH-L 1 4p14 AD late none n.a. 
NR4A2 2q22-23 AD late none n,a, 
PARI<3 2p13 AD late dementia in some patients yes 
PARI<4 4p14- AD late some relatives postural tremor; yes 
16.3 dementia; 
autonomie dysfunction; 
weight 1055 early in disease 
PARI<8 12p11.2- AD late none no 
q13 
PARI<JO 1 p32 late none n.a, 
a Lewy boc/ies have been reported in one patient with parkin mlllations35; AR alltosomal 
recessive; AD ~, alltosomal dominant; LB = Lewy Bodies; n.a. = information not available 
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PO gen es and loci, clinical anc! nemopathological phenotypes 
Several families with mendelian patterns of inheritance had been described in detail 
without hard evidence for a genetic basis of PD, until the discovery of the first 
familial PD gene in 1997. Iq At present, five genes (alpha-synuclein; parkin; UCH-L 1; 
DJ-1; NR4A2) have been identifiecl in familial PD. 19,20,23,25,28 A further six loci across 
the genome (PARK3; PARK,ti; PARK6; PARK8; PARK9; PARK 10) harbour yet 
unknown genes (Tabie 1 ).:>1,n,2-I,e,26,27 Despite the unknown causative genes 
contained in the latter loci, a characterisation of their clinical aml pathological 
phenotype could shecllight on possible overlap and differences with the phellotypes 
associated with the known PD genes. Recessive genes and loci are listed first, 
followed by dominant gen es anclloci. 
Parkin (PARK2) 
In 1998, mutations in a newly iclentified gene, parkin (PARK2, chromosome 6q25.2-
q27), were described in Japanese families segregating early-onset parkillsonism as 
an autosomal recessive trait. 20 Several clinical features clistinguish parkin-linked 
parkinsonism from sporadic PD, such as the wide range of ages at onset varying 
from early childhood to late adulthood, frequent dystonia and slow progression. 
Symptoms range from classical parkinsonism to dystonia in different degrees of 
severity, with frequently oCClJrring dystonia and dyskinesia upon clopaminergic 
treatment. 29,30 On functional neuroimaging in parkin-linked parkinsonism, the 
uptake of dopamine tracer was reduced in both hemispheres in the putamen as weil 
as in the caudate nucleus. 31 ,32 On the contrary, in sporadic, non-familial PD, the 
reduction in dopa uptake is initially unilateral and primarily illvolves the 
putamen,33,34 Neuropathological studies in a small number of patients with 
mutations in the parkin gene showed selective degeneration of the nigrostriatal tract. 
Remarkably, L.ewy bodies were absent. 7 One exception to this has been reported in 
a patient with parkin mutations who was found to have typical Lewy bodies at 
autopsy.35 This could imply an occasional role for Lewy bodies in parkin-linked 
disease, and alternatively occasional Lewy-body neurodegeneration superimposed 
on parkin-linked parkinsonism. 
Parkin is a large gene spanning 1.5 megabases and containing twelve exons, 
in which to date over 70 mutations have been identified (Bonifati, personal 
communication). New developments in the detection of mutations in the gene are 
expected to increase this number further. The protein product of parkin is an E3 
ubiquitin ligase. 36 Ubiquitin i~;, as its name suggests, one of the most abundant 
proteins in the brain anel, like alpha-synuclein, contributes to the formation of Lewy 
bodies. 37 A particular form of alpha-synuclein has been shown to be the substrate 
for parkin,38 thus linking these lwo PD genes by the ubiquitin system. 
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OJ-7 (PARK7) 
In 2001, shortly after the localisation of the PARK6 locus/4 a second locus on 
chromosome 1 p36, PARK7, was reported. PARK7 is a good 25 centiMorgans (cM) 
removed from the PARK6 locus. Linkage to the PAR/U locus was first identified in a 
kindred from a genetically isolated population in the South-West of The Netherlands 
segregating autosomal recessive early-onset parkinsonism'yJ and subsequently was 
confirmed in an Italian family.40 DJ-1 parkinsonism is c1inically characterised by 
variabie severity of disease and slow progression of symptoms with sustained 
response to levodopa treatment. In addition to parkinsonism, in the original kindred 
and in one of the patients in the Italian DH fami Iy with DJ-1 mutations, psychiatric 
co-morbidity was reported. 39,41 Pathology of carriers of DJ-1 mutations is not yet 
available, but functional neuroimaging showed a symmetrical decrease in dopa 
uptake in putamen as weil as in caudate nucleus, a picture resembling that in 
parkin- and PARK6-linked parkinsonism.41 
Recently, mutations in the DJ-1 gene were reported to be associated with 
parkinsonism in these two kindreds. 25 The patients in the Dutch kindred carried a 
homozygous deletion of OJ-1 rendering the gene product absent, and affected 
individuals in the Italian family were homozygous for the L 166P mutation. The 
function of 0)-1 is unknown, but there is evidence tor a role in the cellular response 
to oxidative stress. The mutant OH protein may therefore have an impaired ability 
to limit oxidative damage. Transfection studies showed 1055 of the diffuse cytosolic 
patterns associated with the wild-type, and co-Iocalisation of the mutant OH 
protein in mitochondria, although the mutant protein is 03150 present in the nucleus. 
This points towards a pathogenic 1055 of cytoplasmic activity for mutant OJ-1. 
PARK6 
In 2001, linkage to chromosome 1p35-36 was reported in a large Italian family, the 
Marsala kinclred. 24 This locus, named PARK6, is associated with early-onset 
parkinsonism with an autosomal recessive pattern. The clinical presentation of 
PARK6-linkecl parkinsonism resembied typical PO, apart from an early age at onset 
(ranging from 32 to 48 years) and a slow progression of symptoms. Furthermore, 
tremor was a predominant sign and dystonia was not reported. Response to 
levodopa tl·eatment was good and lasting. 42 A functional neuroimaging study 
showed symmetrically decreased dopa uptake in putamen as weil as in caudate, 
much like in parkin-parkinsonism.43 No post-mortem data are yet available on 
PARK6-linkecl parkinsonism. Since its identification, linkage to PARK6 has been 
confirmed in a number of small European families, reducing the candidate interval 
to 9 CM.42 
PARK9 
Kufor-Rakeb syndrome is a juvenile-onset neurodegenerative disorder with an 
autosomal recessive pattern of inheritance. The first clinical repolt on an Arab 
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consanguineOLls kindred datecl {rom '1994,44 The name of the syndrome denotes the 
area of origin of the kindred, Kufor--Rakeb syndrome clinically resemblecl typical PD 
with a good response to levoclopa treatment with respect to the extl-apyramidal 
dysfunction. Although listed as a mendelian parkinsonism, there were many 
additional features of the PARK9 phenotype (spasticity, dementia and 5upranuclear-
gaze paralysis), which did not resembie typical PD. On neuroimaging, there was 
significant atrophy of the globus pallidus, which in a later stage became generalised_ 
No neuropathological data are available_ Linkage to a region of 9 cM on 
chromosome 1 p36 was described in 2001. 26 The PARK9 status subsequently was 
assigned, although to date, no official report is available (The Genorne Database, 
URL: http://www.gdb.org). 
Alpha-synuclein (PARK]) 
Two different mutations have been identified in the alpha-synuclein gene (PARK]) 
on chromosome 4q21. In 1997, the A53T mutation was foune! in a large 
Italian/American family (the ContursÎ kindred)45 as weil as in three unrelated families 
of Greek descent, in which PD was inherited with an autosomal dominant pattern. 19 
The common haplotype in the families suggested a common founder due to the age-
old historical ties between the two regions of origin_ Since, this mutalion has been 
found in a small number of other families. The second mutation, the A30P 
mutation, has been reported in one German family.46 Clinical characteristics of the 
patients with the A53T rnutation differed from sporadic PD with respect to a slightly 
younger age at onset, a considerably lower prevalence of tremor, a more rapid 
clinical deterioration_ Furthermore,. concomitant dementia, myoclonus and central 
hypoventilation have been reported in parkinsonism associated with the A53T 
mutation.45,47,4B Conversely, the clinical phenotype of A30P alpha-synuclein 
parkinsonism closely resernbled sporadic PD.46 Neuroimaging features in alpha-
synuclein parkinsonism were concordant with those observed in idiopathic PD. 49,50 
Post-mortem examination in patients with a mutation in the alpha-synuclein gene 
showed the pattern of neuronal degeneration and the Lewy bodies 50 characteristic 
of PD. 19 In the original Contursi kindred,45 a recent neuropathological studyalso 
revealed tau inclusions, suggesting that the alpha-synuclein neurodegenerative 
process is not entirely identical to that seen in typical idiopathic PD brains. 51 
The identification of alpha-synuclein's involvement in familial PD has been a 
breakthrough in the hitherto limited knowledge about the pathogenesis of the 
disease. Alpha-synucleill was first described as a presynaptic protein in Torpedo 
caljfornica. 52 The protein is involved in synaptic plasticity, as was shown in an 
ortholog-protein study on song learning in the zebra finch. 53 FurthelTTlOre, alpha-
synuclein transgenic DrosophiJa and mouse models exhibited progressive 
locomotor dysfunction and 1055 of dopaminergic neurons, mimicking the phenotype 
of PD. 54,55 Alpha-synuclein is abundantly present in brain, and, upon the 
identification of the mulations in its encoding gene, was identified to be a principal 
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component of Lewy bodies. 56 In vitro experiments suggested that the mutant protein 
facilitates fibril formation, giving rise to Lewy bodies. The A53T-mutated alpha-
synuclein formed fibrils more easily than the A30P-mutant. 57 The lesser complexity 
of the A30P-linked clinical phenotype (resembling typical PD) may therefore reflect 
its lower degree of alpha-synuclein fibrillogene5is in vitro. 
UCH-L 7 (PA/~K5) 
In 1998, the 193M mutation in the ubiquitin carboxy-terminal hydroxylase L 1 (UCH-
L 1) gene on chromosome 4p14 was identified in a family of German descent in 
which PD was inherited in an autosomal dominant fashion. 23 By the time the 
described family came to attention, all reportedly affectecl individuals, except for 
two affected siblings, were deceased. The clinical phenotype in these siblings 
consisted of dopa-responsive parkinsonism, resembling idiopathic PD. Onset of 
symptoms in the two siblings occurred at the ages of 49 and 51 years. To date, 
neither radiological nor neuropathological data on this family are available. 
Mutations in the UCH-L 1 enzyme reduce its catalytic activity in vitro, therefore 
possibly leading to a tendency of various protein metabolites to aggregate. 58 In 
immunofl uorescence studies, Lewy bodies stained positive for UCH-Ll, suggesting 
it also contributes to the ubiquitin-proteasome pathway implicated in alpha-
synuclein and parkin-linked parkinsonism. 23 
NR4A2 
A recent report described two mutations in the I\IR4A2, or NURR1 gene. 28 The 
clinical phenotype in the patients with mutations in NR4A2 was concordant with 
late-onset PD without atypical features. Radiologicalor neuropathological data are 
not available. NR4A2 (chromosome 2q22-23) is a gene involved in the 
differentiatioll and maintenance of dopaminergic neurons. Due to its function, 
previous studies had already suggested NR4A2 to be a candidate gene for PD. 59,60 
NR4A2 was studied in a series of 107 individuals with familial PD (70 of whom had 
a history of PD over at least two generations). Two heterozygous mutations (-
291Tdel and -245T ~G) were revealed in 10 individuals, who were all of European 
descent. Both mutations affect a non-coding exon (exon 1) of the gene and lead to 
marked decrease in NR4A2 mRNA levels. The mechanism by which this mRNA 
transcription is targeted is not vet clear. 
PARK3 
In 1998, linkage was reported to chromosome 2p13 in six families in which PD was 
inherited in an autosomal-dominant fashion. 21 Clinically, there was typical dopa-
responsive parkinsonism. However, dementia occurred in two of the PARK3-linked 
families. Ages at onset of disease ranged from 37 to 89 years. Autopsy findings 
showed degeneration of dopaminergic neurons in the substantia nigra and Lewy 
bodies, but 03.150 Alzheimer-like neurofibrillary tangles and neuritic plaques in some 
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patients. 61 The PARK3 phenotype may therefore encompass a wide pathological 
spectrum, ranging from parkinsonism to dementia. The PARK3-critical region spans 
a distance of 2.5 Mb. Analysis of the genes contained within this region has not vet 
revealed any causal mutation. 62 The disease-associated haplotype was also observed 
in clinically unaffected relatives, suggesting a penetrance of less than 40 percent. 
Two families of Northern Gerrnan and Southern Oanish descent showed strongest 
evidence for linkage anel a comlTlon haplotype at PARK3, raising the possibility of a 
common ancestor due to the vicinity of the regions of origin of these two fami lies. 
PARK4 
In 1999, a haplotype on chromosome 4p (PARK4) was reported to Ix~ segregating 
with PO as weil as with postural tremor in an autosomal dominélnt pattern. 22 
Parkinsonism in this American kindred typically presented with asymrnetrical limb 
'heaviness' anel rigidity, rather lhan with tremor. The postural tremor did not seem 
to be an early manifestalion of parkinsonism as it remained a separate clinical entity 
over time. Many atypical features in the kind red were observed, i.e. autonomic 
dysfunction, dementia, early-stage weight 1055, myoclonus and seizures, which are 
not concordant with typical PD. The onset age was considerably lower than in 
sporadic PO (mean 33.6 years), and progression to death was rapid. 63,65 On 
neuropathological examination in individuals with parkinsonism, Lewy bodies were 
found, the distribution of which was consistent with the neuropathological diagnosis 
of typical PO. 22 No neuropathological data are available on the family members 
with isolated postural tremor. Variabie expression of the unknown gene is suggested 
by the occurrence of the PARK4 haplotype not only in individuals with 
parkinsonism, but also in individuals with isolated postural tremor. The PARK4 
family was not large enough to achieve significant linkage, and lillkage to the 
PARK4 region has not vet been confjrmed in other studies. In the 8.5-clvI spanning 
locus, no causal mutations have been identified so faro UCH-L 1 (PARK5) on 
chromosome 4p1423 is just outside the candidate region, and could be I~xcluded. 
PARK8 
In 2002, linkage to chromosome 12p11.2-q13.1 was described in a Japanese family 
with autosomal dominant parkinsonism, the Samigahara family.8 The features of 
parkinsonism in this family resembied typical PO, with a good response to levodopa 
treatment. The mean age at onset of disease was 51 years. Neuropathological 
examination in four cases of PARK8 parkinsonism revealed 'pure nigral 
degeneration' lacking the Lewy bodies so typical of PO. By pararnetric linkage 
analysis, the maximum LOD score was 4.32; non-parametric linkage analysis 
increased the LOO score to 24.9. The PARK8-linked haplotype was al50 observed in 
some unaffected family members, suggesting incomplete penetrance. So far, none of 
the analysed genes in the 13.6-cM wide candidate-gene interval have mutations. 
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PARK 70 
Unlike previously reported genes and loci, which all exhibit mendelian inheritance 
patterns, PAf\K1O is a locus for late-onset non-mendelian PDY Clinical features in 
the PARK1()·linked families were concordant with typical, sporadic PD. Eighty-four 
percent of patients had onset of disease later than 50 years, with a mean age at 
onset of 65.8 years. No neuropathological or neuroimaging features have been 
reported. Sased on a nationwide database of clinical and genealogical information, 
significant clustering for PD previously had been shown amongst these patients 
compared to control individuals. 66 Fifty-one familie~; could be linked to one another 
in a large pedigree, suggesting a genetic aetiology. Significant linkage (LOD score 
4.9) was reported for a haplotype of 7.6 cM on chromosome 1 p32 in those families, 
each of which contained more than one PD patient. 
Table 2. I"opulation attribution of PD genes and loci 
Gene/locus 
Parkin 
Dj-1 
PARK6 
PARK9 
alpha- synucl2in 
UCH-L1 
NR4A2 
PARK3 
PARK4 
PARK8 
PARK 10 
Replication e/sewhere Estimated attributable risk 
(percentage of PO explained) 
yes 
yes 
yes 
no 
yes 
na 
no 
no 
no 
na 
Icelandic data set 
PD overall: 0.4-0.7 percent; 
within late-onset PD: smalI; 
with in early-onset sporadic PD: 9-18 %; 
within early-onset recessive PD: 49 % 
locally in Dutch isolate: 
33 % of early-ol1set cases; 
general population: unknown 
within early-onset recessive PD: 
up to15 "Ia' 
(single report) 
smal I 
(single report) 
unknowil 
small b 
(single report) 
(single report) 
unknown ( 
'Based on /inkage data; b PARK3 was implicated in onset age of PO in a genomic screen/Ol; 
, Linkage to omet age of PO was reported to the region containing PARK1 0 in a genomic screen 9 
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PO gen es and loci: population athilbution 
From a clinical perspective, the increasing knowledge of genes in PD raises the 
question to what extent mutations in these genes account for PD in the general 
population. Studies on polymorphisms (variants of a gene commonly occurring in 
the general population) in the farnilial-PD genes alpha-synuclein, parkin and UCH-
L 1 do not provide conclusive evidence for association with typical PD."l-7" Amongst 
the 11 genes and loci in PD, mutations in some have not been replicated in families 
other than the originally reported kindred, whereas others are associated with PD in 
a substantial proportion of cases around the world (Tabie 2). 
Population attribution b)l gene/locus 
The parkin gene (PARK2) is one of the largest gen es known (seconcl-Iargest after 
dystrophin, the Duchenne muscular dystrophy gene76). A considerable proportion of 
cases of early-onset autosomal recessive parkinsonism and isolated jlJVenile-onset 
parkil1sonism in several ethnic groups have mutations in the parkin gene. I0,7ï,78 In a 
multi-ethnic series of families with autosomal recessive early-onset PD, 49 percent 
were found to have parkin mutations (Figure 1 a). In sporadic, non-fami lial PO 
patients with disease onset below age 45 years, parkin mutations wen~ detected in 
18 percent. The prevalence of parkin mutations in this study decreased rapidly with 
later onset: 77 percent of patiellts with onset of disease at or below 20 years, 26 
percent of patients with onset between 21 and 30 years, and only three percent of 
those with onset over 31 years carried mutations in parkin. 30 Another study of 
community-derived PO patients with onset of disease below 50 years reported the 
proportion of parkin mutations to be nine percent.l8 Oetailed data on the proportion 
of patients with early-onset, autosomal recessive forms amongst PO in the general 
population are not available, which hampers calculation of the attribution of early-
onset fami lies with recessive inheritance and parkin mutations. In tl-'e Rotterdam 
Study, a large, population-based cohort study in The Netherlands, the prevalence of 
PD patients with onset below 45-50 years at baseline was four percent.' The 
Rotterdam Study, being population-based, possibly generates less bias than hospital-
derived patient series, in which a higher prevalence of early-onset cases by patient 
selection is expected. If parkin Illutations account for 9-18 percent of sporadic early-
onset PD/O,78 the parkin gene explains approximately 0.36-0.72 percent (0.09*4 -
0.18*4) of all sporadic PO in the general population (Figure 1 b). This i,;, however, 
expected to be an underestimalion of the true proportion. Novel parkin mutations 
such as intronic and exonic rearrangements are likely to explain more disease cases 
in the future. 
The contribution of the OJ-1 gene (PARK7) to the general population is still 
unknown. The DH deletion was not observed in a sample of 200 Outch controls 
from elsewhere in The ~.,jetherlands, and the point mutation was not either in 160 
controls from elsewhere in Italy,;'5 In contrast, OJ-1 was shown to account for a 
considerable proportion of early-ollset parkinsonism locally. In the genetically 
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isolated population of the original kindred in the Southwest of The Netherlands, 
four of 220 randomly drawn individuals from the local population were 
heterozygous for the DJ-1 deletion, yielding an estirnated mutant allele frequency of 
almost one percent. 25 No other homozygotes were observed. In a survey on 
parkinsonisill conducted in the isolated village from the original kindred, 39 six 
individuals with early-onset parkinsonism were observed, four of whom were 
homozygous for the DJ-1 deletion (Dekker et al., unpublished work). Therefore, 
two-thirds (67 percent) of early-onset parkinsonism in this population can be 
explainecl by DJ-1. Furthermore, regarding the observation of two mutations in the 
Dj-1 gene in families from different countries, mutations in the Dj-1 gene are 
expected in more ethnic groups. 
It is clifficult to estimate the contribution of Illendelian-PD loci to PD overall. 
Until the causative gene is identified, such estirnates only have limited value. 
Linkage to tne PARK6 locus was replicated in families of Italian, British, German 
and Dutch clescent. 42 The absence of a comillon haplotype amongst these families 
suggests that the PARK6-linked form of familial parkinsonism occurs in several 
European countries, possibly as a result of independent mutational events in the 
unknown gene. The eight PARK6-linked families from the study by Valente et al. 
were derived from a series of 28 families with early-onset autosomal recessive 
parkinsoni~;1ll without evidence for parkin mutatiolls. 42 No detailed information is 
available on the criteria for selection of these 28 families. Furthermore, caution 
should be taken when calculations are based on a sillall number of families, and on 
linkage to a locus rather than on the causal gene. Yet, based on the aforementioned 
numbers, PARK6 may account for approxirnately 29 percent (8/28) of parkin-
negative eéll'ly-onset cases with an autosomal pattern of inheritance, and thus for 15 
percent of early-onset autosomal recessive PD overall (i.e., 29 percent of 51 percent 
families with early-onset recessive inheritance of PD without parkin mutations) 
(Figure 1 a). 
Figure la) 
linkage 
Inutations PARK6 
,49%) (15%) 
b) 
",,""--
(/ /'Mkm 
rnutatlons 
\ 10.4-0.7%) 
""--------
a) Attributioll of mende/ian genes to ear/y-onset PO with autosoma/ recessive inheritance 
b) Attribution of mendelian genes to PO in the genera/ popu/ation 
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The A53T mutation in the alpha-synuclein gene (PARK]) was ,eported in a 
dozen families, possibly with a common founder. 19 The Eastern-Ivlediterranean 
origin of the families reported to carry the A53T mutation further supports this 
notion.47,79,BO The other mutation in the alpha-synuclein gene, A30P,. has been 
reported in one German family only.46 Studies in various populations have pointed 
out that mutations in the alpha-synuclein gene are very rare, explaining a small 
proportion of sporadic and familial PD overall. B1 -B5 Yet this gene was the first gene to 
be identified in familial PO, and unraveling the role of alpha-synuclein in PD has 
been a first step towards understanding the pathogenesis of the comrnon form, or 
forms, of the disease. 
Since the identification of the 193M mutation in the UCH-L 1 gene (PARKS 23 ) 
this mutation or other mutations have not been found in several other studies, 
indicating that mutations in the UCH-L 1 gene are a very rare cause of PD. n ,B6-BB This 
could mean that, similar to the paucity of reported mutations in the APP gene in 
presenile dementia,B9 the 193M mutation is one of the only viabie mutations in the 
UCH-L 1 gene, other mutations being incompatible with late-onset PD or even with 
life. Alternatively, the 1931v1 rnutation could be a rare polymorphism, coincidentally 
found in a sib pair with PD, rather than a causal mutation. 90 
Oue to the recent identification of NR4A2/B few replication reports in other 
patient series are available at present. 91 ,92 Ahaplotype analysis performed in the 
originally reported families with the -291Tdel mutation showed ahaplotype shared 
by six individuals from three famil ies with German ancestry, raising the possibility 
of a common founder. Mutations in NR4A2 were observed neither in 94 individuals 
with sporadic PO and in 221 unaffected controls/B nor other series of familial-PD 
patients.91 ,92 More inforrnation is to become available to assess the frequency of this 
gene at population level. 
The PARK3 locus was reported to segregate with PO in six families, and 
strongest evidence for linkage was observed in two families, possibly with a 
common ancestor. 21 Neither in PO patients who originate from the same region, nor 
in patients from elsewhere in Germany was linkage to the PAfUO region 
confirmed. 93 Recently, however, suggestive linkage was reported to PARK3 in a PD 
sib-pair genome scan designed to detect modifjers of age at onset. 94 
The extent of involvement of the PARKI0 IOCUS27 in PD is intriguing. Linkage 
results pointing towards the PAI~KI0 locus are based on 117 individuals in 51 
families, all of Icelandic descent and genealogically linked to one another. Data 
about what proportion of these 51 families is explained by PARKI0 are, however, 
not available. A previous genealogic study by the same research group('6 described a 
group of 772 PO patients ascertained throughout Iceland, from which the 117 
individuals who were Llsed for the linkage study were derived. This would mean 
that the gene contained within the PARK 1 0 locus may account for up~o 15 percent 
(117/772) of PD in the Icelandic: population. The role of the PARKI0 in the 
remaining 655 Ic:elandic PD patients66 is not yet known. Similarly, involvement of 
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PARK70 in populations outside Iceland remains to be confirmed. Shortly before the 
PARK 1 O-report was published, another group also reported linkage to chromosome 
1 p32, vet this linkage concerned the age at onset of PD. 95 
The linkage results to the PARK4, PARK8 and PARK9 loci,8,22,26 finally, have 
not been replicated in independent families. 
Discussion 
Eleven PD genes and loci have been identified since 1997. They provide valuable 
opportunitie~; to study the genetic and phenotypical heterogeneity of PD, anel thus 
the variety of pathogenic routes and their outcome, Nevertheless, even more 
questions have emerged, Some genes and loci are associated with Lewy bodies, 
others are not, but neuropathological data on many PD genes and loci is still 
unavailable. Two genes are involved in protein metabolism (parkin and UCH-L 1), 
but others probably encode an antioxidant protein (D)-l), or play a role in the 
mesencephalic genesis of dopaminergic neurons (f\jR4A2), Yet all these genes and 
loci lead to PD, The genes and loci reviewed in this paper at present explain only a 
minor fraction of PD in the general population. Despite this, they have had 
immediate irnplications for genetic counseling in partiCLdar families and individuals, 
as weil as for the development of novel therapeutic strategies. 
Cenetic counseling 
With the iclentification of the five PD genes, interest in genetic counseling and risk 
prediction in PD is growing. Genetic counseling particularly applies to patients with 
(familialor sporadic) juvenile to early onset of PD (parkin, D)-1), and families with 
mendelian sf~gregation of PD (alpha-synuclein; parkin; UCH-L1; Dj-l; NR4A2). The 
value of genetic testing in PD is not vet dear, since in most patients it is a clearly 
disabling, yet non-Iethal condition. Furthermore, there is no detailed knowledge 
about the penetrance of the respective mutations. Outside the scope of genetic 
counseling are families testing negative for the established PD genes. If, however, 
linkage to other familial-PD loci (PARK3;-4;-6;-8;-9;-10) is present, these families 
could serve research purposes by reducing canclidate-gene intervals and facilitate 
identification of the responsible gene. 
Therapeutical implications 
In terms of p~1armacological applications, the PD genes mark the transition to at new 
era. Unlike currently used, mainly palliative, anti parkinson treatment, new 
neuroprotective and curative strategies may make use of protein targets from the 
newly uncovered neurodegenerative pathways. In this way, abnormal protein 
aggregation élnd excessive oxidative damage may be arrested, and even be reversed 
or prevented, in an early stage. Equally important in this respect is the identification 
of possible exogenous, environmental factors, whic:h could initiate or accelerate 
nigral degeneration. In the future, treatment according to apatient's genetic make-
16 
CENETICS OF PARKINSON'S OISEASE- A REVIEW 
up could thus be tailored to fit individual genetic susceptibility, environmental-risk 
profile and drug-metabolism characteristics. 
Further research strategies 
The large body of genetic evidence in PO is overtaking the environmental 
hypothesis9,96 Vet the role for certain environmental factors in the risk of IrlJ, such as 
pesticides, is still to be clarified. Hl In spite of this revolution in PD genetics, 
however, the origin of PD in the vast majority of patients is unresolved. A major 
susceptibility gene for common, sporadic PO, such as apolipoprotein E (APOE) is in 
Alzheimer's disease,97 could not be identified. Polymorphisms in various other 
(groups of) genes were candidate for a role in the pathogenesis of PD, a concise 
overview of which can be found elsewhere.98 Inadequate numbers ui cases and 
controls, inconsistencies in diagnostic criteria for PO, ethnic origin of the study 
population and composition of the control group all contribute to conflicting results 
across studies. As appeared from a large meta-analysis, only six polymorphisms 
showed evidence of association with PD overall, and further study is warranted to 
validate these results. 99 The PARK10 IOCUS27,95 could prove to be a susceptibility 
factor in PO and needs to be validated in other populations to assess the extent of 
involvement in the common iorm of PD and its onset age. Similar to this approach, 
but using unrelated families, are genomic screens on large numbers of affected sib-
pairs or on nuclear families segregating PO.lOO,lOl These studies reported association 
to, amongst others, loci containing the tau gene, the PARK3 locus and the PARK10 
locus, respectively.102,94,95 Some of these concern loci that may control age at onset 
of PO by an unknown mechanism?,,95 The association with the tau gene, however, 
was refuted in another study. 103 
As more genetic pieces of the aetiological jigsaw emerge, the classical 
definition from 1817 by james Parkinson,'04 typical PO being of unknown aetiology, 
is gradually losing ground. Should mendelian forms be separated into nosological 
entities or be regarded as rare genetic, causes of PO ? A reclassification compatible 
with the 21 st century on clinical-genetic grounds is required, as clinicopathological 
features alone no longel' justify all PIJ to be clustered as one entity. 
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SCOPE OF TH IS THESIS 
Parkinson's disease (PO) encompasses several genetic sub-types, but a very small 
proportion of PO overall can be explained by presently known geilE~s: the vast 
majority is of unknown cause. This thesis aims to genetically dissect PD using an 
isolated population. Such communities with small founding populations and 
minimal inward and outward migration are likely to harbour a more genetically 
homogeneous variant of PO, and have proven a powerful setting for genetic 
research. This applies to common, late-onset PO as weil as to PO variants with early 
onset. 
Within a decade, great progress has been made in the field of clinical 
genetics by the identification of five genes and several loci in familial PD, as 
outlined in Chapter 1.1. PO has been known to cluster in families for over a 
century. Although several PD genes have now been identified in families with 
mendelian inheritance patterns, the prevalence of PO with complex inheritance is 
far higher. In the latter, usually late-onset, form of PO, any inheritance pattern is 
diffjcult to define and is likely 10 be determined by multiple low-penetrance genes 
and environmental factors. 
In a genetically isolated population in the Southwest of The Netherlands, we 
ascertained a kindred with early-onset PO with autosomal recessive inheritance 
(Chapter 2). By means of homozygosity mapping, a new PO locus :PARK7) was 
localised as described in Chapter 2.1. We identified the responsible gene, DJ-I, 
which is likely to play a role in the cellular defense against oxidative stress and is 
the fourth familial-PO gene identified worldwide (Chapter 2.2). Apart hom typical 
early-·onset parkinsonism, the phenotype in the Outch patients with OJ-! mutations 
was characterised by additional psychiatrie and neurological traits, which are 
addressed in Chapter 2.3. The phenotype observed in this family also encompassed 
other remarkable physical traits, upon which a c1inical-genetic and radiographic 
analysis was performed (Chapter 2.4). Finally, carriers of a OJ-l mutatioll, although 
c1inically unaffected, may have preclinical disease visualised by functional 
neuroimaging. In order to assess cerebral dopamine and glucose Illetabolism 
properties, Chapter 2.5 conlains a PET neuroimaging study performed in 
heterozygotes and homozygotes for the OH deletion, as weil as a non-carrier 
relative_ 
Chapter 3 describes gelletic studies of sporadic PO, without all apparent 
familial pattern of inheritance. On a population level, the genetic basis of PO is 
assessed by genetic-epidemiologic methods. Firstly, Chapter 3.1 reviews advallces 
and prospects of the genetic epidemiology of neurological disease. The same 
genetic isolate as in Chapter 2 was the setting for a study on PO patients who were 
at first sight unrelated. Clinical characteristics of these PO patients, the extent of 
familial aggregation and results of a candidate-gene study are discussed in Chapter 
3.2. Results of a genomic screen in the patients described in Chapter 3.2 are 
outlined in Chapter 3.3. The DJ-l gene (Chapter 2.2) is likely to play a role in 
defense mechanisms against oxidative stress, which may therefore be a causal factor 
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in PD. Excessive iron deposition in the body is acondition with increased oxidative 
stress. Therefore, in Chapter 3.4, the role of rnutations in the HFE gene, the major 
gene for the iron-storage disorder haemochrornatosis, was studied in two series of 
patients wit1 common, sporadic PO and, since the phenotype might include 
atypical clinical features, parkinsonism overall. 
Fil1ally, Chapter 4 concludes this work by a discussion of methodological 
strategies and findings described in this thesis, anel possible implications of our 
findings fm patients and further research. 
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CHAPTER 2 
fAMlllAl PARIKINSONISM 
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CI,IAPIER 2.1 
PARK7, a novel locus for autosomal recessivlE' 
early-onset parkinsonism, on chromosome 1 p36 
Abstract 
Although the mie of genetic factors in the origin of Parkinson's disease has long 
been dlisputed, several genes involved in autosomal dlominant and recessive forms 
of the disease have been localised. Mutatuons associated with early-onset 
auto somali recessive parkinsonism have been identified illl the parkin gene, and 
recently 2l second gene, PARK6, involved in early-onset recessive parkinsonism 
was localisedl on chromosome lp35-36. We identified a family segregating {~arly­
onset parlkinsonism with multiple consanguinity loops in a genetically isolated 
population. Homozygosity mapping resulted in significant evidence for linkage on 
chromosome lp36. Multipoint linkage an;alysis using MAPMAKER-HOMOZ 
generated a maximum lOD-score of 4.3, with nine markers spanning a disease 
haplotype of 16 cM. On the basis of several reoombination events, the n~gion 
defining the disease haplotype can be dearly separated, by 25 cM, from the more 
centromeric PARK6 locus on chromosome 1 p35-36. Therefore, we condude that 
we have identified on chromosome 1 a second locus, PARK7, involved in 
autosomal recessive, early-onset parkinsonism. 
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Parkinson's disease (pO [MIM 168600]) is a neurodegenerative disorder 
characterised by bradykinesia, resting tremor, muscular rigidity, and postural 
instability. The cerebral pathology includes 1055 of dopaminergic neurons, in 
particular at the substantia nigra and cytoplasmatic eosinophilic inclusions (i.e., 
lewy bodies). The role of genetic factors in the origin of PO has long been disputed. 
However, several families segregating the disease as a dominant or recessive trait 
have been identified. At present, four genes implicated in autosomal dominant 
forms of parkinsonism have been identified or localised, including the alpha-
synuclein gene" the ubiquitin carboxy-terminal hydrolase-ll gene,2 and two yet-
unidentified genes- PARK3 on chromosome 2p13 3 and PARK4 on chromosome 
4p14-16.3.4 Until now, most mutations have been found in the parkin gene5 and 
lead to a recessive form of juvenile parkinsonism (ARJP [MIM 6001 Hij). The onset 
age may vary from 20 to 65 years, but in most patients the onset is <40 years of 
age.6 Parkin mutations are estimated to explain up to 50% of familial patients with 
ARjF'.6 Recently, a new locus, f'ARK6 (MIM 605909), involved in autosomal 
recessive early-onset parkinsonism was localised on chromosome 1 p35-36 in a 
single Italian family.7 In the present report, we describe a family segregating early-
onset parkinsonism with multiple consanguinity loops that we identified in a 
genetically isolated population. We report the findings of a genome search using 
homozygosity mapping in an effort to localise the gene involved in the disease. 
Patients were from a genetically isolated community in the southwestern 
region of The Netherlands. The study is part of a larger research program named 
Genetic Research In Isolated Populations (GRIP). The isolated population was 
founded 1750, by 150 individuals. The scientific protocol of GRIP has been 
approved by the Medical Ethical Committee of the Erasmus MC Rotterdam. From 
the population, initially three patients (VII-2, VII-3 and VII-7) diagnoseel with early-
onset parkinsonism were ascertaineel, including two affected siblings and one 
apparently sporadic patient (Figure 1). 
The patients anel their first-elegree relatives were personally examined by the 
research physician, a neuroiogist, anel a clinical geneticist. Clinical eliagnosis of 
parkinsonism required the presence of at least two of the three carelinal signs (i.e., 
resting tremor, bradykinesia, anel rnuscular rigidity) and absence of atypical features 
and of signs of involvernent of other neurological systems (pyramidal, cerebellar, or 
autonomic). The extrapyramielal signs were evaluated by Hoehn-Yahr staging (Hy)8 
and the Unified Parkinson's Oisease Rating Scale (UPORS; maXilYUm of motor 
subscale = 108).9 Furthermore, structural and functional brain-imaging studies were 
performed. The clinical examinations of available relatives revealed a fourth affected 
individual (VII-6), who was not known to have the diagnosis of parkimonism. 
The clinical details of the four affected subjects are reported in Table 1. 
Onset of symptoms was before age 40 years in three subjects (VII-2, \111-3, and VII-
7). The fourth affected inclividual (VII-6), who was age 40 years at the time of the 
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Figure 1. Pedigree of family with autosomal recessive early-onset parkinsonism, and haplotypes of marker loci spanning the linked region on chromosome 
1 p36. To proteet patient confidentiality, a diamond symbol has been used to mask the sex of all family members. Individuals VI-2, VI-3, and VII-l to VII-
7 were examined clinicall)'. Black symbols indicate definitely affected individuals; black bars denote the disease-associated haplotype. 
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clinical examination, was newly diagnosed with parkinsonism and could not 
indicate the age at onset of the disease. None of the patients exhibited atypical 
features or signs of involvement of additional neurological systems. The 
parkinsonian signs responcled weil to therapy with L-dopa or dopamine agonists in 
two patients (VII-3 and VII-7); at the time of clinical examination, the two other 
patients still had not been treated with antiparkinsonian drugs. One patient (VII-7) 
showed motor fluctuations of the "wearing-off" type, levodopa-induced c1yskinesias 
in the "on" ph ase, and "off"-phase dystonia (i.e., laterocollis). Mild blepharospasm 
was present in patient VII-3, who receives dopamine-agonist therapy. Tendon 
reflexes in lower limbs were brisk in three of the patients (VII-3, VII-6, and VII-7). 
Babinski sign was absent. Two of the patients also showed neurotic signs, and one 
had suffered from psychotic episodes. In all patients, the progression of disease was 
slow. Structural brain images were unremarkable, in agreement with the diagnosis 
of idiopathic parkinsonism. Brain single-positron emission computecl tomography 
with dopamine-transpolier tracer, performed in patients VII-2 and \111-3, showed 
severe abnormalities consistent with presynaptic dysfunction of nigrostriatal 
dopaminergic systems. Autopsy data are not available. At the time of clinical 
examination, the ages of unaffected individuals VII-l, VII-4 and VII-5 were 54, 50, 
and 46 years, respectively. 
Tabl€! 1. Clinical phenotype offour patients with parkinsonism 
S)/mptom 
Patient AaE AaO RT PT B R P AS Therapy HY UPDRS Other 
characteristics 
VII-2 50 40 X X X X untreated 11 29 psychotic 
episodes 
VII-3 48 31 X X X X X X pergolide 111 57 neurotic signs; 
blepharospasm 
VII-6 40 n.a. X X X X untreated 111 22 neurotic signs 
VII-? 38 27 X X X X X L-DOPN 111 42 INeari ng-off; 
IDD;enta- dyski nesias; 
capone off- dyston ia 
AaE =~ age at exam; AaO·= age al onse!; n.a. ~ not available; RT resting tremor; PT ~ 
postural tremor; B ~ bradykinesia; R ~~ museular rigidity; P ~ loss of postura/ reflexes; AS ~ 
asymmetrie ons et of symptoms; /00 =. dopa-deearboxylase inhibitor; HY ~ Hoehn and Yahr 
score; UPORS ~ Unified Parkinson's Oisease Rating Scale 
The genealogical history of the isolate has been computerised as far back as 1750. 
Although the patients were not aware of consanguinity in their family, the pedigree 
of each of the two sibships showed multiple consanguinity loops (Figure 1). The 
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pedigree is drawn on the basis of the two shortest consanguinity loops for both 
parent pairs (VI-1N-2 and VI-2NI-3), which links the two sibships to a common 
ancestor six generations ago. However, other connections between the sibships 
exist, including a second loop linking VI-l anel V-2 to a common ancestor, who is 
also related to VI-2. 
The pedigree structure is consistent with an autosomal recessive mode of 
inheritance, and the kind red therefore was considered to be suitable for 
homozygosity mapping. lO For all patients and avai lable fi rst-degree relatives, 
genomic O~JA was isolated from peripheral blood, according to the method 
described by Miller et al. 11 For the systematic genome scan, short tandem-repeat 
polymorphisrns (5TRPs) from the ABI PRI5M Linkage Mapping 5et MO-l0 (Applied 
Biosystems) were used. Additional markers for fine-mapping and the PARK6 region 
were obtained irom the Généthon and Marshfield (Center tor Medical Genetics, 
Marshfield Medical Research Foundation) genetic-marker sets. Marker order and 
distances were obtained from the Marshfield (Center for Medical Genetics, 
Marshfield Medical Research Foundation) integrated linkage map. Markers were 
amplified from genomic ONA, according to rnethods specified by the 
manufacturers. PCR products were pooled and loaded onto an ABI377 automated 
sequencer (fi iter set 0; 5% denaturing FMC LongRanger acrylamide gel), and data 
were analysed by ABI GENE5CAN3.1 and ABI GENOTYPER2.1 software. 
In the initial screens, only three definitely affected individuals (VII-2, VII-3, 
and VII-7) were genotyped. We first tested for linkage of our family to known PO 
loci,I-5 using 5TRPs from the ABI PRI5M Linkage Mapping 5et MO-l0. At 
chromosome 4q22, the markers 045414 anel 0451572 were assessed; at 
chromosome 4p14, markers 045419 and 04S405; at chromosome 4p14-16.3, 
markers 045419 and 0451592; at chromosome 6q25.2-q27, markers 0651581 and 
065264; and. at chromosome 2p13, markers 02S337 and D2S2368. The analysis of 
the markers flanking the known PO genes elid not show evidence for homozygosity, 
indicating that the disease in the family cannot be explained by one of these known 
genes (data not shown). We then performed a sy~;tematic genome screen. LOO 
scores were generated by the program MAPMAKER-HOMOZ12 under the 
assumption5 of equal recombination for males anel females, autosomal recessive 
inheritance, and gene frequency 0.004. In the initial genome screen, the family 
structure used in the analysis is depicted in Figure 1, and allele frequencies were 
estimated on the basis of the ONA of 51 spouses of patients participating in the 
various studies in GRIP. The three individuals included in the initial screen (\/11-2, 
VII-3, anel VII-7) were homozygous for six markers, located on chromosomes 1, 5, 
11, 17, and 21. Only for the chromosome 1 region, two adjacent markers (015468 
and 015214) were found to be homozygous in all patients, leading to a maximum 
LOO score of 2.8. 
The newly diagnosed patient (VII-6) was identified after this initial screen 
and was typed, together with unaffected first-degree relatives (VI-2, VI-3, VII-l, VII-4, 
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and VII-5), only for the five regions at which the first three patients were 
homozygous. 
Homozygosity remainecl only for markers on chromosomes 1, S, and 17. On 
chrol11osomes S and 17, homozygosity was found with very-frequent (34% and 
42%, respectively) alleles of the markers OSS 1981 and 0175944. For closely linked 
(i.e., < 10 cM distant) markers, all four patients were heterozygous, illdicating that 
the observed alleles for these rl1arkers could be identical by state (IBS). In contrast, 
the population frequency of the homozygous allele at 015468 was 9%. The 
chances that the homozygous allele in our distantly related patients i~; IBS are very 
small. In addition, all four patiellts were homozygous for the flanking marker 
015214, indicating that the alleles were most likely identical bl' descent. We 
therefore saturated the region surrounding 015468 and 015214 with 13 additional 
markers and found that all patients were homozygous for 9 of the markers studied, 
whereas the unaffected parents and two unaffected siblings were all either 
heterozygous or non-carriers of the disease haplotype (Figure 1). When lOO scores 
for the disease haplotype were calculated, equal allele frequencies for each marker 
were assumed, because population allele frequencies were not available. 
Penetrance was assumed to be '100% by age 40 years. The most conservative 
analysis that is, under the assumption that there is a second-degree relationship 
between the parents of the sibships, resulted in a maximum multipoint LOO score 
of 4.3. 5ubsequent haplotl'pe analysis showed homozygosity of all four patients, for 
a region of 16 cM on the sex-averaged linkage map. The first recombination events 
were observed for marker 015243 on the telomeric side in individual \/11-6 and for 
marl,er 015244 on the centromeric side in individual VII-3. 
Because of Valente et al. 'S7 recent report of linkage of an early-onset 
autosomal recessive form of parkinsonism to chromosome 1 p35-36, we investigated 
whether we could exclude linkage to the PARK6 region in the family that we 
studied; we tested nine markers from the PARK6 region (Tabie 2). The patients in 
this family showed no homozygositl' at anl' of these markers. The PARK6 critical 
region, between markers 015483 and 015247, is localized 25 cM centromeric of 
our critical region. Considering the evidence that the critical region in the family 
that we studied does not overlap with the region encompassing the PARK6 gene 
identified by Valente et al. 7 and taking into account the recommendations that 
lancJer and Kruglyak13 have made with regard to the reporting of linkage findings, 
we report a significant linkage fincling for the presence, on chromosome 1 p, of a 
second locus for autosomal recessive early-onset parkinsonism; and we propose to 
name it "PARK7." 
Both PARK6 7 and PARK7 were identified by homozygosity mapping. 
Although this is a very powerful approach in consanguineous pedigrees,10 some 
possible methodological problems recently have been raised in articles published in 
the American Journalof Human Genetics. 14 Miano et al. 14 have shown that patients 
may be homozygous for large regions bl' chance in particular if there are multiple 
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loops in the pedigree, such as occur in the pedigree that we studied. However, our 
most conservative analysis, based on an analy~;is assuming a second-degree 
relationship, still yielded a lOD score >4. In addition, the tact that the affected 
individuals {rom the two sibships share an identical homozygous haplotype, 
whereas none of the unaffected first-degree relatives was homozygous for this 
haplotype, makes a false-positive finding less likely. 
Table 2. Genotypes of affected individuals, for markers of the PARK6 region 
Genotype of affected individual 
Marker' VII-2 VII-3 VII-6 VIP 
D15199 2 5 3 5 2 5 3 4 
015483 1 2 1 2 2 
015478 3 5 1 3 3 S 2 3 
0152828 4 4 5 4 1 4 3 
0152732 2 4 2 3 2 4 4 
0152702 2 4 2 3 2 4 4 
0152734 5 4 5 5 5 4 4 1 
0152885 4 1 4 2 4 1 3 
015247 4 2 6 4 :2 3 5 
Source: Va/ente et al.'; 'Order is according to the Marshfie/d (Center for Medica! Genetics, 
Marshfie/d Medica/ Research Foundation) integrated !inkage map. 
Using homozygosity mapping, we have iclentifiecl a third locus for autosomal 
recessive early-onset parkinsonism: PARK7. 5imilar to what has been reported in 
other studies of early-onset parkinsonism and parkin mutations,6 the disease in the 
patients of the family that we studied is characterised by a slow progression. 
Dystonic features, including blepharospasm and laterocollis, and brisk tendon 
reflexes have also been found in patients with parkin mutations.6,lS,16 PARK7 is the 
second locus, in the chromosome 1 p36 region, involved in autosomal recessive, 
early-onset parkinsonism. The region defining the disease haplotype can be c1early 
separated from that of the more centromeric PARK6 locus. Although the genomic 
sequence of the critical region is far from complete and many gaps remain, a first 
analysis of the Project Ensembl and Human Genome Project Working Draft at 
UCSC databases showed that inside the critical region 25 genes are located, 
including 7 genes with an unknown function. Possible candidate genes are the gene 
encoding the vesicle-associated membrane protein 3 (VAMP3) and the gene 
encoding protein kinase C, zeta (PRKCZ). Telomeric of 015243, a ubiql1itin-
conjl1gating enzyme has been localised. Although this would be an obvious 
candidate, its location is outside the candidate region, The observation,. on 
chromosome 1 p, of two c10sely linked loci for early-onset parkinsonism raises the 
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question whether there might have been a duplication of this chromosomal region 
during evolution; however, comparison of the gene contents from the PARK6 and 
PARK7 critical regions and the syntenic region in the mouse does not support this 
idea. 
Recessive mutations in the parkin gene have been shown to be a common 
cause of early-onset parkinsonism. 6 Our findings and those of Valente et al. 7 strongly 
suggest there may be other recessive mutations, in at least two unidentified genes 
involved in the disease. Analysis of additional families with early-onset 
parkinsonism lacking parkin mutations will reveal the importance of these two new 
loci for early-onset parkinsonism. 
The frequency of recessive mutations in early-onset parkinsonism may even 
have masked the genetic origin of PD for a long time, since familial aggregation and 
the identification of consanguinity require extensive genealogical research. 
Therefore, it remains to be determined whether these common recessive mutations 
are involved in late-onset forms of the disease as weiL Studies of inbred and/or 
isolated populations such as GRIP may therefore help to further dissect the 
pathogenesis of PD. 
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CHAPTER 2.2 
Mutations in tlu~ DJ-l gene associated with 
autosomal recessive early-onset parkinsonism 
Abstract 
The DH gene encodes a ubiquitous, highly conserved protein. Here, we show 
that OH mutations are associated with PARK7, a mOl1Jogenic form of hIlIman 
parkil1Jsol1Jism. The function of the DH protein rI~mains unknown, but evidence 
suggests lts involvement in the oxidative stress r,esponse. Our findings inclicate 
that 1055 of OH function leads to neurodegeneration. Elucidating the 
physiological role of DH protein may promote ur'lderstanding of the mecghalllisms 
of brain neillronal maintenance and pathogenesis of Parkinson's disease. 
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The causes of Parkinson's disease (PD), a common neurodegenerative disorder, 
remain largely unknown but genes identified for rare mendelian farms have 
increased our understanding of disease pathogenesis. 1,2 By homozygosity mapping 
in two consanguineous families from genetically isolated communities in The 
Netherlands and Italy, we local ised a gene for autosomal recessivE' early-onset 
parkinsonism, PARK7, to a 20-cM interval on chromosome 1 p36 (Appendix). 3,4 
Fine mapping by typing available and newly developed short tanclem repeat 
(STR) or single nucleotide polymorphism (SNP) markers, reduced the critical region 
in the Dutch family to a 5.6-Mb I'egion of homozygous sequence, spanning six 
contigs and five gaps in NCBI build 29 of the human genome5 and containing as 
many as 90 genes (Figure 1).6 We sequenced obvious canclidate genes from 
genomic DNA, but no mutations were detected in the two families (Appendix). 
We then performed a systematic screening of the transcripts in the region, 
using reverse-transcriptase-polymerase chain reaction (RT-PCR) material obtainecl 
from Iymphoblastoid cell lines of one patient in each family ancl a normal contro!. 
One .of the cDNAs analysed, omesponding to the whole DJ-1 gene open reading 
frame (ORF), coulcl not be amplified in the Dutch patient (Figure Al Appendix). 
Amplification of DH exons 1 A/B to 5 from genomic DNA yieldecl no produets in the 
same patient, whereas the two more centromeric exons 6 and 7 were normally 
amplified. This confirmed the presence of a homozygous genomic deletion ancl 
placed the centromeric border of the deletion in intron 5 of the DJ-1 gene. From the 
telomeric side, we could amplify exons of the neighboring gene TNFRSF9, as weil 
as sequences from the intergenie region, delineating DJ-1 as the only gene involved 
in the deletion. 
Using a PCR-based strategy, we cloned the deletion breakpoint (Appendix). 
A novel fragment of about 2000 base pairs (bp) was amplified only from the 
individuals carrying the disease aIleie. Sequencing this fragment confirmed the 
joining of the telomeric and centromeric borders, delineating a deletion of 14,082 
bp, which inclucles 4 kb of sequence upstream of the DJ-1 gene ORF start. 
Interestingly, ALU elements flank the deleted sequence on both sides, and the 
breakpoint occurs within 16 bp of sequence identical in the two ALUs, suggesting 
that unequal crossing-over was likely at the origin of this genomic rEmrangement 
(Figure Al Appendix). 
The deletion showed complete cosegregation with the disease allele in the 
Dutch family (Figure Al Appendix), whereas it was absent in 380 chromosomes 
from the genera I Dutch populatioll, which supports the position that it is a 
pathogenie mutation. We also investigated the frequency of the DJ-1 deletion within 
the genetically isolated population where the Dutch PARK7 family was identified. 3 
Among 440 independent chromosomes from the genetic isolate we found four 
heterozygous and no homozygous carriers of the deletion. Moreover, the cleletion 
was absent in 400 chromosomes from the regions closely surrounding the genetic 
isolate. Together with our results from the general Dutch population, t1ese findings 
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indicate that, although the mutant allele is present at 0.9% within the isolated 
population, it is likely confined to this population. None of 42 late-onset PD 
patients from the isolated community carried the deletion, indicating that they have 
a different aetiology. 
Figure 1. Cenetic and physical maps of the PARK7 region 
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a) Cenomie organisation of the OJ-! gene. The location of the eight exons and the mul:ations 
found in the Duteh and Ita/ian families are shown. b) BACIPAC clone coverage of a SOO-kb 
region spanning the OJ-! gene. Crey and black bars indicate finished and unfinished c:Iones, 
respectively. c) Physical map of the PARK7 region. Vertical bars above contigs indieate the 
loeation of the polymorphic markers typed in this study. The centra I contigs depicted in bright 
grey eontain ful/y informative, homozygous markers in the Outch family patients. The flanking 
regions depicted in dark grey eontain heterozygous markers in at least one patient. The most 
telomeric con tig, depicted in middle grey contains homoz'lgous, non-informative markers. The 
con tig NT 022058 contains informative homozygous markers and is therefore placed within the 
PARK7 critica.' regiol1. lts position in the NBC! assembly (build 29) is more te/omeric. The 
remaining contigs are ordered as in the NCBI assembly. Heterozygous markers placed in con tig 
NT 004321 telomerical/y and NT 032970 centromerically, flank 5.6 Mb of homozygous 
sequence and define the new PARK7 critica I interval (outer arrowheads). d) Cenetic map; the 
intermarker genetic distance is given in centiMorgans, according to (he Marshfield integrated sex 
average linkage map. Markers flanking the PARK7 locus in previous mapping studies are 
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indicated with the arrows. The marker D 1516 72, Jacated 80 kb centromeric ta Ihe DJ- i gene, is 
indicated by the centrally pJaced arrowhead (c and dJ. 
We then sequenced the DJ-l cDNA from the Italian patient anel iclentified a 
homozygous point mutation (T --7C transition at position 497 from the ORF start in 
cONA), resulting in the sllbstitlltion of a highly conserved leucine at position 166 
(Le1l 166) of the OH protein by a proline (Figure 2b). This change showed complete 
cosegregation with the clisease allele in the Italian family (Figure Al Appendix) and 
was absent from 320 chromosomes hom the general Italian poplilation. ~~o further 
changes segregating with the clisease in the Italian family and absent in the general 
population were detected. 
Although PARK6 and PARK? seem to be separate, close loci (Appendix), it 
will be interesting to search the Pllblished PARK6 family for mutations in DJ-l. 7 We 
have tested a limited number of early-onset familial and sporadic PO patients that 
did not have mutations in the parkin gene; we did not find a mutation in 0)-1 
(Appendix). 
The D)-l gene contains 8 exons distributed over 24 kb (Figure la). The first 
two exons (1 A and 1 s) are noncocling and alternatively spliced in the DJ-l mRI\JA. 5 
One major transcript of about 1 kb contains a 570-bp ORF, encoding a protein of 
189 amino acids, that is ubiquitously expressed in body tissues and brain areas, 
including those more affected in PO (Figure 2a). D)-l belongs to the Thij/Pfpl family 
(pfam01965), which inc:ludes ThiJ, a protein involved in thiamine biosynthesis in 
prokaryotes; Pfpl and other bacterial proteases; araC and other bacterial 
transcription factors; anel the glutamine amidotransferases family (including bacterial 
catalases) (Figure 2d). 
To investigate the structllral consequences of the Leu 166pro mlltation, a 
molecular model of D)-l was built using the programs WHAT IF8 anel YASARA.9 
With 23 % sequence iclentity to the known structure of protease PH 1704 hom 
Pyrococeus horikoshii10 anel an almost gapless alignment spanning 170 residues, 0)-
1 can safely be assumed" to adopt the same aJ~ sandwich structure as PH 1704 
(Figure 2e). According to the model, Leu 166 is placed right in the middle of the 
carboxyl-terminal helix. Proline is a strong helix breaker12 and its presel1Ce in the 0)-
1 mutant is therefore likely to destabilise the terminal helix. The PH1704 protease 
was found to form a hexameric ring strueture made of a trimer of dimers. lO The 
general pattern of salt bridges anel hydrophobie packing in the trimerization region 
of PH 1704 is conserveel in the OH model, which makes it likely ti1at OJ-l also 
forms higher aggregates. 
To explore the functional consequences of the 0)-1 mutation, we transfected 
wild-type and mutant OJ-l in cell cultures (Figure 2, e to j). In COS anel PC12 cells 
transfected with wild-type OJ-l we observed diffuse cytoplasmic and nuclear 0)-1 
immunoreactivity similar to findings from previous studies. 13,14 Transfection of the 
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DH carrying the Leu 166pro mutation showecl a similar uniform nuclear stammg, 
whereas the cytoplasmic staining appearecl mostly colocalisecl with mitochondria. 
Taken as a whoie, our findings indicate that the DJ-l protein is lacking in the 
Dutch family and is functionally inactive in the Italian family because of the 
Leu l66Pro change. The mutant DH (Leu 166Pro) is still present in the nucleus, which 
suggests that the 1055 of cytoplasmic activities is pathogenic, or that the nuclear 
activity is affected by the mutation even if the protein retains its translocation 
capability. 
Figure 2. D)-l protein analysis, and transfection experiments 
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a) Northem b/ot - different human lissues and brain regions. Upper panels: OJ-] probe. Lower 
panels: eontro/ probe (j3-aetin). OJ-7 expression is higher in subcortical regions (caudate nucleus, 
tha/amus, s.nigra) than in eOltica/ regions. b) Alignment of OJ-/ hom%g, showing the 
conservation of the amino acid mutated in the Ita/ian fami/y (Leu'66). c) Mo/ecu/ar mode/ of OJ-
/. The ribbons eorrespond to a-helix and j3-sheet structures. Indicated is the position of the 
residue (Leu'66) mutated in the Ita/ian fami/y. d) Phy/ogenetie tree of O}-/ and other ThiJjpfpl 
fami/~' proteins. The /ength of the connecting /ines ref/eets evo/utionary distanee be/ween fami/y 
members. e to j) COS ce"s transfectec1 wilh constructs expressing wild -type (e to g) or Leu'66Pro 
mutant (h to j) v5-His-tagged Oj-l protein. Immunostaining: v5-His tag [bright signal (e and h)]; 
HsP60, a mitochondria/ marker [bright signa/ (f and gil; v5-His tag and HsP60 mergeel (g anel i). 
The function of 0)-1 is unknown. Human 0)-1 was first identified as an 
oncogene13 and later as a regulatory subunit of an RNA-binding protein (RBP).14 
Moreover, 0)-1 binds to PIAS proteins, 15 a family of SUMO-1 ligases that modulate 
the activity of various transcription factors. 16 0)-1 itself is sumoylated at lysine 130.15 
Interestingly, in human and murine cell lines, 0)-1 has been identified as a 
hydroperoxide-responsive protein that is converted into a variant with a more acidic 
pi in response to oxidative stimuli like H202 or the herbicide Paraquat, which 
suggests a function as an antioxidant protein. 17,18 The transcription of YOR533C, a 
yeast 0)-1 homolog, is induced together with genes involved in the oxidative stress 
response. 19 
Oxidative damage has been implicated in the mechanisms of neuronal death 
and the pathogenesis of PO.20 Normal dopamine metabolism produces reactive 
oxygen species, making nigral neurons particularly sensitive to oxidative stress, and 
signs of oxidative stress are found in postmortem studies of PO brains 2 ,lO Emerging 
evidence also links oxidative stl'ess to mutations in alpha-synuc/ein and parkin, two 
PO-related genes. 21 ,22 
It is possible that 0)-1 participates in the oxidative stress response by directly 
buffering cytosolic redox changes, and/or by modulating gene expression at 
transcriptional and post-transcriptional levels (Figure A2 Appendix), inleracting with 
RBP complexes and transcriptional cofactors such as PIAS or other, unknown 
factors. 
Our discovery of OJ-1 mutations in PARK7 opens new avenues for 
understanding the neuronal function of 0)-1, that, when lost, causes 
neurodegeneration. Furthermore, the observation that 0)-1 may be involved in the 
oxidative stress response links a genetic defect in this pathway to the development 
of parkinsonism, with possible impl ications for understanding the pathogenesis of 
the common forms of PO. 
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MUTATlor-.JS IN THE DH GENE, APPENDIX 
Materials and methods 
Marker development and genotyping 
Sequence data from selected BAC or PAC dones were downloaded from GenBank. 1 
Short Tandem Repeat (STR) sequences were selected by repeat length and typed 
using the program FileProcessor.2 Single Nucleotide Polymorphisms (SNPs) were 
downloacled hom NCBI 3 or they were generated through use of the Celera 
Discovery System and Celera's associated databases. STR markers were typed by 
radioactive polymerase chain reaction, essentially according to Weber and May.4 
SNP markers were typed using a touch-down PCR protocol and digestion with 
restriction enclonucleases. Heterozygosity of markers was determined using a panel 
of independent chromosomes from the general population. The complete lists of 
typed STRs and SNPs are available on request. 
Genetic analyses 
Genomic Dr--~A was isolated from peripheral blood using standard protocols. 
For mutation analysis of the 0}-7 gene, PCR reactions were performed in 25 or 50 
~I containing 1 x GibcoBRL PCR buffer, 1.5mM MgCl2, 0.01 % W-1, 250~M of each 
dNTP, O.4~M forward primer, O.4~M reverse primer, 2.5 units of Taq DNA 
polymerase (GibcoBRL) and 50 ng genomic DNN2'j fll of PCR volume. For exon 2, 
the concentration of each primer was 2~M. For eXOJl 1, DMSO 7% was used. Cyde 
conditions were: 5 min at 94°C; 35 cydes of 30 s denaturation at 94°C, 30 s 
annealing ai temperatures reported bel ow, anc! 90 sextension at 72°C; final 
extension 5 min at 72°C. Primers, annealing temperatures, and size of amplified 
fragments were as follows: 
Exon Fwel Primer 5'~3' Rev Primer 5'~3' anneaiing T size (bp) 
1NB CACCTACACTCG TTCTGGACGCTTC 70°-->60'(1 '/cycle), then 60° 405 
GCCGGAC AGCGTTG 
2 TACCAACTACTTA TATTTATTCTTATG 66°-,58'(1°/cycle), then 58° 359 
CTCTCCTTG TCATCTCTG 
3 CAGCTGTGTAAAC A TTCTGT A TCAAC 65°--.56'(1 o/cycle), then 56° 546 
GTTACfC CAATTGCC 
4 CTATCTCCTGTACT ACAGAACA T AAGC 66°--):;8"(1°/cycle), then 58° 254 
TCCCAC AGATGCTG 
5 TCAGA.AA TGCCTT GCT A TTTGGAATC 70°-,60"(1 °/cycle), then 60° 354 
GCTTCCC AAACCATCG 
6 TTTGCCAGA TGTG ACTGCACTCCAGC 68°,tOl:al:3S cycles 495 
CTCAGCAAA TCG CTGGGCGA TGG 
7 CACA T AGCCCA TT AGCTGCAAA TGAA 66°--.58"(1 D/cycle), then 58° 504 
AGGATGTC GGTGATAC 
Direct sequencing of both strands was performec! using Big Dye Terminator ver. 3.0 
chemistry (Applied Biosystems). Fragments were loaded on an ABI3100 automated 
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sequencer and analysed with DNA Sequencing Analysis (ver 3.7) and SeqScape (ver 
1.1) packages (Appl ied Biosysterns). 
Figure Al. Mutation analyses 
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a) Cosegregation of the genomic de/etion in the Duteh fami/y. Dup/ex PCR from genomic DNA 
using primers designed to amplify the de/etion breakpoint (2011 bp band) and one of the 
de/eted DJ-l exons (exon 5 - 354 bp band), Exon 5 is absent from all patients (homozygous 
de/etion, lanes 2,3,6,8); the de/etion breakpoint band is present in homozygous (/anes 2,3,6,8) 
and heterozygous (/anes 4,5,7,9) carriers of the mutant al/e/e (note the dosage effect), Individua/ 
1 is not earrying the disease hap/otype, in agreement with data".b). Cosegregation of the L166P 
mutation in the Ita/ian fami/y. Alle/e speeific oligo hybridisation: mut - mutant; wt - wild-type; C 
- unrelated norma/ contro/. e). Sequenee of the de/etion breakpoint in the Duteh (ami/y showing 
the joining of the te/omerie and centromerie borders. The breakpoint lies within a 16 bp of 
sequence identica/ in the A/us and is depicted in a frame. The specific nucleotides in te/om eric 
and centromeric sequences are indicated by upper /ines. dj. E/ectropherograms showing the 
L166P mutation in the Italian fami/y, Sequencing from genomie DNA and cDNA e), Scheme of 
the geonomie rearrangement in the Duteh rami/y. {). RT-PCR amplifieation of a 741 bp fragment 
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corresponding to the Dj-l cDNA indicates absence of expression in the Dutch patient, and 
presence of expression in the Ita/ian patient. Ta exc/ude the possibi/ity of a po/ymorphism in 
one of (he primer binding sites this was rep/icated using six different primer combinations (data 
not shown). A 285 bp fragment of the KIAA08.3.3 cDNA is amplified as internal peR contra/ in 
the left lanes. 
Analysis of the genomic deletion found in the Dutch family. 
For sequencing purposes, a 1761 bp DNA fragment containing the deletion 
breakpoint was amplified using 21lM forward 5'-GCAAATAGCCAAAAGTGAAGTC-
3' and 2IJ.M reverse 5'-CGTACAAGACCTGCCAGGG-3' primers. PCR conditions 
were as above, with annealing temperatures of 700~60° (-l°/cycle), then 60°, total 
35 cycles. 
For testing the cosegregation in the Dutch family and the occurrence in 
population controls, a 2011 bp fragment containing the deletion breakpoint was 
amplified using 11lM forward 5'-GCAAATAGCCAAAAGTGAAGTC-3' and 11lM 
reverse 5'-TACTTTCAGCAGAATCATAAGG-3' primers; a 354 bp fragment 
containing exon 5 of DJ-7 gene was also amplified in the same PCR reaction using 
0,21.lM forward 5'-TGAGAAATGCCTTGCTTGGG-3' and 0.21lM reverse 5'-
GCT ATTTGCAATCAAACCATCG-3' primers. peR conditions were as above, with 
annealing temperatures of 700~60° (-l°/cycle), then 60°, total 35 cycles, Fragments 
were resolved using agarose 1.5% gel electrophoresis, 
For fU-PCR analyses, Iymphoblastoid cell I ines were established from one 
patient of each PARK7-linked family and one unrelated normal contro!. Total mRNA 
was isolated, and cDNA was prepared according to standard protocols. The 
following primers (O.4IlM each) were used to amplify the OJ-7 cD NA: forward-I 5'-
CGGTGCAGGCTTGT AAACA T-3', reverse-I 5' -TG ACTTCCA T ACTTCCGCAAA-3', 
forward-II 5'-CGCGTCCGCAGGAAGACG-T, reverse-II 5'-
T AGACACAA TTTGT AGGCTGAG-3', forward-lil 5' -GCGTGCTGGCGTGCGTTC-3', 
The primers were used in the following combinations: forward-Ilreverse-I (product 
size 741 bp); forward-II/reverse-I (763 bp); forwarcl-lIllreverse-1 (770 bp); forward-
IIreverse-11 (780 bp); forward-II/reverse-II (802 bp); rorward-lIllreverse-1i (809 bp). In 
some experiments, a 285 bp fragment of the KIAA833 cDNA was amplified as 
internal PCR control, using O.4IlM forward 5'-AGCTGCCGTCGTGCTGTAC-3' and 
O.4I.lM revel"se 5'-GGGTTGGTGCTTGCAATAAC-3' primers. PCR conditions were 
as above, with annealing temperatures of 66°--+'58° (-l°/cycle), then 58°, total 35 
cycles. 
For al/ele specific oligo (ASO) hybridization, PCR products containing DJ-7 
exon 7 were blotted into Hybond-N + membl"anes (Amersham Biosciences). The 
blots were hybridised for 1 hour at 37°C in .5X SSPE, 1 % SDS and 0,05 mglml 
single straM salmon sperm DNA with either the Ilormal or mutated sequence oligo. 
Filters were washed until a final stringency of 0.3 x S5C10.1 % SDS at 37°c:. The 
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following oligos were used for hybridisation: wild-type allele TITGCGC}TGCAATI, 
mutated allele (L166P) TTIGCGCÇTGCAATI. 
Northern blot analysis was performed according to manufacturers protocols 
(Clontech). 
Gen Bank accession numbers 
DJ-7 genomic sequence: AL034417. 
DJ-7 transcripts: AB073864, AF021819, BC008188, 061380. 
OJ-1 protein: CAB52550, BAB7! 782, AAC12806, AAH08188, BAA09603. 
Bioinformatics of DJ-7 protein 
Multiple sequence alignments were produced with CiustalW5 at the European 
Bioinformatics Institute (http://www2.ebi.ac.uk/clustalw). The phylogenetic tree of 
OJ-1 protein family was generated with TreeTop at GeneBee.6 
Molecular modeling of DJ-I protein 
Initial alignments for OJ-1 were obtained from the 30-PSSM fold recognition seNer7 
which identified POB entry 1 G21 as the closest homolog of known structure. The 
alignment and also the model does not cover the N-terminal th ree and C-terminal 
16 residues of OJ-1 protein. Side chains were built using WHAT IF.8 The model was 
energy minimized with the YASARA NOVA force field which was shown to 
improve models.9 Validation of the model with WHAT_CHECKlO showed a 
Ramachandran Z-score of -2.46 and all other quality Z-scores about one standard 
deviation below the ave rage high resolution X-ray structure, which is good for a 
model based on only 23% sequence identity. 
DJ-7 expression vectors 
Wild-type and mutant (L166P) OH cONAs were cloned in pcm~A3.1/V5-His 
TOPO TA vector (Invitrogen) and checked by sequencing using the Big Oye 
Terminator ver. 3.0 chemistry (Applied Biosystems). 
Cell culture and transfection 
COS cells were cultured in DMEM supplemented with 10% fetal calf serum, 100 
units/mi penicillin and 1000g/ml streptomycin and were kept at 37°C in 5% C02 (all 
from GIBCO BRL). PC12 cells were grown in OMEM supplemented with '10% horse 
serum (Sigma) and 5% feta I ealf serum, 100 units/mi penicillin and 100flg/ml 
streptomycin and kept at 37°C in 10% C02. COS and PC12 cells were transiently 
transfected with the constructs mentioned above using the Lipofectamine+ Reagent 
(Gibco) according to the manufacturer's recommendations. Transfected eells were 
fixed for immunofluorescence staining 24 and 48 h after transfection. 
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Immunoffuorescence staining 
Cells were rinsed with phosphate-bufferecl saline (PBS), fixed with 3% 
paraformaldehyde (10 min), permeabilized with methanol (15 min), blocked with 
PBS/5% bovine serum albumin /0.15% glycine (15 min) and incubated for 1 h with 
monoclonal mouse anti-V5 antibody (Invitrogen), dilution 1 :500. FITC-conjugated 
goat anti-mouse immunoglobulin G (1 :500 1 h) was used as secondary anti body 
(Sigma). Cells were mounted in Vectashield media (Vector) containing DAF'I and 
examined with a Zeiss Axioplan 2 microscope equipped with digital camera. 
Mitochondrial staining was performed by using rhodamine-conjugated MitoTrack 
(1 :2000) or by double-Iabeling immunofluoresc:ence with rabbit anti-HSP60 
anti body (I :200, 1 h Stressgen) and TRITC-c:onjugated goat anti-rabbit 
immunoglobulin (1 :500, 1 hl. 
Figure A2. Model of putative D)-l function 
r G redox signals , multilnerlzatlcn : nuclear DJ-1 
• --. DJ-1 actlve ~ 
antloxidative ChemI! shift \ 
buffer 
post-transcrlptlonal 
regulation of 
ox-stress response 
Modifiration of the 0}-1 protein (by chemica/ or multimerization changes) may direct/y buffer 
cytosolic redox f/uctuations; activated 0}-1 may intJuence expression of genes for oxidative 
stress response post-transcriptiona/ly (binding to RBP camp/exes); 0}-1 mayalso trans/ocate to 
the nucleus, be sumoy/ated, and inf/uence gene transcription. 
Clinical studies 
The Dutch and Italian PARK7-linked families have been described previously.ll,12 
The diagnosis of parkinsonism required the presence of two of three cardinal signs 
(resting tremor, bradykinesia, muscular rigidity), absence of atypical features 
(dementia early in disease course, ophtalmoplegia, pyramidal or cerebellar 
involvement), and no other identifiable causes. Brain imaging with computed 
tomography and/or magnetic resonance was unremarkable. Response to levodopa 
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or dopamine agonist therapy was present in all patients, except two who were 
untreated at the time of study. Autopsy data are not available. Functional brain 
imaging studies perfornled in patients of the Dutch family using dopamine-
transporter tracers and SPEeT or PET showed severe abnormalities, indicating 
presynaptic dysfunction of the nigrostriatal dopamine system, the patiern typically 
observed in Parkinson's disease (PD).13 
In comparison with classical, late-onset PD, the clinical phenotype in the 
Dutch and Italian PARK7-linked families is characterized by an early onset (in the 
thirties) and a slow disease progression. Furthermore, behavioral anel psych ic 
disturbances, and dystonic features (including blepharospasm) have been reported 
in both families. ll ,12 However, more detailed genotype-phenotype correlation 
studies are needed to accurately define the clinical spectrum associated to mutations 
in 0}-7 gene. 
Fine-mapping studies 
The PARK7 locus as delineated b)' initial linkage studies 11 ,12 spans more than 8 Mb 
in the current physical map of the Human Genome (NeB I, build 29), including 9 
contigs separated by 8 gaps, containing a large number of genes. 
In the last four NeB I buileIs of the human genome, released during the 
course of this study, the order of several contigs inside and in the proximity of the 
PARK7 region has fluctuated considerably, and for some contigs the internal 
assembly remains provisional. In order to overcome these difficulties, we have used 
extensive homozygosity mapping by typing available STR or SNP markers in the 
two definitely linked families to characterize each of the contigs located inside and 
flanking the PARK7 genetic borders. For contigs where STRs or SNPs were not 
available or not informative we developed new polymorphic STR markers by 
scanning c10nes of interest for repetitive sequences, 
Analysis of candidate genes 
The refinement of PARK7 critical interval allowed us to exclude many genes located 
in contigs showing heterozygous markers, including obvious candidates: UBE4B 
and Ubc6p, encoding enzymes involved in ubiquitination; ISG7S, encoding an 
ubiquitin-like protein; FL}10782 (PANK4), encoding a homolog of the gene mutated 
in pantothenate kinase-associated neurodegeneration, an autosomal recessive 
neurodegenerative disease, and FRAP7, encoding an immunophilin ligand, Obvious 
candidate genes located in contigs showing homozygous markers were analysed by 
direct sequencing from genomic DNA (primers and peR conditions are available on 
request). 
We detected no mutations in the coding region of the following genes: 
WOR8, encoding a protein containing WD40 repeats, a domain also found in 
ubiquitin ligase protein complexes; VAMP3, encoding a vesicle-associated protein, 
possibly involved in docking or fusion of synaptic vesicles; FL}70737, encoding a 
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protein with a Dna) domain, also present in moleculal' chaperones; KCNAB2, 
encoding a subunit of the potassium voltage-gated channel, shaker-related 
subfamily. 
Strategy for cloning the deletion breakpoint 
In order to identify the deletion breakpoint, we designed primer sets to ampl ify 
fragments of DNA evenly distributed between the minimal deleted area and the two 
flanking areas of non-deleted sequence. Iteration of this technique reduced the 
interval between the deleted region and the flanking, non-deleted borders to less 
than 3 kb. We then used primers placed on the non-deleted borders to amplify a 
fragment of about 2000 bp across the deletion breakpoint. In the normal 
chromosomes, these two primers are separated by about 16 kb. 
Replacing the reverse primer with another primer located 250 bases 
upstream yielded a novel fragment of about 1750 bp in the same individuals, 
confirming the specificity of the reaction and the presence of the deletion (data not 
shown). Cloning of the deletion breakpoint allowed us to test for the presence of the 
mutation in both heterozygous or homozygous state using PCR. 
Relationship!l between PARK6 and PARK7 
A different locus for autosomal recessive earl)! onset parkinsonism (PARK6) has 
been localised 25 cM centromeric of PARK7 on chromosome 1 p35-p36, in a single 
large pedigree. 14 Given the similarities between PARK6- and PARK7-assoeiated 
phenotypes, and the proximity of the two loci, it is possible that mutations in similar 
or functionally-related genes underlie both forms. As an alternative possibility, a 
large genom ie rearrangement could account for both I inkage reports. Linkage 
analysis of autosomal recessive parkinsonism i:; eomplicated by the small size of 
most recessive pedigrees, presence of further locus heterogeneity, proximity of the 
two loci on chr.1 p. As aresuit, the assigment of additional smaller families to either 
PARK6 or PARK7 must be considered as provisional 12•1S 
Mutation analyses of DI-1 gene in smaller families ~lInd isolated early onset cases 
Nine additional families with a diagnosis of c1inically definite idiopathic 
parkinsonism in at least two siblings, possible autosomal recessive inheritance 
(affected sibs, unaffected parents), disease onset before age 50 in at least one 
sibling, exclusion of linkage to the PARK2 locus, or parkin gene mutations excluded 
by sequencing and exon dosage, were available 1'01' analysis. 
By haplotype analysis, four of these families were compatible with linkage to 
PAR/U; three families to both PARK7 and PARK6; and two families to PARK6 
only.16 None of the above-mentioned families could be definitely linked to either of 
the two loci. Furthermore, 22 patients with idiopathic parkinsonism, negative family 
history and onset below age 40 were also studied. In nine cases mutations in parkin 
gene had been excluded by genomic sequencing and exon dosage. 
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Sequencing the exons and exon-intron boundaries of the Dj-l gene in the 
patients and families described above revealed no pathogenie mutations. Among 
the same patients and families, there were no carriers of the Dj-l deletion identified 
in the Dutch family. However, detection of compound heterozygosity fOt' different 
genornic rearrangements requires gene dosage analysis, which is currently being 
developed and therefore will be the subject offuture studies. 
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Clinical features and neumimaging in PARK7~liniked 
pillr'kinsonism 
Abstract 
We recently reported linkage to chromosome l1p36 (the PARK7 locus) in a family 
with early-onset parkinsonism. Linkage to this locus has since been confirmed in 
an independ,ent data set. We here describe clinÎ<Cal and neuroimaging features of 
the four patients in the original PARK7-linked kindred. Ages at onset of 
parkinsonism varied from 27 to 40 years. Clinical progression was slow, and 
response 10 dopaminergic therapy good. lhe clinical slpectrum ranged from mild 
hypokinesia and rigidity, to severe parkinsonism with levodopa-indluced 
dyskinesias and motor fluctuation. lhree of fom patients with PARK7-liinked 
parkinsonism exhibited psychiatric disturbances. Strudural neuroimaging was 
unremarkable, but functional imaging of the brain, performed in three patÏlents, 
showed significant evidence for a presynaptic dopamine deficit, and assessment of 
cerebral g~ucose metabolism, as performed in one patient, showed possible 
cerebellai' Învolvement. 
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Introduction 
The c:ause of Parkinson's disease (PO), one of the most c:ommon neurodegenerative 
diseases in the elderly, is largely unknown. In recent years, however, attempts to 
disseet the genetic background of familial, mostly early-onset, PO have been 
successful. 1 In PO with an autosornal dominant pattern of inheritance, five genes 
and/or loci have been identified. 2-6 For autosomal recessive early-onset PO, so far 
one gene and two loci have been reported. The parkin gene (chromosome 6q25.2-
27f encodes a ubiquitin-protein ligase and accounts for a large part of early-onset 
PO.8 The range of ages at onset in patients with mutations in parkin is very wide, 
and the clinical picture varies from parkinsonism to levodopa-responsive dystonia, 
with varying severity. Response to levodopa therapy is good and progression of 
disease is slow. After administration of levodopa, motor fluctuations and dyskinesias 
frequently occur. 8 PARK6 (chromosome 1 p35-p36) is a second locus for autosomal-
recessive parkinsonism, and is associated with sustained response to levodopa and 
slow progression of symptoms.9 In PARK6-linked parkinsonism, symptoms often 
reported in patients with early-onset autosomal recessive parkinsoni sm, such as 
early dystonia and sleep benefit, were not observed. 10 
We recently mapped a third locus (PARK7) in a c:onsanguineous pedigree 
with early-onset autosomal recessive parkinsonism. ll The PARK7 critical-region lies 
on chromosome 1 p36, and is clearly separated from PARK6 by 25 cM. Since, 
linkage to PARK7 has been confirmed in an independent set of families. 12 In this 
paper, the clinical and neuroimaging features of the original PARK7-linked family 
are described and compared to other forms of autosomal recessive early-onset 
parkinsonism. 
Methods 
Patients 
This study was performed within the framework of a larger research programme 
named Genetic Research in Isolated Populations, or GRIP. The scientific protocol of 
GRIP' has been approved by the Medical Ethics Committee of the Erasmus Me. 
Genealogical information of the PARK7-linked family was obtained and extended 
by means of local municipal and church records, as weil as computerised registers. 
Patients were ascertained through their general practitioners, who informed them 
about the study and requested their cooperation. 
Neurological examination 
A neurological examination in each patient and available relative was carried out 
by two neurologists, blinded to the genotype status. The clinical diagnosis of 
parkinsonism was established by the presence of at least two of the three cardinal 
signs (resting tremor, muscular rigidity and bradykinesia) without atypical features 
or signs of other neurological systems (autonomic, pyramidal and cerebellar) being 
involved. The extent of motor dysfunction was evaluated by Unified Parkinson's 
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Disease Rati ng Scale (UPDRS) 13 and Hoehn ancl Yahr scores. 14 One patient had 
previoLisly Llnclergone an extensive work-Llp for mitochondrial encephalomyopathy, 
dopamine-responsive dystonia and other metabolic disease (screen for 
mitochondrial-DNA point mutations, biopterine-excretion assessment, bone-marrow 
and muscIe biopsies), which did not yield evidence for those disorders 
(unpublished clata). 
Neuroimaging 
During the assessment of neuroimaging results, the researchers were unaware of the 
genetic status of the patients. Structural brain-irnaging data were obtained and 
reviewecl. Functional brain-imaging was perforrned in three out of four patients. In 
all three patients, the presynaptic nigrostriatal system was assessed. Furthennore 
was assessed the postsynaptic nigrostriatal system in two patients, and brain 
glucose-metabolism in one patient. The scans were made in three medical centres 
in The Netherlands over a six-year period, since patients were treated by different 
neurologists. For this reason, the methods of neuroimaging could vary from one 
patient to the next. One patient (patient VII-2) had a 1231-N-omega-fluoropropyl-
2beta-carbomethoxy-3beta-(4-iodopheny!) nortropane si ngle-photon emission CT 
(FP-CIT SPECT) scan made. In another patient (patient VII-3), 1231-iodobenzamide 
(I BZM) ancl FP-ClT SPECT scans were made. In the third patient (patient VII-7), 
IBZM, 2-beta-carboxymethoxy-3-beta-(4-iodophenyltropane (beta-CIT) SPECT, 18F_ 
deoxyglucose (FDG) and 18F-dopa (F-DOPA) positron ernission tomography (PET) 
scans were performed. 15-17 
Results 
Patients 
The PARK7 kindred consisted of two nuclear families, inclicated as family 1 and 
family 2. 11 A genealogical study linked the patients to one common ancestor six 
generations ago in a pedigree which contained several consanguineous loops 
(Figure 1). All four patients were homozygous, and two out of three unaffected 
siblings as weil as the parents of patient VII-7 were heterozygous for the disease 
haplotype. The third unaffected sibling (VII-l) did not carry the disease haplotype. 
Patient VII-3 from family 1 and patient VII-7 from family 2 were receiving 
neurological treatment at the time of the study (pergolide in patient VII-3 and 
levodopa with entacapone in patient VII-7). Neul'Ological examination of the rest of 
the sibship of patient VII-3 (consisting of five other presumedly unaffected siblings) 
revealed two more affected individuals not previously known to have parkinsonism 
(patients VII-2 and VII-6). The patient in the second sibship (patient VII-7, family 2) 
had no other affected close relatives. 
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Figure 1. Pedigree of the PARK7-kindred 
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The symbol on top represents (he comrnon ancestor, and the symbols on the bottom row the 
examined individuals. 81ack symbo/s indicate affected individuals. Asterisks mark (he presence 
of additional psychiatrie features. 
Neurologieal examination 
Neurologieal examination in the parents and two siblings heterozygous for the 
disease haplotype, and in the sibling not carrying the haplotype yielded no 
evidenee of neurological abnormalities. Clinical features of the four patients are 
listecl in Table 1. Ages at onset of disease varied from 27 years to 40 years. Patient 
VII-6 was 40 years old at first neurologieal examination (which established the 
diagnosis of parkinsonism). All four patients showed the cardinal signs of 
parkinsonism without atypical (pyramidal, eerebellar, autonomie) features. Two 
patients had signs of focal dystonia: blepharospasm oecurred in patient VII-3, and 
lateroeollis and foot dystonia in patient VII-7, the latter worsening in the off-phase 
of medication Patient VII-3 could not indicate whether the blepharospasm 
preceded therapy for parkinsonism, or only arose afterwards. In patient VII-7 the 
lateroeollis oceurred within a month of initiation of treatment. Patients VII-3 and 
VII-7 were treated with pergolide and levodopa with entaeapone, respeetively, and 
newly diagnosed patients VII-2 and VII-6 did not reeeive any dopaminergie 
medieation. Patient VII-7 developed dyskinesias and dystonias within one month 
from levodopa treatment. In addition to parkinsonism, all three patients VII-2, \111-3 
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Table 1. Clinical features of PARK7-linked parkinsonism 
Patient 
Age at examination (yrs) 
Age at ünset (yrs) 
Resting Tremor 
Rigidity 
Bradykinesia 
Posturallnstability 
Asymmetry at onset 
Oystonia at 
examination 
Hyperreflexia 
Oopaminergic drugs 
(daily dosage in mg) 
Side-effects levodopa 
UPDRS score (on/off phase) 
Hoehn and Yahr stage (on/off phase) 
Psych iatric symptoms 
Psychotropic drugs 
(daily dosage in mg) 
V!!-2 
50 
40 
+ 
+ 
+ 
+ 
n.a. 
29 (n.a.) 
111 (n.a.) 
V!!-3 
48 
3î 
+ 
+ 
+ 
+ 
+ 
blepharospasm 
+ 
pergolide (1.5) 
n.a. 
57 (on) 
III (on) 
anxiety; anxiety 
psychotic episodes; 
paranoid delusions 
Oiazepam(5); temazepam (10) 
haloperidola; 
olanzapine" 
UPDRS ~ Unified Parkinson 's Disease Rating Sca/e; tOD ~ dopa-decarboxylase inhibitor 
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V!!-6 
40 
flul K.flUWfi 
+ 
+ 
+ 
n.a. 
22 (n.a.) 
III (n.a.) 
anxiety 
diazepam (5) 
V!!-7 
38 
27 
+ 
+ 
+ 
+ 
laterocollis; 
foot dyston ia 
+ 
I-dopa (+ 100); 
entacapone (187.5/600) 
dysk i nesias/dyston ias; 
motor f!uctuations 
25 (on) 
111 (on) 
a tntermittent usage, last time of administration at least six months before neurological examination 
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and \111-6 in family 1 exhibited valying degrees of anxiety, which was reported to 
have existed for years before onset of parkinsonism. Patient VII-2 was also known to 
have suffered from recurrent psychotic episodes with paranoid delusions, for which 
treatment was aften declined. In patient VII-7 of family 2, na such psychiatrie or 
behavioural symptoms were noted. 
Neuroimaging 
During the assessment of neuroimaging results, the researchers we re unaware of the 
genetic status of the patients. Structural brain-imaging data were obtained and 
reviewed. Functional brain-imaging was performed in three out of four patients. In 
all three patients, the presynaptic nigrostriatal system was assessed. Furtherrnore 
was assessed the postsynaptic nigrostriatal system in two patients, and brain 
glucose-metabolism in one patient. The scans were made in three medical centres 
in The Netherlands over a six-year period, since patients were treated by different 
neurologists. For this reason, the methods of neuroimaging could valy from one 
patient to the next. One patient (patient VII-2) had a 1231-N-omegOl··fluoropropyl-
2beta-carbomethoxy-3beta-(4-iodophenyl) nortropane single-photon emission eT 
(FP-eIT SPEeT) scan made. In another patient (patient VII-3), 1231-iodobenzamide 
(IBZM) and FP-ClT SPEeT scans were made. In the third patient (patient VII-7), 
IBZM, 2-beta-carboxymethoxy-3-beta-(4-iodophenyltropane (beta-ClT) SPEeT, 1BF_ 
deoxyglucose (FDG) and 18F-dopa (F-DOPA) positron emission tomography (PET) 
scans were performed. 15-17 
Table 2. Functional neuroimaging in PARIO-linked parkinsonism 
Patient Scan performed Results 
VII-2 FP-ClT SPECT uptake putamen and caudate bilaterally 
and symmetrically decreased 
VII-3 FP-eIT SPECT,IBZM SPECT 
VII-6 
uptake putamen and caudate bdaterally 
and symmetrically decreased; 
normal dopamine-D2 receptor binding 
VII-7 beta-CiT SPECT,IBZM SPEeT, uptake putamen bilaterally decreased; 
F-DOPA PET,FDG PET uptake caudate unilaterally decreased; 
normal dopamine-D2 receptor binding; 
uptake putamen and caudate bilaterally 
decreased, more sa contralateral to most 
severely affected body side; 
diffuse cerebellar hypometabolism 
FP-CIT SPECT ~ 1231-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodopheny/) nortropane 
sing/E~photon emission CT; tBZM SPEeT ~ 1231-iodobenzamide SPECT; beta-CiT SPEeT '" 2··beta-
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carboxymelhoxy-3-beta-(4-iodophenyltropane) SPECT; F-DOPA PET ~ 18F-dopa PET; FOG PET ~ 
1BF-deoxyglucose PET 
Neuroimaging 
Structural brain imaging was available for patients VII-3 (computed tomography 
images) and VII-7 (magnetic resonance images), and was unremarkable. Functional 
brain-imaging was performed in three of four patients (VII-2, VII-3 and VII-7). Results 
are listed in lable 2. The fourth patient (VII-6) has not undergone neuroimaging. On 
SPECT imaging, two patients (VII-2 and VII-3) had a significant, symmetrical 
presynaptic dopaminergic deficit, which was present bilaterally in putamen and 
caudate nucleus. The putamen was more severely affected than the caudate 
nucleus. Striatal dopamine-D2 receptor binding (assessed in patients VII-3 and VII-7) 
was normal on IBZM neuroimaging. Patient VII-7 showed a strongly reeluced 
presynaptic dopaminergic neurotransmitter function on both sides in putamen and 
caudate nucleus on PET and SPECT imaging. Uptake was more reduced in the 
hemisphere contralateral to the clinically more affected body side, and the putamen 
was more severely affected than the caudate nucleus. Furthermore, the FDG PET 
scan performed in patient VII-7 showed elecreased glucose metabolism in the 
cerebellum. 18F-DOPA PET images of patient VII-7 anel of an age-matched healthy 
control subject are shown in Figure 2. 
Figure 2. 18F-DOPA PET images of a healthy contra I subject and patient VII-7 
Two trallsaxia! planes through the brain of all age-matched hea!thy contro! subject (upper row) 
and patient Vf.I-7 (/ower row). The subjects are viewed from the feet. Compared to the contra! 
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subject, uptake into putamen and caudale nucleus in patient VII-7 is markedly reduced on both 
sides. 
DiscLission 
Baseel upon observations in this original kindred, PARK7-linked parkinsonism is of 
variabie severity. Some of the patients had overt parkinsonism, receiving levodopa 
or dopaminergic therapy to which they responded weil. Others had mild 
parkinsonism for which medical attention was never sought. Patients VIII-3 and VII-7 
had most pronounced motor elysfunction, and were on anti parkinson treatment. The 
latter two patients also had focal dystonia. Patient VII-7, who receiveel levoelopa, 
developed this within a month of starting dopamine therapy, as weil as motor 
fluctuations, on-phase elyskinesias and off-phase elystonia. In all four patients, 
progression as observed over the 3-year period of our study was very ~;Iow. The 
features in early-onset parkinsonism mentioned above, such as the variabie severity, 
the positive response to, with motor complications of, levodopa anel slow 
progression of disease, are comparable to the phenotype of parkin-related8 and 
PARK6-linked parkinsonism.9 Similar observations were made in other PA/~K7-
linked kindreds. 12 In families with PARK6-linked parkinsonism, however, focal 
dystonia was not observed and resting tremor prevailed. lO Although the number of 
patients studied is too small to draw firm conclusions, PARK6- and PARK7-linked 
parkinsonism appear to be entities which are genetically as weil as clinically 
distinct. 
The siblings and parents who were heterozygous for the f'ARK7-linked 
haplotype showed no symptoms of parkinsonism at neurological examination. As 
for parkin and PARK6, being a heterozygous carrier of the PARK7 disease-haplotype 
is probably not sufficient to confer clinical parkinsonism. 
All patients in family 1 had symptoms of anxiety, for which they had been 
receiving benzodiazepine treatment for years. (Patient VII-3 had been using 
benzodiazepines even before parkinsonism was diagnosed and treated). Since the 
three siblings were treated by different general practitioners, this common 
medication cannot have been due to the propensity of one physician to pl"escribe 
benzodiazepines. In this family, complaints of anxiety may have been superimposed 
on, or confused with, initial "ymptoms of parkinsonism. In family 1, the three 
siblings who were unaffected with parkinsonism (VII-l, VII-4, VII-S) had no 
psychiatric symptoms either. These psychiatric symptoms may thus constitute part of 
the PARK7 phenotype. In olle patient of the independent family with significant 
linkage to PARK7,12 psychiatric and behavioural problems at onset of disease were 
al50 present- aggression, irritabi lity anel obsessive-compulsive disorder. Hl In parkin-
linkeel disease, psychiatric features, such as pronounced anxiety requiring treatment, 
have been reported occasionally,19.21 and in classical, idiopathic PO, anxiety is also 
commonly observed.22 Oue to the consanguineous structure of our pedigree, 
however, psychiatrie symptoms may form a 'private' trait in family 1 only, anel be 
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unrelated to the PARK7 phenotype. Additional families are therefore required to 
study psychopathological aspects of PARK7-linked parkinsonism. 
On FP CIT and beta-CiT imaging in patients VII-2 and VII-3, there was 
significant evidence for a symmetrical presynaptic dopaminergic deficit. In patient 
VII-7, who underwent PET and SPECT neuroimaging, dopa uptake was greatly 
reduced bilaterally in both putamen and caudate nucleus. This was more 
pronounced in the cerebral hemisphere contralateral to the more severely affected 
body side. lIlF-DOPA PET-scan series perforl11ed in parkin patients and carriers23-25 
showed a bilaterally and symmetrically decreased dopa uptake, in which putamen 
as weil as caudate nucleus were affected. Furthermore, asymptomatic parkin-
heterozygotes showed a mild but significant decrease in dopa uptake, suggesting a 
sub-clinical disease process in heterozygotes. 24 In idiopathic, non-familial PD, dopa 
uptake is primarily asymmetrically decreased, affecting the putamen much more 
severely than the caudate nucleus.26 
The dopa-uptake reduction is symmetrical in two patients in our study, but 
asyrnmetrical in a third patient, which does not permit straightforward comparison 
to dopa-uptake patterns in parkin-linked parkinsonism or to those in idiopathic PD. 
On the other hand, the presence of impaired uptake in putamen as weil as in the 
caudate nucleus in our patients resembles parkin-linked parkinsonism more than 
idiopathic PDY-25 More data on PARK7-linked parkinsonism are therefore required 
to further delineate its functional-neuroimaging pattern. 
The FDG PET image of patient VII-7 showed cerebellar hypometabolism of 
glucose. This may either be a primary phenomenon in the disease process, or occur 
sec:ondary to striatal deafferentation. A decreased glucose metabolism in the 
cerebellum was also observed on FDG PET imaging in patients with a deletion in 
the parkin gene,23 suggesting another feature that PARK7- and parkin-linked 
parkinsonisrn have in common. Furthermore, clinical cerebellar dysfunction and 
neuropathology have been described in Japanese and Dutch families with parkin-
related parkinsonism. 27-28 In addition to the observations in parkin-related 
parkinsonisrn, aSPECT study reported symmetrical cerebellar hypoperfusion in an 
early-onset patient without parkin mutations. 29 Cerebellar involvement in autosomal 
recessive parkinsonism is still unclear and therefore requires further research. 
In PET-neuroimaging studies on parkin-linked parkinsonism, "C-raclopride 
binding, assessing status of postsynaptic dopamine-D2 receptors, was shown to be 
significantly reduced.24 In patient VII-7, a (.-rac:lopride PET scan has unfortunately 
not been performed, but IBZM imaging in this patient and in patient VII-3 showed 
normal doparnine-D2 receptor binding. Finally, functional-neuroimaging studies of 
the PARK7-positive c:onfirmation families and the PARK6 families are not vet 
available, nor are neuropathological data. 
The number of patients of this newly described form of parkinsonism is 
smalI, but nevertheless demands comparison to other forms of recessive 
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parkinsonism and idiopathic PD. Our first delineation of the PARI<7 phel10type can 
be refined as more PARKl-·linked families become available. 
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CI-IAPTER 2.4 
Brachydactyly and short stature in a kindll'€d 
with eaB'ly··onset parkinsonism 
AbsîratCt 
In <11 consanguineous family from The Netherlands, we have identified a deletion 
of the DH gene leading to early-onset parkinsonism in those homozygous for the 
deletion. lIhe function of OJ-1 is not known, although it is likely to play a mie in 
the cellul<1lr response to oxidative stress. At clillical examination of these 
parkinsonism patients, we also observed shmt stature and brachydactyly .. This 
prompted us to illvestigate body height and hand radiographs in patients and their 
relatives, as weil as in a control group from the genetically isolated population the 
kindred originated from. Using the DH deletiml as a marker for the 5 .. 6-Mb 
homozygosity region on chromosome 1 p36 (PARK7), we found a signHicant 
associ<1ltion of the deletion with body height, adjusting for age and glender 
(p = 0.005). This association suggests that either a gene or regulatory element 
elsewhere in linkage disequilibrium with OJ-l, or Dj-1 itself is implicated in short 
stature. Analysis of hand-bone length showed incomplete segregation of the 
deletion with brachydactyly, rendering it unlikeiy that the brachydactyly is fully 
expiainedl by <11 gene in the OJ-1 region. Vet patients with parkinsonism, 
hOlllozygous for the DH deletion, had a more prollouncedJ overall bone-I,ength 
reductiol1l than relatives unaffected wüth parkinsonism, heterozygous for the 
deletion. Given the difference with the patients affected with parkinsonism, a 
modifier gene for brachydactyly may oe present in the homozygous region 
containing tile DH gene. 
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Introduction 
Recently, we identifieel mutations in the OJ-1 gene leading to early-onset 
parkinsonism with autosomal recessive inheritance in two consanguineous families 
from The Netherlands and Italy ([OMIM 606324], PARK7lY Unlike the other four 
PO genes identified to date, alpha-synuclein,3 parkin,4 UCH-L 15 and \,JR4A2,6 the 
OJ-1 protein possibly has a function in the defense against oxidative stress. 7 This 
indicates a novel pathogenetic mechanism for Parkinson's disease (PD). The 
ubiquitous OH protein is relatively small (189 amino acids) and has been highly 
conserved across species elwing evolution. 2 These characteristics suggest DJ-l to 
have a relevant role in cell physiology. The exact function of the gene is, however, 
not vet elucidated. A comprehensive description of the phenotype associated with 
OJ-1 mutations may sheel more light upon its function. 
The PO patients in the originally reported Outch kindred were homozygous 
for a region on chromosome 1 p36 of 5.6 megabases (Mb), containing 90 genes. In 
the PO patients, a homozygous deletion was found involving five of the seven 
exons of the DJ-l gene, inclueling the start codon. Within the boundaries of the 
deletion, no other known genes Ol" regulatory elements are contained. At clinical 
examination, the patients with parkinsonism in the Outch kindred also had a 
proportionately short stature and remarkably small hands and feet. This raised the 
question whether a gene in the PARK7 homozygosity region or DJ-l itself could 
account for the phenotype in the Dutch kindred. In order to assess the association of 
body height and segregation pattems of the hand phenotype with (the homozygosity 
region around) DJ-1, we carried out a systematic c1inical-genetic and raeliographic 
analysis of all patients with parkinsonism and their relatives in the original kinelred, 
ascertained in a genetically isolated village. In order to assess the specificity of the 
traits, we also studied a control group derived from the same genetically isolated 
community. 
Methods 
Patients 
The kindred in this study came to attention originally because of its four members 
suffering from early-onset parkinsonism.' Patients and relatives were ascertained as 
part of the research program me named Genetic Research in Isolatecl Populations 
(GRIP). The GRIP study takes place in a genetically isolated community of 
approximately 20,000 inhabitant~; in the Southwest of The Netherlands. All 
participants have provided informeel consent prior to inclusion into the study. The 
scientific protocol of GRIP has obtained approval of the Meelical Ethics C:ommittee 
of the Erasmus MC 
The genetic analysis of the kindred described in this study has been 
described elsewhereY The early-onset parkinsonism is explained by a recessive 
mutation in the OJ-1 gene at chromosome 1 p36. In this kindred, it concerns a 
deletion affecting approximately 14 kilobases (kb), extending from 4 kb telomeric to 
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the stalt codon of the gene to 10 kb into the gene. LJsing the homozygosity mapping 
programme MAPMAKER-HOMOZ8 in a genomic screen with an inter-marker 
distance of approximately 10 cM, four other regions of homozygosity could be 
detected, which were present in all parkinsonism patients and not in relatives 
unaffected with parkinsonism. 1 These regions on chromosomes 5,11,17 and 21, 
however, concerned alleles with a high allele frequency, which were also very 
common in a control group. 
Figure 1. Pedigree of the kindred. 
o---,----ó 
II IIIJ 
:~~ 
VI 
VII () 
2 3 4 
Branch 1 
2 
5 6 
• 
7 
Branch 2 
3 
The symbol on top represents the common ancestor. Symbols on the bottom rows indicate the 
examined individuals by Arabic numerals. Black symbols indicate individuals affectecl with 
parkinsonism. 
Initially, patients were ascertained in two nuclear families. Using a 
genealogical database, these families were connected to a common ancestor six 
generations ago. Figure 1 shows both branches of the pedigree and their common 
ancestor. All four patients with parkinsonism (VII-2, VII-3, VII-6 and VII-7) were 
homozygous for the deletion in the DJ-1 gene. Two of the three other siblings in 
Branch 1 (VII-4 and VII-S) were heterozygous for the deletion, and sibling VII-1 had 
the wild-type genotype (did not carry any deletion). The parents of patient VII-7 
(Branch 2) were heterozygous for the deletion.;! Individual genotypes are listed in 
Table 1. 
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Table 1. Genetic and clinical characteristics of the kindred 
Individual Gender Genotype Height (m) Neurological examination 
VI-2 m del/nor 1.65 normal 
VI-3 del/nor 1.60 normal 
VII-1 m nor/nor 1.60 normal 
VII-2 del/del 1.50 parkinsonism; anxietv 
VII-3 m del/del 1.50 parkinsonism; psychosis 
VII-4 m del/nor 1.64 normal 
VII-5 m del/nor 1.62 normal 
VII-6 m del/del 1.58 parkinson ism; anxiety 
VII-7 m del/del 1.58 parkinsonism 
a Details of the neurologieal and psychiatrie features in this kindred are provided e/sewhere. 1,9 
m = male, f = female, del = deletion of 0/-7 gene, nor = normal (no deletion) 
Clinical examination and anthropometric assessment 
Patients with parkinsonism and their relatives were ascertained as described 
previouslyY The diagnosis of pal'kinsonism was verified by two independent 
neurologists. Researchers were blinded to the OJ-1 genotype at the time of 
examination. A clinical geneticiSf[ performed a systematic anthropometric and 
dysmorphologic assessment of all family members indicated by Arabic numerals in 
Figure 1. Body height and 0)-1 genotypes were also assessed in a control group 
derived from the same genetically isolated population within the framework of 
another study, consisting of 88 individuals. In order to exclude influence of a 
secular trend of increased body height in younger age groups, the age range of these 
control individuals closely approximated the age range of the individuals in the 
ki ndred. Furthermore, a manual for body height in the Outch general population 
was used for reference. 1o 
Radiographic analysis 
For this study, radiographs of distal extremities were collected. From planar hand 
radiographs, metacarpal and phalangeal bone lengths were determined. Foot 
radiographs were used for visual inspection only, since standardised assessment of 
metatarsallphalangeal bone lengths is not available. The analysis of hand structure 
was performed using the metacarpophalangeal profile (MCPP) program." IC rom 
bone lengths (in millimeters), Z-sc:ores were calculated, representing the statistical 
difference (in standard deviations) of the mean bone length compared to a sample of 
control individuals. Parkinsonism patients and relatives in the kindred were firstly 
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compared to a baseline reference group, consisting of 44 individuals randomly drawn 
from the general (Outch, caucasianl population. 11 Since the kindred originated from a 
genetically isolated population, a trait may not be specific to the kindred with 0)-1 
deletions and early-onset parkinsonism, but rather represent a characteristic of the 
isolate. Therefore, in order to compare individuals from the 0)-1 kindred to other 
individuals from the same genetically isolated population (the GRIP populationl, we 
secondly studied MCPP profiles in 12 unaffected non-related controls from 
independent nuclear families segregating triphalangeal thumb ascertained in the same 
community (TPTl. 12,13 
Statistical analysis 
Body height was analysed as a continuous trait by multiple regression analysis 
adjusting ror age and sex. The OH genotype was defined by the presence of deleted 
0)-1 genes/ and was used as a marker for the 5.6-Mb homozygosity region on 
chromosome 1 p36. Oegrees of significance were expressed as two-sided p-values. 
Results 
Clinical examination 
Clinical-genetic and anthropometric features are surnmarised in Table 1. On general 
clinical examination, all four patients with parkinsonism were found to have a 
proportionately sholt stature and small hands and feet. Figure 2 shows a photograph 
and a radiograph of one of the parkinsonism patients (VII-3). 
Figure 2. 
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At physical examination, the five relatives unaffected with parkinsonism (VII-1, VII-
4, VII-S in Branch 1, and VI-2, VI-3 in Branch 2) also had a degree of short stature, 
but not to the same extent as the patients. Body height of all individuals in the 
kindred was equal to or below the third percentile according to reference taloles for 
the Outch population. 10 
In the body-height control group, two individuals were heterozvgous for the 
OJ-1 deletion (a female of 1.54 m élnd a male of 1.67 m). These two subjects were 
included the group of heterozygotes for the OJ-1 deletion. Figure 3 gives the mean 
height for homozygotes (n = 4), heterozygotes (n = 6) and non-carriers (wi Id-type 
genotype, n =86), as measured in the pooled sample of the members of the kindred 
and controls. In this isolate-based pooled sample, the OJ-1 deletion wa,. significantly 
associated with body height (p=O.OOS, adjusted for age and sex). Compared to 110n-
carriers, mean height was 13 cm reduced in homozygotes for the region c:ontai ning 
the OJ-1 deletion. The mean body height in heterozygotes for the deletion was on 
ave rage 5 cm reduced (p for trend =" 0.006). 
Figure 3. Association between the DJ-1 deletion and body height in the original kinclred and 
population contrals 
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Radiographic analysis 
Hanels 
Z-plots of the MCPP profiles of individuals in Branch 1 and Branch 2 of the kindred 
are depicted in Figure 4a and 4b, respectively. Numbers VII-2, VII-3 and VII-6 
(Branch 1, Figure 4a), and VII-7 (Branch 2, Figure 410) represent the homozygous 
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patients. VII·A, VII-5 (Branch 1), VI-2 and VI-3 (Branch 2) are heterozygous for the 
deletion, and VII-l (Branch 1) is not carrying the deletion. All parkinsonism patients 
had metacarpal and/or phalangeal bone lengths, which were at least two standard 
deviations shorter than the general-population mean, represented by the X-axis. 
Cornpared to the heterozygous/wild-type genotype relatives, they represent the 
shortest bone lengths overall in Figures 4a and 4b. 
Figure 4. Z-scores of Branch 1 (a) and Branch 2 (b) 
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The numbers on the X-axis represent hand bones, The)' are listed as metacarpal bones I to 5 
(Me I-Me 5), proximal phalanges I to 5 (PPH l-PPH 5), middle phalanges 2 to 5 (MPH 2-
/VIPH 5) and distal phalanges I to 5 (DPH I-DPH 5). The Y-axis represents the Z-scores. The 
zero line is the genera/-population mean. 
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MCPP prafiles 
In the MCPP profiles of all parkinsonism patients, nadirs were observed at the 
proximal phalanx of digit 1 (PPH1) and middle phalanx of digit 2 (IvIPH2), 
indicating reductions of three to four standard deviations from the general-
population mean. These nadirs at PPH 1 and IvIPH2 were also present in the 
heterozygous relatives in both Branch '1 and 2, albeit to alesser degree. The relative 
in Branch 1 who carried the wild-type genotype, however, also showed a nadir at 
PPH 1. In Branch 1, for the middle phalanges 2 and 3, the heterozygotes displayed 
shorter bone lengths than the relative carrying the wild-type genotype. For all other 
metacarpals, proximal phalanges and middle phalanges, however, there was no 
clear··cut relation of bone length and DJ-1 genotype status (Figure 4a). In Branch 2, 
there is a conspicuous similarity between the profiles of both parents, which may be 
explained by the consanguinity (Figure 4b). 
Contrals 
For comparison, Figure 5 contains a Z-plot of the MCPP profiles of a control group 
of 12 unrelated controls from the same genetic isolate. For better vi"ibility MCPP 
plots only contain information of up to six curves." Therefore, only six indivicluals 
from different nuclear families are shown. The MCPP profiles of the isolate-based 
contrals cluster around the reference line, suggesting no significant dii'ference hom 
the randomly selected contrals fram the general population. Brachydactyly was not 
observed in any of the contral inclivicluals. 
Figurl~ 5. Z-plot of six individuals from independent nuclear families in the same genetically 
isolated population 
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Bone length of the feet was not quantified since a standardizecl methocl was not 
available. On inspection of foot radiographs, short metatarsals were observed, most 
pronounced in the three patients from Branch 1. In these three patients, a pes 
equinus-like deformation was al50 present (data not shown). This cleformity 
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rendered measurement of foot bones in a two-elimensional plane unreliable. The 
patient in Branch 2 also had short metatarsals, albeit to alesser degree. 
Discussiolll 
Body-height phenotype 
In this family with early-onset parkinsonism, we observed a proportionately short 
stature anel brachydactyly. Short stature and brachydactyly can be found in a variety 
of syndromes, 14 but no known short-stature syndrome corresponds to the type of 
brachydactyly observed in our study. 
All individuals in the kindred had some degree of short stature, but the four, 
homozygous, patients had the lowest body height of all. Several aspects of this 
finding need mentioning. Firstly, since short stature is genetically heterogeneous, 
the short stat ure observed in both branches in the kindred could be a familial trait. 
Regarding D)-l deletion status and body height overall (in individuals from the 
kindred and in controls from the isolate), an additive effect in the association with 
body height was noted. Vet on an individual level, the sibling carrying the wild-type 
genotype was not the tallest individual in Branch 1, which possibly indicates the 
presenc:e of other genetic and/or environmental factors acting upon body height. 
Secondly, short stature may be more common in chronic: disease with early onset, 
usually occ:urring secondary to the chronic: nature of the disorder. Short stature, 
however, is 110t a feature of parkinsonism associated with mutations in parkin, the 
other gene for early-onset parkinsonism,15 and therefore, parkinsonism per se is 
unlikely to be responsible for impaired growth since childhood. Thirdly, considering 
the genetic i:;olation of the GRIP population, reduc:ed body height may be alocal, 
genetically cletermined trait not specific to our kindred. Mean body height in 
control:; deri'led from the same genetic isolate was significantly increased compared 
to members of our kindred. Furthermore, the fincling of a 0)-1 deletion in two 
controls with a shorter stature than ave rage (both > 1 standard deviation below the 
gender-specific: means) supports the, highly significant, association between the 
homozygosity region containing the 0)-1 deletion and short stature. 
Brachydactyly phenotype 
The brachydactyly, most pronounced in the proximal phalanx of the thumb and the 
middle phalanx of the index finger, was present in the parkinsonism patients 
(homozygous for the 0)-1 deletion), in the heterozygous relatives of Branch 1, but 
also in the relative with the wild-type genotype. Brachydactyly was neither observed 
in a control group from the general population, nor in a control group from the 
same isolated community. The parkinsonism patients showed a very pronounced 
reduction of the proximal and middle phalangeal bones. In the members of Branch 
1, complete segregation with the 0)-1 deletion (a reduction of bone length by 
number of 0)-1 gene deletions) was observed for only 2 of the bones in the hand. In 
Branch 2, this cannot be fully assessed, since relatives with the wild-type genotype 
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were lacking. The inconsistent relation of brachydactyly with the OJ-1 deletion may 
therefore indicate brachydactyly to be genetically different from the body height and 
the parkinsonism phenotypes. 
Brachydactyly is of ten present in upper and lower distal extremities. 16 A 
standardised method to quantify foot-bone length such as the MCPP profile method 
is not available. Short metatarsals were evident, but a pes equinus-I ike deformation 
in the feet of all th ree individuals from Branch 1 of the kindred rendered 
measurement of bone lengths based on aplanar radiograph unreliable. 
Genetics 
It is not evident which gene or genes are responsible for the short stature and for the 
brachydactyly in this kindred. Firstly, a genomic screen with 10-cM marker spacing 
has been performed on all but three individuals (VII-1, VII-4, VII-S) of the kindred. 1 
The individuals included in the genomic screen shared other homozygous regions, 
but these concerned very common alleles. Vet individuals not included in the 
genomic screen, as weil as the limited inter-marker distance, may have caused 
another homozygosity region 10 remain undetected. Furthermore, this approach 
assumes the mode of inheritance to be recessive. Since the observed phenotype 
(parkinsonism, short stature, brachydactyly) possibly consists of genetically 
independent phenotypes, modelling a trait as recessive may not apply to 
phenotypes such as brachydactyly and height. 
The PARK7 homozygosit)' region,l later shown to contain a deleted OJ-1 
gene, spans about 5.6 Mb and harbours approximately 90 genes. 2 The breakpoints 
of the deletion in this kindred have been cloned; the deletion does not affect other 
known genes or regulatory elements. A gene located elsewhere in the homozygous 
regiol1, however, could account for the association with body height. Therefore, the 
OJ-1 deletion can presently onl)' be considered a 'marker' for short stature and 
brachydactyly. A search for genes in the PARK7 candidate-gene interval with a 
likely function in growth, however, has yielded no obvious candidates 50 far (data 
not shown). 
The observation that four patients from distantly related nuclear families with a rare 
form of early-onset parkinsonisll1 due to homozygosity to the OJ-1 region showed a 
similar degree in reduction in hand-bone length is, however, remarkable from a 
clinical and genetic perspective. Regarding the fact that bone-Iength reduction was 
less pronounced in heterozygotes, this raises the question whether there may be a 
gene in the OJ-1 region that 1l10difies bone length. 
About the other originally reported family with early-onset parkinsonism and 
a OJ-1 mutation, the L 166P point mutation,2 no detailed anthropometric i nformation 
is available to date. To our knowiedge, however, body height and hand size in 
patients and relatives was unremarkable (Bonifati, personal communication). It 
therefore remains to be determined whether short hands and stature are al50 present 
in families segregating other 0)-1 mutations, thus supporting the p:esence of a 
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monogenie trait. More families with mutations in OJ-1 will help delineate its 
phenotype. 
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CI-IAPTER 2.5 
PET neuroimagilng in a kind red with 
DJ-11 assodated parkinsonism 
Abstract 
Mutations in the OH gene lead to autosomal reoessive early-onset parkinsonism. 
In parkin and PARK6 associated parkinsonism, heterozygotes we re shown to have 
mild yet statistically significant dopaminergk dysfunction on functional 
neuroimaging, suggesting the involved gene tn bie haploinsufficient. In order to 
assess th'e effect of one or more 0j-1 mutations upon dopaminergic metabolism, 
we performed 6-[18F]-fluoro-L-3,4-dihydroxYlPhenylalanine (F-OOPA) and [lUF]_ 
fluorodeoxyglucose (FOG) PET neuroimaging in 2 homozygotes (parkinsonism 
patiienits), 3 heterozygotes for a OH mutatiol1l and a non-carrier (clinically 
unaffected). 80th homozygous patients with jJlarkinsonism had, regardless of ithe 
degree of clinical severity, significantly redl.lced f,·OOPA uptake concordant with 
typücal PO, and putaminal FOG hypermetaboliism. In all heterozygotes for a OH 
muitation alild a relative not carrying a deletüol1i, IF-OOPA metabolism was 
unremarkable. From F-OOPA PET imaging in heterozygotes, a 0j-1 do sage effect 
appears to be absent. Oue to the small Inllmber of participants in this study, 
however, dopaminergic function must be assessed in more individuals with OJ-1 
muitations when they become available. 
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Introduction 
Mutations in the DJ-l gene (PAfU<7) are associated with early-onset autosomal 
recessive parkinsonism. 1 DJ-l was ~;uggested to be part of the response to oxidative 
stress,l,3 supporting the long-standing vet still unproven hypothesis of oxidative damage 
in the aetiology of typical Parkinson's disease (PD).4 The exact propeliies of DJ-l, 
however, remain to be determinecl. Since neuropathology of individuals with DJ-l 
mutations is not vet available, functional neuroimaging may provide important 
pathophysiological clues about DJ·l associated parkinsonism in vivo. Some patients in 
the originally described kindred with Dj-1 mutations from The ~~etherlandsl,5 
previously underwent PET anel SPECT neuroimaging. 6 These patients had a 
dopaminergic deficit typical for PO, but a more pronounced bilaterality and 
involvement of the putamen as weil as the caudate nucleus distinguished their pattern 
from typical PD.6,? Furthermore, the patient who underwent PET neumimaging 
displayed diffuse cerebellar hypometabolism of glucose. 6 
6-[lBF]-fluoro-L-3,4-dihydroxyphenylalanine (F-DOPA) PET imaging performed 
in heterozygotes for parkin mutations and the PARK6 haplotype, two other forms of 
recessive parkinsonism,B,9 showed a modest vet significant reduction in dopa uptake on 
F-DOPA PET imaging, inelicating a mild form of preclinical disease ill heterozygous 
inelividuals.lO,ll Neuroimaging studies in heterozygotes for Dj-1 mut2,tions have not 
been performed before. In order to assess striatal dopamine decarboxylase capacity 
and cerebral energy metabolism, we carried out an F-DOPA and allel [lBF]_ 
fluorodeoxyglucose (FDG) PET study in homozygotes, heterozygotes and a non··carrier 
for DJ-l mutations from the original Dutch kindred. 
Methods 
Participants 
Patients with parkinsonism alld their relatives were ascertained within the fran1ework 
of an ongoing study on the genetic determinants of chronic disease, cal led Genetic 
Research in Isolated Populations (GRIP). Two patients in two nuclear families came to 
attention because of their early-onset parkinsonism. Upon clinical examination, two 
more siblings in the first family vvere diagnosed with parkinsonism. By means of 
genealogical research, both nuclear families were shown to have a common al1Cestor 
six generations ago.5 The genetic allalysis of the participants to this study is specified 
elsewhere. 1 Briefly, all parkinsonism patients were homozygous for a deletion of 5.6-
kilobase (kb) in the Dj-1 gene, which renders the gene product absent. Apart from the 
DJ-l gene, no other known genes or regulatory elements are contained within the 
deletion. Because this study coulel possibly concern preclinical pathology, data on age 
and gender of the clinically asymptomatic participants are not givell. This PET-scan 
study has obtained approval of the Medical Ethics Committee of the Erasmus Me. 
Participants in this study have provided informed consent in both stages of the study, 
and have, upon their request, remailled unaware of their genetic status. 
95 
OH MUTATIONS ANO PET IMAGING 
Cl i n ical exam i nation 
Two independent neurologists specialised in movement disorders examined the 
participants in this study. The diagnosis of PO was based on presence of the cardinal 
signs (bradykinesia, tremor and rigidity) and clinical improvement upon 
dopaminergic treatment if applicable. Neurological examination was performed 
blinded to genotype status. 
Neuroimaging 
F-DOPA and FOG PET scans were performed at the PET Centre of the University 
Hospital Groningen. Patients were scanned on a Siemens ECAT Exact HR+ scanner 
(Siemens, Munich/Erlangen, Germany). F-OOPA and FOG scans were performed 
consecutively over a two-day period. One hour prior to F-OOPA administration, 
participants were given 2 mgJkg carbidopa orally in order to block peripheral 
decarboxylation. A bol us injection of approximately 200 MBq was given 
intravenously one hour later. Ninety minutes after injection, '30' PET scans were 
made of the brain in static mode. Scanning time was 6 minutes. Attenuation 
correctiol1 was obtained by means of a standard mathematical algorithm. Regions of 
interest (ROl) were localised and analysed by means of a ROl template. The ROl 
analysis was performed blinded to the genotype status of the participants. The 
striato-occipital uptake ratio index was calculated (striatal uptake minus occipital 
uptake, divided by occipital uptake) by estimation on a pixel-by-pixel basis. For 
reference were used F-OOPA scans of 10 patients with idiopathic PO who had 
undergone I=-OOPA PET scans twice: the first time when newly diagnosed (de 
novo), and the second time two years later. For FDG-scanning, approximately 180 
MBq FOC was injected intravenously 30 minLltes prior to a performing a '30' static-
emission scan over 30 minutes. Attenuation correction was obtained via the 
standard mathematical algorithm. In the FOC PET images, anatomical ROl were 
selected from a larger series of ROl in Talairach stereotactic space using a standard 
template (thalamus; putamen; caudate nucleus; cerebellum; various regions in 
frontal, temporal, occipital and parietal cortex). For each participant, ratios were 
calculated comparing the standard FOC uptake value for each individual ROl to the 
overall-ROl mean of that individual. Reference values for FOC uptake were derived 
from a control group of 13 healthy individuals of approximately the same age range. 
Results 
Clinical E'xamination 
Six members of the originally described kindred with OJ-1-associated 
parkinsonisml,s participated in this study. Two participants with parkinsonism 
(individuals VII-6 and VII-7) were homozygoLis for the deletion. On first 
neurological examination two years previously, individual VII-6 had no complaints 
concordant with parkinsonism, but displayed bradykinesia, rigidity and was 
diagnosed with parkinsonism. Upon examination for this study, patient VII-6 had 
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also developed a tremor. The UPDRS··1I1 score was 22. Oopaminergic medication 
was never required but for symptorns of anxiety, benzodiazepine treatrnent was 
prescribed (diazepam 5 mg dailyl. Patient VII-7 has been clinically described 
elsewhere. 6 In this patient, disease duration was at least 15 years. Briefly, patient 
VIi-7 displayed signs and symptoms of parkinsonism and a good, sustained response 
to levodopa vet complicated by dyskinesias and dystonia. The UPORS-III score on 
medication was 25. Three othel' members from the original kindl'ed were 
heterozygous for the DJ-1 deletion, and one member had a normal genotype 
without deletions. In the latter participants, clinical examination was unremarkable. 
Figure 1. F-DOPA PET imaging 
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Neuroimaging 
F-DOPA and FDG PET results are depicted in Figures 1 and 2. One of the 
heterozygotes did undergo the F-DOPA scan but subsequently declined the FDG 
scan. The striato-occipital ratio index of F-DOPA uptake in putamen and caudate 
nucleus in the two patients (VII··6 and VII-7) was significantly decreasecl (0.82 and 
0.65 for putamen and 1.04 and 0.90 for caudate nucleus, respectively). Compared 
to a group of typical-PD patients, their values were concordant with a disease 
duration of 2 years (Figure 1). In the heterozygous relatives as weil as the relative 
with the wild-type genotype, individual values for the uptake ratio index were 
within the normal range. 
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Both parkinsonism patients displayed FDG hypermetabolism in the putamen 
and to alesser degree in the caudate nucleus (Figure 2a). In two first-degree relatives, a 
homozygote (patient) and a heterozygote, significant glucose hypometabolism was 
observed in the cerebellar, parietal and occipital regions (fourth and fifth bars hom the 
left in Figure 2b). FDG uptake ratios in the other ROl were unremarkable in all 
participants (homozygous, heterozygous, non-carrier). 
Figure 2. Individual FDG uptake ratios by ROL 
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Disclilssion 
In this parkinsonism kindred with rnutations in the OJ-1 gene, we have visualised 
striatal dopaminergic and cerebral glucose metabolism by PET imaging. This is the first 
report on functional neuroimaging characteristics in asymptomatic carriers of a 
mutation in the OJ-1 gene. 
In all clinically unaffected relatives heterozygous for OJ-1 deletions and the 
relative without a OJ-1 deletion, F-DOPA PET imaging was unremarkable. This suggests 
that heterozygosity for a OJ-1 mutation is compatible with a normal presynaptic 
dopaminergic neurotransmitter system in the striatum, and consequently a truly 
recessive property of the OJ-1 gene deletion. Mild yet significant dopaminergic 
dysfunction was reported in dynarnic PET imaging of small groups of heterozygotes 
(n =5 and n=3) for parkin and PARK6-linked parkinsonism. lO,ll The subtie decrease 
obselved in these other forms of recessive parkinsonism indicates that the F-OOPA PET 
results obtained in our study rnay require confirmation in larger patient series. The 
differences between results in the aforementioned studies 10,11 and ours mayalso be due 
to differences in scanning techniques (dynamic10,11 versus static) and concordant 
analyses. A recent study, however, showed no clear advantage of the dynamic 
approach over the static approach. 12 Moreover, the former, dynamic, scanning method 
is a larger burden to patients. 
A further question to be answered is whether heterozygosity for a recessive 
mutation would predispose to typical PO at later age. Ideally, the heterozygous 
individuals in our study should be followed up by neuroimaging in order to detect any 
decrease in dopaminergic function in the future. In a group of late-onset PO patients 
from the same genetically isolated population, however, no Oj-] mutations were 
found,l arguing against a role for a single Oj-] mutation as a susceptibility factor in 
typical PO. 
The two parkinsonism patients (homozygous for a OJ-1 deletion) had 
significantly decreased F-OOPA uptake concordant with observations in typical P07 
and increased FOG uptake in the putamen. The two patients had different degrees of 
clinical severity and different durations of disease (> 15 years in VII-7 versus 2 years in 
VII-66), but both feil within the range of patients with typical PO of a duration of 2 
years (Figure 1). The discrepancy between striatal abnormalities on neuroimaging and 
the clinical phenotype suggests the existence of some unknown compensatory 
mechanism in the basal ganglia, bypas5ing the circuitry that lacks tne OJ-1 protein, 
Simi lar degrees of dysfunction are al50 observed in other menclelian forms,lO,ll 
suggesting a common property of inherited forms of parkinsonism. The possibility 
remains, however, that it is a phenomenon secondary to a long-standing degenerative 
process and reflects the duration of disease. 
On FOG PET imaging, in one of the two parkinsonism patients and a heterozygous 
fi rst-degree relative, uptake ratios were decreased over cerebell um and parietal and 
occipital cortex (Figure 2b). The remarkable similarity between these close relatives 
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suggests another neurological abnormality, whic:h is present in one particular branch of 
the kindred, and not in the other branch. This implies that cerebellar hypometabolism 6 
may not be part of OJ-1 associated parkinsonism per se but rather have resulted from 
another (most likely genetic) defect. The high degree of consanguinity in this family 
could indicate that another gene in the PARK7 region or elsewhere is responsible for 
these abnorrnalities. Unfortunately, no FDG inforrnation was available for the third 
heterozygotes for a OJ-1 deletion. 
In conclusion, our study suggests that dopaminergic function ag rees with 
typical PD in patients homozygous for the Dj-1 deletion, and is normal in 
heterozygotes. More families with Dj-1 mutations are now required for further study. 
Acknowledigements 
This study was supported by a grant from the Netherlands Organisation for Scientific Research 
(NWO) and by the Groningen Academic Hospital (AZG1, The Netherlands. All patients anel their 
relatives, general practitioners and neurologists are thanked for making this study possible. 
Refelrences 
1. Bonifati V, Rizzu P, Van Baren Mj, Schaap 0, Breedveld Gj, Krieger E, et al. Mutations in 
the DH Gene Associated with Autosomal Reces~;ive Early-Onset Parkinsonism. Science 
2003;299:256-9. 
2. Mitsumoto A. and Nakagawa Y. DJ-l is an indicator for endogenous reactive oxygen 
specie:; elicited by endotoxin. Free Radic Res 2001 ;35:885-93. 
3. Mil:sumoto A, Nakagawa Y, Takeuchi A, Okawa K, Iwamatsu A, Takanezawa Y. Oxidized 
forms of peroxiredoxins and DJ-l on two-dimensional gels increased in response to 
subiethal levels of paraquat. Free Radic Res 2001 ;35:301-1 O. 
4. Giasson BI, Ischiropoulos H, Lee VM, Trojanowski JQ. The relationship between 
oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's 
diseases. Free Radic Biol Med 2002;32:1264-75. 
5. Van Duijn CM, Dekker MCj, Bonifati V, Galjaarcl Rj, Houwing-Duistermaat )J, Snijders 
PJLM, et al. PARK7, a novel locus for autosomal-recessive early-onset parkinsonism on 
chromosome 1 p36. Am J Hum Genet 2001; 69:629-34. 
6. Dekkei' MCJ, Bonifati V, van Swieten )C, Leenders KL, Galjaard RJH, Snijders PJLM, et al. 
Clinical features anel neuroimaging of PARK7-linkeel parkinsonism. Mov Disorders, in press. 
7. LeencIers KL, Salmon EP, Tyrrell P, Perani 0, 13rooks Dj, Sager H, ei al. The nigrostriatal 
dopaminergic system assessed in vivo by positron emission tomography in healthy 
volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-8. 
8. Kitacla T, Asakawa 5, Hattori N, Matsumine H, Yamamura Y, Minoshima 5, et al. Mutations 
in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-
B. 
100 
0j-1 MUTATIONS ANO PET IMAGING 
9. Valente EM, Bentivoglio AR, Dixon PH, Ferraris A, lalongo T, Frontali M, et al. Localization 
of a novel locus for autosoma: recessive early-onset parkinsonism, PARK6, on human 
chromosome 1 p35-p36. Am J Hum Genet 2001 ;68:895-900. 
10. Hilker R, Klein C, Ghaemi M, Kis B, Strotmann T, Ozelius LJ, et al. Positron Emission 
Tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism 
associated with mutations in the Parkin gene. Ann Neurol 2001 ;49:367-76. 
11, Khan NL, Valente EM, Bentivogiio AR, Wood NW, Albanese A, Brooks DJ, et al. Clinical 
and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: anl8F-dopa PET 
study. Ann Neurol 2002;52:849:5:,. 
12. Dhawan V, Ma Y, Pillai V, Spetsieris P, Chaly T, Belakhlef A, et al. Comparative analysis of 
striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach. J 
Nucl Med 2002;43:1324-30. 
101 

1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
CH~P1ER 3 1 
1 
1 
1 
1 
1 
1 
1 
1 
SpüRAO\C PARK\NSüN'S O\SEASE 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 

CHAPTER 3.1 
Genetic epidemiollogy of lr1eurologica~ disease 
Absf:rad 
Genetic epidemiology is a young but rapidly developing discipline. Although its early 
years we re largely dedicated to family-based research in monogenic disorders, 
genetic-epüdemiologic research today increasingly focuses on complex, multil'adorial 
disorders. Along with the development of the Ihuman gen ome map and advances in 
molecular t€'chnology grows the importance of genetic-epidemiologic applications. 
Large-s1caie lPopulation-based studies, requiring close integration of genetic and 
epidemioiogic research, determine future research in the field. In this chapter, we 
review the basic principles underlying genetic-epidemiologic research, such as 
moieculaR' genetics and familial aggregation of disease, as weil as the typical study 
appl'Oa<ches of genome screening and candidate··gene studies. 
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Introduction 
Genetic epidemiology is a discipline that covers a broad spectrum of research, ranging 
from studies of disease aggregation in families to studies of the specific molecular 
origin of a disorder. Many developments have contributed to the rapid gmwth of genetic 
epidemiology in the past decade, including the sequencing of the human genome, the 
identification of common genetic variants, and advances in the vast armarnentarium of 
high-throughput methods For studying the human genome. In recent years, research 
interest has shifted from genetic disorders that are caused by a single gene (e.g., 
Huntington's disease) to common multifactorial disorders or complex diseases such as 
Alzheimer's disease, which are likely to result from the interaction of genes and the 
envi ronment. 
This chapter will begin with a discussion of mendelian versus complex (non-
mendelian) neurological disorders, followed by an overview of the st!'ucture of DNA 
and the molecular basis of disease. We will review the methods of genetic 
epidemiology, differentiating family-based studies from population-based studies of 
unaffected individuals. The options for genetic-epidemiologic study designs will be 
presented, with a discussion of strengths and limitations of each approach. Finally, we 
will summarise recent technological developments, and outline important ethical and 
social implications of genetic-epidemiologic research for neurological disordel's. 
Genetic transmissioJ1l of disease 
Mende/ian versus non-mende/ian (comp/ex) diseases 
As a first step in examining the genetic transmission of a disease, classical genetic 
approaches are used to estimate disease heritability. Heritability is the propol1ion of 
the total variance in a trait (or percentage of disease) that can be explained by the 
additive effe cts of genes. Twin studies are the classic method for estimating heritability, 
and studies of the degree of clustering or familial aggregation of disease are also 
valuable. A distinction is of ten made between mendelian and non-mendelian traits. 
Mendelian disorders are usually single-gene disorders caused by eithel' a single 
dominant or two recessive autosomal mutations. Autosomal disease genes are located 
on one of the 22 autosomes, whel'eas sex-linked genes are on either the X or Y sex 
chromosomes. 
For a mendelian disorder, examining the transmission patterns of the disease 
through a family may yield clues to the nature of the mutation involved in the disease. 
If a disorder has an autosomal dominant pattern of inheritance, the disease is expected 
to be present in multiple generations, because having one copy of the mutation is 
sufficient to lead to disease pathology. Since subjects carrying two dominant mutations 
(homozygotes) are rare and of ten incompatible with life, most patients carry only one 
copy of the mutation (hetemzygotes). For a dominant mutation, disease risk is thus 
conferred when an individual receives one mutant form of a gene from either parent.' 
Affected parents will pass on disease to approximately 50% of the offspl'ing, since the 
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probability that the mutant or normal gene is transmitted to offspring is equal. 
Huntington's disease is an example of an autosomal dominant disorder. 
If two defective copies of an autosomal gene are needed to develop disease, a 
mutation is referred to as autosomal recessive. Parents of patients with a recessive 
disorder are most often heterozygous and not affected. Recessive disorders typically 
emerge in consanguineous matings, since these matings increase the probability that 
both parents are carriers of the same mutation. An example of an autosomal recessive 
neurological disorder is parkinsonism associated with mutations in the DJ-1 gene.2 
Cenetic disorders can also be linked to the sex chromosomes. In particular, 
since males only possess one X-chromosome, a recessive mutation may lead to disease 
when only one copy is present whereas in women two defective copies are needed. 
Duchenne muscular dystrophy is a sex-linked recessive disease that shows a typical 
clustering of disease in males, with no male-ta-male transmission. 
A problem in examining mendelian transmission of disease is that mutations 
may not always lead to disease. The cumulative incidence of disease in a mutation 
carrier (penetrance, or the probability that the person develops the disease during life) 
may depend on age, sex and other factors. !Cor many mendelian diseases, the reason 
for reduced penetrance is unknown, but may be related to other genetic or 
environmental factors. The presence of a number of dominant or recessive mutations 
with reducecl age- or sex-related penetrance ma)' result in a disorder that appears to be 
non-mendel ian. 
In contrast to the mendelian inheritallce patterns discussed thus far, the 
inheritance of a non-mendelian or multifactorial (complex) disorder is more diffjcult to 
investigate. Complex diseases, which comprise the majority of neurological conditions, 
are likely to result from several low-penetrance susceptibility genes, each of which 
constitutes a minor contribution to pathogenesis. The relationship between a given 
genotype and phenotype (the observabie trait) is not straightforward. Complex 
disorders are likely explained by the interactioll between multiple susceptibility genes 
(gene-gene interaction), or by the combination of one more susceptibility genes with 
environmental factors (gene-environment interaction). Most common neurological 
disorders such as Alzheimer's disease, epilepsy, Parkinson's disease and multiple 
sclerosis exhibit complex inheritance patterns, which may be the result of expression 
of different genes in combination with exogenous (environmental) exposures. 
Assessment of familial aggregation is the first step in dissecting the genetic 
components of a neurological disorder. Knowledge of the transmission of disease 
(mendelian versus non-mendelian) is crucial for determining the most powerful strategy 
to study the molecular basis of disease. For most complex neurological disorders, 
patients with mendelian disease are relatively rare. Familial aggregation rarely 
comprises more than 10-15 percent of a neurological disorder, and the remaining 
individuals affected are sporadic in nature, with no apparent genetic or environmental 
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causes. The disease aetiology of sporaclic cases is likely to be a complex eombination 
of genetic and environmental factors. 
Ma/ecu/ar basis of neur%gica/ disease 
Genetic information is storecl as deoxyribonucleic acid (DNA). At the molecular' level, 
DNA is made up of a sugar, a phosphate and a base. The DNA sequence is described 
by the order of the bases (adenine, guanine, cytosine, thymine), represented by their 
initials A, G, C, and T. Three-base nucleotides form a codon, which codes from one of 
the 20 amino acids that can be synthesized in the human body. In a process called 
transcription, a string of codons is joined together and copied into single-stranded 
ribonucleic acid (RNA), which i" then processed into protein. Proteins are the building 
blocks of the body's structures such as bone, muscIe, vasculature, neurons, enzymes, 
hormones and neurotransmitters. 
In the 19th century, without knowledge of underlying molecular biology, 
Mendel introduced the term "gene" as the fundamental unit that transmits traits from 
parents to offspring. 1 The most straightforward definition of a gene is the part of DNA 
that encodes for a protein. Genes actually comprise no more than fivE' percent of 
human chromosomes; 3 the large majority of DNA (over 90 percent) does not code for 
proteins. Exons are the parts of a gene that are translated into proteins. Di'-I/\ in the area 
flanking the exons is involved in the regulation and transmission of gene expression. 
Between exons, non-coding regiolls cal led introns occur, and are later removed 
(spliced out) when messenger RNA (mRNA) translates the coding regions (codons) to 
protein. The largest quantity of genomic material lies between genes (intergenic) and 
the DNA in this region has presently unknown function. 
At present, the human genome is estimated to contain 30,000 genes. Mutations 
in exons leading to a change in amino acid in a protein may be pathogenie due to loss 
or gain in the function of the protein. Although introns do not encode for protein, 
mutations in the intronic regions may affect gene spi icing and may subsequently 
change the structure or synthesis of the protein. Nudeic acid changes in the promoter 
region that regulate gene expression can change the level, location or timing of gene 
expression. 
The genetic code is degenerate, meaning that several triplets can code for the 
same amino acid (e.g., the codons A-C-T and A-G-T both code for the same amino 
acid: threonine). Hence point mutations do not always result in changes at the level of 
the amino acid; these silent mutations may be dispersed throughout the population. 
Thus, at one particular locus in the human genome, several forms of the same gene 
(alleles) may exist. These genetic variants are called alleles, and when a variant occurs 
in more than 1-5 % of the population, it is called a polymorphism. Table 1 provides a 
summary of the location of variants in the genome and the expected effects of 
mutations depending on their locatiorl on a chromosome. 
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Table 1. Predicted relative risks for SNPs in candidate-gene association studies according to type, location and functional effect of genetic variant 
Type of genetic Location Functional effect Frequency in Predictive relative 
variant gcnOlTIC risk 
Nonsense rnriino C;PflllPnrp nrpm~fllrp tprm in;::ttinn {)f \/PI\I Ir)\Af \fAn! ctrnna ~~~"'O ~~-,-~' .~~ r-" _ ... _~_. - ~_ ....... _~.~ .. ~. ''''-'1 ......... • ....... J -'''-' ..... ··0 
(exon) amino-acid sequence 
Missense/ coding sequence changes in amino acid in protein to low weak to very strong 
non-synonymous (exon) one with similar properties depending on 
location 
Insertion/deletions coding sequence changes the frame of the protein-coding low very strong, 
(framesh i ft) (exon) region, usually with very negative depending on 
consequences for the protein location 
Insertion/deletions coding or changes amino-acid sequence low weak to very strong 
(in frame) non-coding 
Sense/ coding sequence does not change the amino acid sequence in medium weak to strong 
synonymous (exon) the protein - but can alter spi icing 
Promoter/ promoter, does not change the amino acid but, can low to medium vveak to strong 
reguiatory region untransiated regions affect the ievel, iocation or timing of gene 
expression 
Splice site/ within 10 base pairs might change the splicing pattern or low weak to strong 
intron-exon ofexon efficiency of introns 
boundary 
Intronic deep within introns no known function, but might might affect medium weak 
expression or mRNA stability 
Intergenie non-coding regions no known function, but might might affect high very weak 
between genes expression through enhancer or other 
mechanisms 
Adapted with permission from Tabor et al. 33 
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A distinction commonly encountered in literature is that between mutations and 
polyrnorphisms. At a molecular level, however, this distinction is not clear-cut. 
Mutations have low frequency (generally less than one percent, as high as five percent) 
but are thought to be highly penetrant, resulting in disease pathogenesis in a majority 
of carriers. For example, in virtually all carriers, mutations of the presenilinl (PSEN1) 
gene lead to Alzheimer's disease with an onset before 55 years of age 4 In contrast to 
disease-causing mutations, polymorphisms may not be related to the risk of disease or 
may be associated with only a modest increase in disease risk. They are said to be 
disease-associated rather than disease-causing variants. 
The number of affected nucleotides in a genetic variant can range from a single base 
pair to thousands of base pairs such as the Huntington's disease gene. There are 
several types of polymorphisrns including nucleotide insertions and deletions and 
nucleotide repeat polyrnorphisms, but most polymorphisms in the genome are single 
nucleotide polymorphisms (SNPs). SI\lPs are increasingly utilised in genetic research. 
Table 1 provides a summary of the predicted relative risks for SNPs in candidate-gene 
association studies according jo type and location of genetic variant. This Table 
illustrates how polymorphisms ean be prioritised for study based on the nature of a 
variant and the predicted functional effect on its protein product. 
Example 1. An example of a disease-assaciated palymarphism is the apalipoprotein r,4-allele 
(APOE*4), which has an alle Ie frequellcy of appraximately 17% in Caucas/ans. The risk of 
develaping Alzheimer's disease far carriers of the APOE*4 allele is 1.5-2.5 fald increased5 
Nevertheless, APOE*4 is neither Ilecessary Ilar sufficiellt ta develap Alzheimer's disease. 6 
Methods in genetic epidemiology of neurological disease 
The primary goals of genetic epidemiology are to identify specific genes that contribute 
to the pathogenesis of neurological disorders, and to quantify the impact of a given 
gene or genetic variant on the OCCUITence of a disease in the general population. The 
strength of the association between a genetic variant and disease may be obtained 
either from a cohort study that compares disease incidence in carriers to that in non-
carriers, or from a case-control study that contrasts the frequency of the genetic variant 
among cases and controls. 7 In this section, we describe two different strategies for 
discovering susceptibility genes: genome screening and candidate gene studies. 
Cenome screening 
A genomic screen may be conducted to partially or completely search the genome for 
genes involved in a disorder. This approach often begins with no a priori knowledge of 
the genes that are involved. In some cases, however, linkage studies can have provided 
some information that certain regions on certain chromosomes are more promising 
than others. A genomic screen is carried out by genotyping a set of polymorphic 
markers that are distributed across the genome. Usually, these markers cover all 
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chromosomes and are approximately equally distributed across the genome. In some 
studies, however, markers are distributed more densely in gene-rich regions of certain 
chromosomes or in regions where previous studies have indicated the likely presence 
of a disease-associated gene. These markers are not necessarily located in a gene, but 
often are located in non-coding areas not involved in any biological process. 
The I'ationale behind genome screening is that a causally related mutation or 
polymorph i5m should be found more often in patients than in controls. However, 
given th at the genome contains over 3 billion base pairs,8 the probability that a random 
marker is located at a disease mutation by chance is virtually zero. The basic principle 
underlying genome screening is that our genetic information is linearly arranged in 
chromosomes. Loci physically close together on a chromosome are likely to be 
transmitted together from parent to offspring. Therefore, patients who inherit a disease 
gene from a common ancestor often not only receive the disease mutation, but also 
adjacent parts of the chromosome. Any marker that is physically located near a causal 
mutation should be present more of ten in cases than in unaffected relatives or 
unrelated controls, and can serve to flag the mutation. Using this principle, disease 
genes can be identified by screening the genome of patients by means of a limited 
number of markers covering the genome. 
Example 2. A recent study used poo/ed DNA samples to screen the who/e genome for disease-
associatec! markers in a study of multiple sc/erosis (M5) patients and controls. 9 The genome scan 
was conducted with microsatellite markers spa eed Q,5 centil\1organs apart using DNA pools (i.e" 
combined DNA samples) from 216 1\15 cases, 219 controls and trio families (745 affected 
individuals anel their 1490 parents). Ten markers were associated with 1\15, including three markers 
previously identjfied within the HLA region on chromosome 6p (0651615, 0652444 and TNFa), 
four markers trom regions previously identified in linkage studies, and th ree markers from novel 
sites not yE't found with linkage analysis (0151590 at 1 q; 0252739 at 2p; and 045416 at 4q), This 
stud)' providecl evidence 10 support 1\15-linked regions on chromosomes 6p, 17q, 19q and 1 p. 
Candidate-gene studies 
Candidate--gene studies offer an alternative to genome screening. Investigators who use 
this strategy begin with knowledge of disease pathogenesis and identify promising 
candidate genes. These are genes that may be expected to play a role in disease 
pathogenesi" based on the gene product, the protein, or homology to a gene that is 
known to be involved in the disease. Candidate genes chosen by this method are then 
sequenced from DNA obtained from a number of individuals, with the purpose of 
identifying specific mutations or polymorphisms of a nucleic acid that differ from the 
normal (wild-type) sequence. If a gene has two or more variants (alleles), th en a group 
of cases with a neurological disease can be c:ornpared with a control group to 
determine whether the allele occurs more frequently in one group than the other (i.e., 
an allel ic association). Gene-disease associations can also be examined according to 
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the genotype of an individual. The genotype depends on whether she or he carries one 
normal allele and one variant allele (heterozygote), or two variant alleles 
(homozygote), using the group with two normal alleles (wild type) as the comparison 
group. A dose-response relationship is saicl to occur if the relative risk for homozygotes 
(2 variant alleles) is higher than the relative risk for heterozygotes (1 variant aIleie), and 
this finding strengthens the evielence of a causal relationship between the marker and 
disease risk. 
A major challenge of the candidate gene approach is that a priori knowledge of 
the pathogenesis of the disease is requireel, anel biological evidence must argue for a 
role for a given protein in the pathogenic process before the large expense of 
genotyping assays are justifieel. For a large number of neurological elisorders, 
knowledge of proteins involved in the aetiology is limited or absent. For example, 
before c10ning of the PSEN genes involved in early-onset Alzheimer's disease, the 
presenilin protein and its function were unknown. 4 
Another problem in studies of candiclate genes is that having a :.arge Ilumber of 
candidate genes may create a multiple testing problem because a number of 
associations, even those that are not true, will arise on the basis of chance alone. For 
genomic screens in families with multiple affected generations, established criteria are 
available to adjust for multiple testing basecl on the number of tests th at can be made 
given the size of the genome and the linkage between regions. In the context of 
candidate gene studies, however, adjustment for the multiple-comparison problem is 
not as straightforwarcl: a large Ilumber of candiclate genes, each with several 
polymorphisms of interest, may quickly accumulate a large number of associations that 
require statistical tests of significance. 
EXoilml)le 3. A great number of proteins may be hypothetically involved in diseases such as 
Parkinson's disease, based on proteins detected post-mortem in brain tissue, or on the large number 
of dopamine-regulating proteins in the substantia nigra and striatum such as thE' dopamine 
transporters, dopamine receptors, and the enzymes monoamine oxidasE'-B and tyrosine 
hydroxylase. Given the large number of genes that can be tested in this context, ae/justment of 
statistical significance levels for multiple testing is necessary. If hune/reds of (e.its are performed, 
testing using a significance level of 0.05 will yield a large number of false-positive findings 
(approximate/y 5 false positive findings for every 100 genetic markers tested). For candidate-gene 
studies, the debate on how to adjust for multiple testing is ongoing since standard corrections for 
multiple comparisons such as the Bonferoni method are too conservative. IO• i1 Ahhough adjustment 
for multiple testing is necessary in candidate-gene studies, the need for replication of findings in 
different populations is even more important. False-negative findings mayalso .00502 problems for 
candidate-gene association studies, especia/ly when the frequency of the variant alleles is less than 
5-10%. In this case, only large association studies will have enough statistica I power to detect 
associations. It may be arguecl, however. (hat it is most important to iclentify polymorphic genes of 
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relalively high frequency (e.g., APOE*4, 17%) because a greater percentage of the papulatian risk 
will be attribu;:able ta such genes. 
Figure 1. Linkage analysis ta localize a mutation transmitted through generations 
NA NA NA NA NA NA NA NA NA A NA A A NA A 
This figure depicts two homologous chromosomes of a founding parent (dashed and grey). In one of 
them (indic:ated by the dashed chromosome), a mutation occ:urred, whic:h will be passed down ta 
50 % of the progeny. Each carrier receiving the mutation may pass it down to offspring with a 50% 
probabilit)l. Along with the mutation, an amount of flanking DNA is transmitted. Due to 
recombinatiofl, the piece of DNA shared by patients cOflsecutively becomes smaller over 
generatioflS. In the figure three markers (1,2,3) flanking the mutation are shown. In a genomic 
search, patienrs in the third generation may no longer share marker 1 and 2 of the mutated 
chromosome, but marker 2 still flags the mutation. 
Studly designs in genetic epidemiology 
Family-based study designs 
Family-based study designs are of great importance to the identification of new genes 
and have been the traditional backbone of genetic-epidemiologic research. Several 
reviews of study design options in genetic epidemiology, including family-based 
designs, are available. 12,13 Using linkage studies of extended pedigrees from affected 
families, remarkable progress has been made in unravelling the aetiology of several 
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monogenetic neurological disorders in which there is a clear-cut relation between a 
genetic factor and occurrence of disease (e.g., Huntington's disease, Duchenne 
muscular dystrophy). 
The objective of a I inkage study is to find markers of alleles that are 
preferentially transmitted to affected individuals within a family. Linkage is based on 
the concept that relatives who develop a disease due to the same mutation are 
expected to share alleles on DNA markers that flank the disease mutation. Linkage 
analysis uses the principle of recombination to localise the disease mutation 
transmitted in a family that confers the disease risk. During the proces, of meiosis, 
homologous pieces of chromosomes may cross over, which results in an exchange or 
recombination of the genetic information encoded on the two chrom05omes. Two loci 
close together on a chromosome will more frequently be transmitted together, whereas 
for two loci located far apart, recombination is likely to occur. The closer two loci are, 
the less likely it is that recombination will occur between them, and as aresuit, the two 
loci are linked to each other. By using genetic markers spaced throughout the genome, 
linkage analysis capitalises this closeness, or linking, to find disease-associaled regions 
by identifying markers that are shared by family members affected with the disease. 
Detailed statistical aspects of linkage studies are beyond the scope of this 
chapter. Basically, in a linkage analysis the number of recombinations between disease 
status and a marker allele (observed in a family) is compared to the expected number 
of recombinations under the null hypothesis. The test statistic for linkage is the log 
odds (LOD) score. The LOD score is the log of the likelihood ratio of linkage of the 
disease to the studied marker, versus the likelihood of no linkage. 13y convention, 
significant evidence for linkage is found when LOD scores exceed 3, whereas LOD 
scores below -2 imply exclusion of the region. 
As it is often impossible to clinically distinguish between patients who 
developed the disease due to a specific mutation and those who have a different 
etiology, recombination between the disease and marker may be falsely inferred; 
therefore the power of linkage analysis in complex disorders is low. Family members 
share environment in addition to genes, and the polymorphism-associated risk may 
depend heavily on presence of other genetic or environmental risk factors, a situation 
making linkage studies unfeasible. In this situation, linkage studies are not informative 
regarding the cause of disease. 
An alternative approach to linkage studies for studying complex disorders is a 
family-based study using affected sib-pairs. Siblings share a high proportion (50%) of 
their genetic material including large segments of DNA. The a priori probability of a 
patient sharing 0 alleles with any other sib is 25%; 1 allele is 50%; :z alleles is again 
25%. For markers located close to the disease mutation, affected sibs are expected to 
share more allel es than the average of 1 aIleie. The test statistic for the analysis is based 
on counting alleles shared by a pair of affected siblings. Counb exceeding the 
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expected value under the null hypothesis (1 allele shared) are compatible with a 
disease locus nearby the marker examined. 
An advantage of the sib-pair design is that two siblings with the same common 
disease are rnore likely to have developed the disease due to the same mutation than 
two distantly related subjects. Furthermore, siblings not only share a high proportion of 
DNA, but also large chromosomal regions. In pl'inciple, the disease gene may thus be 
detected with a limited number of markers. The statistical power of sib-pair studies is 
limited, parflcularly if multiple genes are involved,10 and detecting linkage in such 
disorders will require astronomically large numbers of (affected) sibling-pairs. 
The choice of the most powerful study design (linkage versus sib-pair approach) 
requires studies on clustering of disease in families in order to determine whether the 
disorder is segregated as a mendelian or non-mendelian trait. The most powerful 
design for a mendelian disorder is linkage analy·,is, whereas for a non-mendelian trait, 
sib-pair analysis is more suitable. Among patients with a common non-mendelian 
disorder, however, subgroups with distinctly mendelian segregation may be identified. 
For example, linkage analysis has successfully at identified single- gene mutations for 
early-onset forms of Alzheimer's disease and Parkinson's disease.2,4 Although these 
traits are rare and may only explain a minor fraction of disease in the population, 
knowledge of the molecular genetic origin of the disease in these early-onset cases 
may yield clues toward key proteins involved in pathogenesis. These proteins may 
serve as targets in development of therapy for early-onset as weil as late-onset forms. 
When examining familial aggregation, clustering of a disease may not only be 
due to genetic factors, but also environmental factors. For instanee, nutritional habits 
cluster in families and may explain familial aggregation of disease, as might other 
characteristics such as cigarette smoking and occupational exposures. Hypertension, a 
major risk factor for stroke, is a complex conclition showing strong familial aggregation 
and high heritability. Salt sensitivity is known to be a genetically determined risk factor 
for hypertens'on. For example, in a population with a uniformly low salt consumption, 
genetic contribution to the incidence of hypertension will appear to be low because 
the trait will be less likely to be expressed, whereas in populations with larger variation 
in salt intake the contribution of genetically-conferred salt sensitivity may be 
considerable. For complex disorders, familial aggregation is therefore not a fixed 
property of a trait but can vary with the environmental determinants of disease risk. 
Estimating the risk of a disease mutation in families requires ascertainment of a 
random group of unrelated families. Such studies are expensive and time-consuming, 
and this study design is rarely used to estirnate gene-associated risk. For mutations that 
are extremely rare in the population, such as the Illutations involved in early-onset 
Alzheimer's or early onset Parkinson's disease/,4 astronomical sample sizes would be 
needed to observe enough cases of disease. Studies of genetic and environmental 
factors thaI: Illodify the penetrance of disease may only be feasible in those few families 
segregating the rare diseases. 
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Figure 2. Expected allele sharing in aiTectecl and unaffected siblings 
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This figure shows a pedigree of 2 parents and 5 children. Squares indicate ma/es and circles 
fema/es. Since parents pass 1 of 2 alle/es 10 offspring with equa/ probability, sib/ings share 50% of 
DNA on average. On average, two sib/ings share 1 alle/e. 
Popu/ation-based studies 
Family-based studies constitute the classic approach to determine the genetic aetiology 
of a trait, however, only in monogenic or oligogenic (small nurnber of genes) 
mendelian disorders is this approach feasible. With the exception of rare and 
conspicuous phenotypes, a family-·based approach rarely yields sufficient power to 
detect a genetic cause for common disorders. The affected sib-pair design might seem 
to provide an alternative for genetic linkage analysis, but large number" of affected sib-
pairs are required to gain sufficient statistical power in order to detect genes involved. 
For disorders with a high mortality and/or late onset, affected sib-pairs are difficult to 
tra ce, which further limits feasibility. For these reasons, much of the current focus of 
neurogenetic research is on individuals without affected relatives (i.e., sporadic). 
Migraine, epilepsy, Alzheimer/s clisease, and Parkinson's disease are among the 
diseases in this category. 
Recent years have seen the growth of population-based gene association studies 
because some of the limitations of family based-designs can be avoicled through the 
use of population-based study designs. The rationale behind population-based studies 
is similar to family-based studies because the DNA of the disease-associated gene is 
flanked by DNA that is passed to the next generation, and is thus dispersed throughout 
the population. As a result, a mutation related to disease risk can be ascertained in a 
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genomic screen by identifying chromosomal regions shared by patients (Figure 1). This 
unique alignment of genes along the chromosome is called ahaplotype. 
in the general population, it is diffjcult to. perform a genomic screen for markers 
in linkage disequilibrium with a disease because there is only a small probability that 
any two patients with a common complex disorder have inherited a gene from a 
common ancestor. People with a common trait, randomly derived from the general 
populatio.n, are expected to be only very distantly related, and as aresuit, any two 
people only share a small amount of DNA. As shown in Figure 2, the amount of DNA 
shared progressively diminishes over generations. Thus, in order for a disease-
associated marker to identify a region that may contain a disease-associated gene, the 
marker and disease locus must be very close together. A large number of markers with 
dense spacing and an extensive number of patients are therefore needed for whole 
genome screens to be successful. 14 
Samples derived from the general poplilation are very suitable for candidate 
gene studies, vet candidate gene studies have been widely criticised because of the 
repeated faillIre to replicate results. 
Example 4, Extensive candidate studies have been concluctecl on Parkinson's disease. Impairment of 
enzy'me cletox.ification capacity has long been thought to account for an increased susceptibility to 
Parkinson's disease,15 possibly due to an impaired abilit), to handle environmental neurotoxins. 
Two genes encoding detoxification enzymes, the CYP2D6 gene (encoding for debrisoquine 4-
hydroxylase c),tochrome 1'450) and the NA T2 gene (encoding for N-acetyltransferase 2) have been 
studied exrensively. Due to their function in detoxification, these genes were studied as obvious 
candidates. Although initial findings were positive" they could neither be replicated in individual 
studies nor in a pooled re-analysis of study data. 16 Candidate--gene studies have sometimes proved 
more success/ul when used as fol/ow-up studies after linkage or sib-pair studies identify a 
chromosornal region that may contain a disease-associated variant. 
Example 5. APOP4, the most common genetic factor implicated in Alzheimer's disease, was 
primarily discovered by means of the candidate-gene approach after linkage analysis had suggested 
an Alzheimer':> disease gene on chromosome 19. '7 APOE was considered as a positional candidate, 
because it, gene product, apolipoprotein E, was fOl/nd to be associated with seniIe plaques in 
brains of patients with Alzheimer's disease. 
The importance of population-based genetic-epidemiologic studies 
Population-based studies play a pivotal role in the assessment of risks associated with 
genetic: factors. Population studies are needed to assess the frequenc:ies of disease-
c:ausing mutations and disease-associated polymorphisms so that the proportion of 
disease attributable to genetic factors can be estimated. Furthermore, population-based 
association studies are of critical importance for estimating the strength of the 
association between a given genetic variant and the occurrence of a neurological 
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disorder (i.e., the odds ratio or relative risk associated with a given di~,ease-associated 
polymorphism), and for determilling whether environmental or lifestyle factors interact 
with the disease-associated genotype to increase the risk of the disease. 
Risk estimation for genetic factors follows the classical approach of 
epidemiologic studies. Relative risks of disease may be derived from studies comparing 
risk of disease in carriers to that in non-carriers. Alternatively, relative risks may be 
estimated by obtaining odds ratios for the disease-associated genotypes in case-control 
studies using incident patients derived from a single study base. To obtain absolute 
measures of risk, cohort studies are needed to estimate the difference in disease 
incidence between carriers and non .. carriers of a disease-associated variane 
Example 6. Studies aiming to quantiJ'y the incidence of disease associated with comman 
polymorphisms are /agging behinel eleve/opments in ma/ecu/ar genetics. Few swdies have 
addressed the question whether the incielence of A/zheimer's disease is associateel with the 
APOE*4 alle/e. Upon its identification in 1991, most studies have used prevalent AD patients from 
clinic-based series,6 and no popu/ation-basecl studies have been done. For clinical as weil as pub/ic 
health purposes, unbiased risk estimates are essentia/. Ta date, few follow-up stuelies have been 
conducted in order to assess absolute anel re/ative risks of disease for carrier.; ai the APOE*4 
alle/e.!8 
The importance of assessing gene-emriwnment interactions 
For complex genetic disorders where multiple genetic and environmental factors 
contribute to the development of the disease, it is unlikely that a gene effect is 
independent of that of other risk factors. A key aim of neuroepidemiologic studies is to 
examine how environmental factors act against certain genetic backgrounds to increase 
the risk of developing a neurological disorder. It is believed that many complex 
neurological disorders result from one or more environmental factors acting on a 
background of (or in the preSellC€ of) common disease-associated genetie variants. 
Large··scale epidemiologie studies are therefore needed that collect data on genes and 
environmental factors, in order to dissect the complex aetiology of complex 
neurological diseases. 
Challenges in the conduct of gell1etic association studies 
Genetic association studies often face the same challenges as other epidemiologic 
studies and may fail to identify true associations due to factors such as small 
(underpowered) studies, poor ehoice of control group in case-control studies, over-
interpretation of study results, and unwarranted conclusions that a disease-associated 
genetic variant is a causal factor in disease prior to study replication. 1J In addition to 
the usual study challenges, population-based genetic association studies may be 
influenced by a problem cal led population admixture or population stratification. This 
problem may occur when two or more distinct genetic subgroups are included in a 
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study. For example, the odds ratio from a case-control study can be biased if the 
frequency of the disease-associated genetic variant is more common in certain ethnic 
subgroups than other and if the case and control groups have different ethnic 
compositions. Bias due to population admixture may occur in any genetic association 
study, whether it is a cohort (follow-up) study or a case-control study. In a case-control 
study, cases and controls may be drawn from different subpopulations. 
Population-stratification bias can occur in any study where cases and controls 
are not rnatched for their genealogical history, because many genetic variants differ in 
frequency between individuals from different ancestral backgrounds. Several methods 
have been proposed for minimising or controlling for population stratification bias, 
induding, firstly statistical methods to induce comparability, secondly the use of family 
controls from the same genetic background as cases, thirdly the use of unlinked 
genetic markers to determine whether cases and controls have a similar genetic 
background (genomic controls), and finally conducting studies in genetically isolated 
populations where the genetic background of the residents is homogeneous. 
Addressing the admixture problem by using statistical control for ethnicity 
There has been critici sm on of population-based genetic association studies conducted 
in heterogeneous ethnic populations suggesting that population stratification (the 
mixture of individuals from heterogeneOLls genetic ancestries) undermines the validity 
of these studies. Many epidemiologists believe that the problem of admixture is more 
of a theoretical concern and does not introduc:e material biases into a study in most 
real-life c:ircumstances. They propose that population stratification can be adequately 
addressed by collecting information on the genetic: (ancestral) background of cases and 
controls in the study, and controlling for this potential c:onfounder in the same way that 
other confollnding variables are treated in epidemiologie studies. 
Example 7. Using empirical data on the frequency of N-acetyItransferase (NA T2) slow acetylation 
genotypes and incidence rates of bladder cancer among us. Caucasians from eight different 
European ancestries, Wacholder et al. showed that the re/ative risk for the NA T2 - bladder cancer 
association was minimally biased if the subjects' ethnicities were not adjusted in the statistica I 
analysis. 21J The investigators conc/uded that US. studies restricted to non-Hispanic US. Caucasians 
of European origin are unlikely to be significant/v biased, even when statistical methads that adjust 
for different European ancestral backgrounds are not applied. Despite this empirica I evidence, 
many believe the statistica I control method is inadequate for controlling for the diverse genetic 
backgrounds of subjects who participate in a study, and other approaches are proposed, such as the 
use of family contro/s. 
Addressing the admixture problem by using family controls 
In order to overcome the problem of poplilation admixture, the transmissIon 
disequilibrium test (TDT) can be used. Originally, the TDT was used in family-based 
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studies, but it has been adapted for use in population-based studies.:!l Rather than 
ascertaining a control group, allele~, of parents not transmitted to the patients can be 
used to construct a viltual control genotype. 22 A disease-associated allele will more 
frequently than not be transmittecl to the affected individual. The TOT approach 
requires ascertainment of DNA from the parental generation. For late-onset clisorders, 
this approach is of limited value due to the fact that parents are of ten deceased. 
Although variations of the TOT for sibling controls based on siblings have been 
developed to overcome this problem, the power of the sib-TOT is significantly lower 
than that of a case-control approach.:!I 
Addressing the admixture prablem by using genomic contrals 
Another method for dealing with the problem of population admixture is to use genetic 
markers that differ in frequency according to a person's genetic ancestry, but are 
unlinked (not associated) with the c1isease of interest.24 While the genomic control 
method can identify situations in \Nhich the diseased and non-diseasecl groups are 
similar or dissimilar with respect to population admixture, there is currently no rnethod 
whereby the use of unlinkecl markers allows an investigator to statistically adjust for 
differences in population admixture between groups. 
Addressing the admixture prabJem by studying genetic isolates 
Another way of circurnventing distortions due to admixture is to select genetically 
isolated populations for study. The population of a genetically isolated community 
originates from a limitecl number of ancestors (founclers). Such a founder population 
limits the degree of genetic diver~,ijy introduced, leading to a more homogeneous 
population. Cenetic drift, a random process occurring in small poplliations, further 
reclllces the number of putative susc:eptibility genes in these populations. Studies of 
genetic isolates also merit discus,sion because of their potential value in finding disease 
susceptibility genes. 
Studies of genetic isolates 
In genetically isolated populations, there is a higher probability th at patients have 
developed the disease due to a mlltation inherited from a c:ommon ancestor. Finland is 
a prototypic population that is widely studied as a genetic isolate because it has 
experienced isolation for over 100 generations, and expanded from a small group of 
founc!ers into the 5 million inhabitants of today, reslliting in a genetically 
homogeneous population. lO Another example of a genetic isolate is lc:eland. 25 In 
contrast to studies in the general population, genome screens have proven to be useful 
in genetic isolates. lO 
In addition to studies of populations of prolonged isolation, some studies in 
more recently isolated populations have also been successful. In these populations, the 
founc!er effect is the major determinant of the limited genetic variation. 26 Using 
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populations isolated for as little as 300-400 years (i.e., up to 20 generations), genetic 
loci associ2ted with genetically complex disease have been identified, including 
genetic loci associated with manie depression in Costa Rica and susceptibility loci for 
mycobacterial infection in Maltay,28 A method cal led haplotype sharing, as depicted 
in Figure 3, has been applied with success in studies of recent genetic isolates. 26 
FigUire 3. !\llele sharing in a genetically isolated population 
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affected individuals are all descendants from a comman ancestor. 
One drawback of studying genetically isolated populations is the limited value 
of extrapolation of study results from genetic isolates to other populations. Isolation 
that spans over 100 generations may have caused a population like Finland to have 
obtained a more or less "private" make up of the genome. 29 An advantage of studies in 
populations of more recent isolation is th at the genetic make-up of the isolated 
population may more closely resembie that of the general population. However, it 
remains to be determined whether disease-related mutations or polymorphisms 
detected in an isolated population will also be present in the general population. 
On a population level, studies of rare phenotypes caused by mendelian genes 
have made only a limited contribution to our understanding of the occurrence of 
disease in the general population. The challenge for the future for genetic-
122 
GENETIC EPIDEMIOLOGY OF NEUROLOCICAL DISEASE 
epidemiologic research will be lhe identification of genes involved in the aetiology of 
common sporadic neurological disorders. With the shift in genetic-epidemiologic 
research from monogenetic to complex disorders, its study designs will change 
dramatically. As discussed earl ier, the study of complex disorders will see a shift from 
family-based designs to towards sib-pair and population-based studies. This implies a 
trend of data collection towards ascertainment of large series of patients and affected 
siblings in order to reach sufficient statistical power in a study.14 Such studies require 
large-scale genotyping, and therefore, developments in genetic epidemiology will 
depend heavily on advances in high-throughput molecular genotyping techniques. 
Impact of the Human Genome Project on neuroepidemiology 
One of the most important developments in molecular genetics that will boost genetic 
epidemiologie research is the recent completion of the draft of the Human Cenome 
Project. This accomplishment has resulted in an enormous am ou nt of information on 
genes and genetic variation that will greatly benefit genetic research on complex 
diseases. Along with growing insight into biology of neurological disease, the Human 
Genome Project will create oPPoltunities for candidate genes studies. If major 
improvement of the design of studies can be achieved, then candidate gene studies 
may capture a prominent position in genetic-epidemiologic research. Another 
possibility created by the Human Cenome Project is that of including markers for all 
human genes in a genome screen. This approach differs from a classical genome 
screen because it emphasizes the use of markers that are more I ikelv to have a 
functional effect on the protein (approximately five percent of DNA).14 
A technical development important for the feasibility of large-scale genetic-
epidemiologic research is the introduction of microarrays that include (binary) 
information on the presence or absence of polymorphism in a gene, enabling 
thousands of SNPs to be tested 1'01' association with a neurological condition. These 
technical devices will create the opportunity to rapidly screen for DNA mutations or 
variations in large series of affected individuals. 30, 31 In this respect, identification of 
single-nucleotide polymorphism maps (SI\IPs) throughout the human genome is crucial 
(Tabie 1 ).15 Major progress is anticipated in this field within the next decade. 
Ethical, legal and sodal issues in gelletic epidemiology studies 
The ethics of research involving human participants are continuously evolving as 
society changes and as technology advances. Cenetics, more than any other field, has 
undergone a technological explmion leading to greater understanding of disease 
etiology, but also has challenged existi ng concepts of informed consent and 
confidentiality. Investigators involved in genetics research should be familiar with 
published guidelines on the ethical use of collected samples for DNA studies. The 
American Society of Human Genetics published a report in 1996 on informed consent 
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for genetie researeh. 32 This statement provicles reeommenclations for use of newly 
eolleetecl samples for genetie research as weil as for use of existing samples. 
Futme directions and conclusion 
Although the early years of genetic epiclemiology have been largely dedicated to 
family-basecl research in monogenetic disorders, research in the future will increasingly 
focus on complex multifactorial disorders ancl large-scale population-based studies. 
Perhapslhe most dramatic aspects of genetic-epidemiologic research arising from the 
switch of emphasis from mendelian disorders to complex disorders are the implications 
for clinical medicine and public health. In contrast to the limited number of subjects at 
risk for monogenic disorders such as Huntington's disease, clinical and public health 
implications in studies of complex genetie elisorelers are relevant for a large number of 
subjects. Fulure studies on the genetics of multifactorial disease will therefore require 
close integration of genetic anel epidemiologie research. Hitherto unknown proteins 
involveel in disease pathogenesis will be ielentifieel and enable development of 
diagnostic tests for neurological disorelers anel investigation of protein targets for drug 
development to benefit patients. 
Acknowledgements 
MCI Dekker and CM van Duijn are both supported by a grant of The Netherlands Organisation for 
Scientific Research (NWO). 
Referen ce~; 
1. Speer MC Basic concepts in genetics. In: Haines j, Pericak-Vance MA, et al. Approaches to 
gene rnapping in cornplex hurnan diseases. Wiley-Liss, 1998, pp 17-49. 
2. Bonifati V, Rizzu P, van Baren Mj, Schaap 0, Breedveld Gj, Krieger E, et al. Mutations in 
the D)-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism. Science 
2003;299:256-9. 
3. Nowak R. Mining treasures from "junk" DNA. Science 1994;263:608-10. 
4. Van Broeckhoven C, Backhovens H, Cruts M, De Winter G, Bruyland M, Cras P, et al. 
lv\applng of a gene predisposing to early-onset Alzheimer's disease to chromosome 
14q24.3. Nat Genet 1992;2:335-9. 
5. Slooter AL van Duijn CM. Genetic Epidemiology of Alzheimer's disease. Epidemiol Rev 
1997;1:107-19. 
6. Farrer LA, Cuppies LA, Haines IL, Hyman B, I<ukull WA, Mayeux R, et al. Effects of age, 
sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer 
disease: a meta-analysis. lAMA 1997;349: 1349··56. 
7. Rothrnan Kj, Greenland S. Modern Epidemiology. Philadelphia PA: Lippincott-Raven, 1998. 
8. van Ommen Gj, Bakker E, Den Dunnen F. The human genome and the future of 
diagnostics, treatment, and prevention. Lancet 1999;354 (51):5-10. 
124 
GENETIC I::PIDEMIOLOGY OF NEUROLOGICAL DISEASE 
9. Saweer S, Maranian M, Setakis E, Curwen V, Akesson E, Hensiek A, et al. A wllGle genome 
screen for linkage disequilibriurn in multiple sclerosis confirms disease associations with 
regions previously linked to susceptibility. Brain 2002;125:1337-47 
10. Lander ES, Sc hork NJ. Genetic dissection of complex traits. Science 1994;265:2037-48. 
11. Lee Wc. Testing for candidate gene linkage disequilibrium using a den!;e array of single 
nucleotide polymorphisms in case-parents studies. Epidemiology 2002;13:545-51. 
12. Zhao LP, Hsu L, Davidov 0, Potter J, Elston RC, Prentice RL. Population-based family study 
designs: an interdisciplinal'Y research framework for genetic epidemiology. Genet 
Epidemiol 1997;14:365-88. 
13. Whittemore AS, Nelson LM. Study design in genetic epidemiology: theoretical and practical 
considerations. J Natl Cancel' Inst Monogr 1999;26:61-9. 
14. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 
1996;273:1516-7. 
15. McCann SJ, Pond SM, James KM, Le Couteur DG. The association between polymorphisms 
in the cytochrome P-450 206 gene and Parkinson's disease: a case-contra I study and meta-
analysis. J Neur Sci 1997;153:50-3. 
16. Nicholl DJ, Bennett P, Hiller l., 130nifati V, Vanacore N, Fabbrini G, et al. A study of five 
candidate genes in Parkinson's disease and related neuradegenerative disorders. Neurology 
1999;53:1415-21. 
17. Pericak-Vance MA, Bebout JL, Gaskeil PC Jr, Yamaoka LH, Hung WY, Alberts MJ, et al. 
Linkage studies in familial Alzheimer's disease: evidence for chramosome 19 linkage. Am J 
Hum Genet 1991;48:1034-50. 
18. Slooter AJ, Cruts M, Kalmijn S, Hofman A, Breteler MM, Van Braeckhoven C, et al. Risk 
estimates of dementia by apolipoprotein E genotypes from a population-basecl incidence 
study: the Rotterdam Study. Arch "'leur 1998;55:964-8. 
19. Cardon LR, Bell JI. Associatioll study designs for complex diseases. Nat Rev Genet 
2001;2:91-9. 
20. Wacholder S, Rothman N, Caporaso N. Population stratification in epidemiologic studies 
of common genetic variants allel cancer: quantification of bias. J Natl Cancer Inst 
2000;92:1151-8. 
21. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population 
stratification in association studies. Am J Hum Genet 1999;65:220-8. 
22. Ewens WJ, Spielman RS. The transmissionl disequilibrium test: history. subclivision, 
admixture. Am J Hum Genet 1995;57:455-64. 
23. Slager SL, Huang J, Vieland J. Effect of allelic heterogeneity on the power of the 
transmission disequilibrium tes!. Genet EpidemioI2000;18:143-56. 
24. Ardlie KG, Lunetta KL, Seielstad M. Testing for population subdivision êlnd association in 
four case-control studies. Am J Hum Genet 2002;71 :304-11. 
25. Mclnnis MG. The assent of a nation- genethics and leeland. Clin Genet 1999;:55:234-9. 
125 
GENETIC EPIDEMIOLOCY OF NEUROLOCICAL DISEASE 
26. Houwen RH, Baharloo S, Blankenship K, Raeymaekers P, Juyn l, Sandkuijl LA, et al. 
Genome screening by searching for shared segments: mapping a gene for benign recurrent 
intrahepatic cholestasis. Nat Genet 1994;8:380-6. 
27. Freil1ler NB, Reus VI, Escal1lilla M, Spesny M, Sl1lith L, Service S, et al. An approach to 
invesrigating linkage for bipolar disorder using large Costa Rican pedigrees. Am J Med 
Genet 1996;67:254-63. 
28. Newport Ml, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, Williamson R, et al. A 
l1luto1lion in the interferon-gamma-receptor gene and susceptibility to mycobacterial 
infection. N Engl J Med 1996;335:1941-9. 
29. De La Chapelle A, Wright F. Linkage clisequilibriul1l mapping in isolated populations: The 
e,:ample of Finland revisited. Proc Natl Acad Sci U SA 1998;95:12416-23. 
30. Wang DG, Fau JB, Siao Cl, Bemo A, Young P, Sapolsky R, et al. Large-scale identification, 
mapping, and genotyping of single-nucleotide polymorphisms in the human genome. 
Science 1998;280:1077-82. 
31. C:heung VG, Gregg JP, Gogolin-Ewens Kj. Berno A, Young P, Sapolsky R, et al. Linkage 
disequilibrium mapping without genotyping. i'lo1t Genet 1998;18:225-30. 
32. ASHC report. Statement on informed consent for genetic research. The American Society 
of Human Genetics. Am J Hum Genet 1996;59:471-4. 
33. Tabor HK, Risch Nl, Myers RM. Opinion: Candiclate-gene approaches for studying complex 
genet ic traits: practical considerations. Nat Rev Cenet 2002;3:391-7. 
126 
CHAPTER 3.2 
A clinical-genetic study of Parkinson's d1ise,i:lSi~ 
in a genetiGlll!y isolated community 
Abstralct 
The role of genetic factors in idiopathic, laf:e'·onset Parkinson's disease (PO) remains 
unclear, in spite of the recent advances in the genetics of early-onset forms of 
familial parkinsonism. There is increasing interest in using genetically isolated 
populations to unravel the genetics of complex diseases such as late-onset PD. We 
hav,e studied genetic and clinical features oir 109 patients with parkinsonism from an 
area cornpl'Ïsing a genetically isolated popula1tion in the South-West of The 
Netherlands. Of the 109 patients with parkinsonism, 41 patients with PO could be 
linkedl to a common founder 14 generations ago. lhe distribution of ages at onset of 
PO in 1the g{~netica"y isolated population was signiificantly bimodal (one peak vvith a 
mean at agl:' 67 years and another with a mean at 44 years, the young peak being 
significantly larger than that in a populatiol1-based study, the Rotterdam Study). For 
other dinical features, the only statistically significant difference between early-
onset anc! late-onset PO was decreased motor anel cognitive function in the patients 
witt! late-onset PO. Involvement of other PD genes including OJ-l, a gene implicated 
in a kindmd wÎth early-onset parkinsonism from the same genetic isolate, was 
excludec! in other PO patients in the population. The fil1ding of a common ancestor 
in 41 idiolPathic-PO patients along with the e"dusÎol1 of known PO genes and loci 
suggests the presence of at least one other, yet ul1known, susceptibility gene involved 
in PlO in Ihis population. 
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Introduction 
A genetic contribution to Parkinson's disease (PO) has been suspected since the late 
19'h century.' At present, four genes have been identified in famil ia! parkinsonism. 
Mutations in the alpha-synuclein gene (chromosome 4q22) are implicated in 
autosomal dominant parkinsonism,2 and a mutation in the UCH-L 1 gene (chromosome 
4p14) was found in a family with autosomal dominant parkinsonism 3 The most 
common cause of early-onset parkinsonism with autosomal recessive inheritance 
consists of mutations in the parkin gene (chromosome 6q25.2-q27).4 Another gene for 
autosomal recessive parkinsonism, OH (chromosome 1 p36),5 is implicated in, 
amongst others, a kindred from the genetically isolated population in which the current 
study was performed. Other loci lor familial parkinsonism were reported on 
chromosomes 1 p36/,7 2p13, 8 4p14-16.39 and 12pl1.2-q13.1. 10 Finally, a ~;usceptibility 
gene for late-onset PO in the Icelandic population was mapped on chromosome 
1 p32. 11 In spite of these promising developments, the cause of PO in the majority of 
patients is still unknown. A heritability study in twins suggested that genetic factors 
may play a key role in early-onset, but less 50 in late-onset PO. 12A major obstacle in 
dissecting the genetics of late-onset idiopathic PO is the weak familial aggregation, 
which may only become evident when studying distant relatives of an affected 
individual. This is possible when extensive genealogical data of the study population 
are available, as is the case in Iceland. Icelandic PO patients, randomly ascertained and 
previously thought to be largely unrelated, could be traced back to a common ancestor 
by using a genealogic database. '113 The Icelandic population has, however, been 
isolated over a large number of generations, such that findings may be of limited 
relevance to other populations. 
We performed a pedigree study of idiopathic-PO patients in a young genetically 
isolated population in The Netherlands in order to evaluate the extent of relatedness 
among PO patients. PD-candidate genes and loci were assessed on a possible 
contribution to PO in our study population. To test whether the phenotype of these 
patients was representative of PD in the general population, we compared clinical 
characteristics of PD to those in the Rotterdam Study, a population-basecl study in The 
Netherlands of 7,983 subjects aged 55 years and over. '4 
Methods 
Patients 
Patiel1ts were derived from a genetic:ally isolated community in the Southwest of The 
Netherlands. The stud)' is part of a larger research programme named Genetic 
Research in Isolated Populations (GRIP), which is ongoing in this population. Around 
1750, the population consisted of a mere 150 individuals. Demographically, the GRIP 
population is characterised by minimal inward migration and rapid population growth 
over the last two centuries. Descendants of this population, an estimatecl number of 
20,000 individuals, are now scattered over eight adjacent villages. Church and 
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municipal registers are readily available and date back to the 1800s. Genealogical 
history up to 1600 has been computerised to a large extent. The Medical Ethics 
Committee of the Erasmus MC approved of the scientific protocol of GRIP. 
Patients with parkinsonism were traced through registered general practitioners, 
neurologists and nursing-home physicians, whom were asked about all of their patients 
with parkinsonism. The catchment area consisted of the genetically isolated area and 
its surroundings. An extension to a 20-km rac!ius was made because several PD 
patients, bom and raised in the GRIP area, had been admitted to nursing homes in 
nearby communities. According to the GRIP research-protocol, patients were invited 
by their treating physician to participate in the study. All patients provided informed 
consent, firstly to their own physician and secondly to the research physician. Their 
medical records, and, if available, CT and/or nuclear magnetic resonance (NMR) scans 
of the brain were obtained and reviewed. In all patients, we carried out a questionnaire 
on age al onset, presenting and subsequent symptoms (tremor, rigidity, bradykinesia 
and asymmetry), medical history, medication anc! exposure to putative risk factors for 
PD. 
Clinical exarnination 
The research physician performed a neurological examination in each patient, 
including motor assessment according to the Unified Parkinson's Disease Rating Scale 
(UPDRS). Parkinsonism was diagnosed when at least two out of three cardinal signs 
(bradykinesia; rigidity; resting tremor), as weil as clinical improvement on dopamine or 
dopaminergic therapy were present. The diagnosis of idiopathic PD was established 
af ter exclusion of other causes, and was verified by two independent neurologists, 
according to criteria of EUROPARKINSON as applied in the Rotterdam Study.15 Age at 
onset wa~; defined as the age at which the diagnosis of PD was established. UPDRS,16 
Hoehn and Yahr17 and Mini Mental State Exam (MMSE)18 scores were obtained as 
described elsewhere. 15 For the diagnosis of dementia in PD, onset of PD had to clearly 
precede cognitive decline. Medical records were therefore reviewed in order to assess 
onset, degree and rate of cognitive decline in all patients with an MMSE score below 
24 point,. In PD patients with cognitive or physical conditions hampering reliable 
neurological examination and UPDRS assessment, lJPDRS scores were excluc!ed from 
the statistical analysis (n = 1 0). The MMSE was not performed in patients declining the 
test (n = 31 ancl in patients with profouncl dementia (11 = 6). Basic cl inical characteristics 
such as age at onset of PD were also assessed in patients derived from the baseline 
study population at the start of the Rotterdam Study, a population-based study in The 
Netherlands of 7,983 subjects aged 55 years and over. 14 
Genealogy 
Data 011 pre,ellce of PD, essential tremor and dementia in first-, second- and third-
degree relatives were collected by a family-history questionnaire. Genealogical 
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information such as name, date and place of birth of parents and granclparents was 
obtained from the participants. By means of local municipal, church and computerised 
registers, this information was extended up to 16 generations. In order to detect any 
subclinical or untreated parkinsonism, first-degree relatives of patient~; underwent 
neurological examination. 
Cenetics 
From each patient, 20 mi of venous blood was obtained for ONA isolation. 13100d was 
also collected from relatives including parents (if alive), spouses, children and sibs. In 
all PO patients the 0)-1 gene was sueened for mutations by means of a peR protocol 
specific for the deletion observed in the community. The parkin gene was screened for 
mutations by direct sequencing in 6 out of 7 patients with early onset of poY All 
otller known PO loci and genes were studied in a subset of distantly related patients 
(n = 20). On Iy distantly related patients were selected, since the inclusion of closely 
related patients would in that respect lead to dependency arnongst genetic 
obselvations. Cenetic markers flanking all known PO genes and loci 2-11 were therefore 
studied in 3 of 7 early-onset distantly related PO patients, and in 17 of 34 late-onset PO 
patients, also distantly related. Only a subset of patients was studied due to a transient 
delay in data collection at the time of the candidate-gene study. At chromosome 4q22 
the markers 045414 and 0451572 were assessed (alpha-synuclei n, PARK 1); at 
chromosome 6q25.2-q27 markers 0651581 and 065264 (parkin, PARK2); at 
chromosome 2p13 markers 025337 and 0252368 (PARK3); at chromosome 4p14-
16.3 markers 045419 and 0451592 (PARK4); at chromosome 4p14 markers 045419 
and 045405 (UCH-L 1, PARK5); at chromosome 1 p35-36 markers Dl 5199 and 
015234 (PARK6); at chromosome lp36 markers 015468 and 015214 (0)-1; PARK7); 
at chromosome 12pll.2-q13.1 markers 012585 and 0125345 (pA R K8) , at 
chromosome 1p36 markers 01S234, 015199 and 0152697 (PARI<9), and at 
chromosome 1p32 markers 01S2797, 0152890 and 015230 (PARK10). 
Statistica! methods 
5tatistical analysis of clinical clata was performed using Mann-Whitney and Fisher's 
exact tests, with degrees of significdnce expressed in (two-sided) p-values .. For the age-
at-onset graph, in order to assess modality (i.e., the presence of one versus that of 
multiple distributions), the distribution of age at onset of PO was plotted as the natural 
logarithm of onset age versus frequency of onset age amongst patients. 19 5tatistical 
evidence for linkage of the aforementioned genetic markers to PO was assessed using 
the 015LAMB programme.20 
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Table 1. Clinical features in 7 early-onset « 55 yrs) and 34 late-onset (> 55 yrs) patients with 
idiopathic Parkinson's disease from the genetically isolated population 
Early-onset PO Late-onset PO 
« 55 years) (? 55 years) 
n=7 n =34 
Wornen (nurnber) 3 (43%) 24 (71%) n.s. 
Mean age at onset (years) 44.6 (±4.8) 67.1 (±6.5) p<O.OOOl 
Mean duration of illness (years) 7.0 (± 71) 5.6 (±4.3) n.s. 
Levodopa treatrnent 6 (86%) 31 (91 %) n.s. 
daily closage (rng/day) 497 (±411) 541 (±470) n.s. 
dyskinesia/dystonia (nurnber) 3 (43%) 7 (21%) n.s. 
Clinical syrnptorns at onset (nurnber) 
trernor 7 (100%) 25 (74%) n.s. 
bradykinesia 3 (43%) 23 (68%) n.s. 
asymrnetry" 7 (100%) 22 (73%) n.s. 
Clinical signs at exarnination 
(number) 
rigidit/) 6 (100%) 24 (96%) n.s. 
Bradykinesiab 6 (100%) 23 (92%) n.s. 
resting trernorb 6 (100%) 17 (68%) n.s. 
Mean HOE'hn and Yahr score at exarn 2.3 (±0.9) 2.8 (±1.1) n.s. 
Mean UDPRS score at exarnination b 17 (±5) 29 (± 11) P<0.05 
Mean MMSE,core at exarnination C 29 (±3) 25 (±4) P<0.05 
MMSE score < 24 C (nurnber) 1 (14%) 15 (44%) n.s. 
Farnily history cl (nurnber) 
Parkinson's disease 0 3 (9%) n.s. 
Essential tremor 0 3 (9%) n.s. 
Dernentia 2 (29%) 6 (1 ~)%) n.s. 
,) About laterality at onset, information was not avai/able in four late-onset patients. b Due to 
dementia, or due to motor impairment in physical conditions, no reliable neurological examination 
cou/cl be performed in 9 late-onset patients and ol1e early-ol1set patient. These patients were 
exc/uded frolT! .'he UPDRS scores. C Nine late-oflSet patients did l10t take the Mini Mental State Exam 
(th ree dec!ining cooperation; six due to profound dementia). cl In 1 st-degree relatives. 
UPDRS 0' Unilïecl Parkinson's Disease Rating Scale; lvlf'vlSE = Mini Mental State Exam; n.s. =not 
signitJcant 
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Of 113 individuals with parkinsonism ascertained from the genetically isolated 
population and its surroundings (Figure 1), 109 subjects (44 men, 65 women) were 
willing to participate in the study. Alter clinical and genealogical worle-up, 52 of 109 
parkinsonism patients had no ancestors hom the GRIP region. The rel11aining 57 (52 
percent) were linked to one coml11O!"1 ancestor 14 generations ago. Of the 57 patients 
from the genetically isolated population, 16 were excluded from the present study of 
idiopathic PD. Of these 16 patients, 11 had other causes of parkinsonisl11 (i .e., previous 
stroke in two patients, non-progressive syl11ptoms in five patients and suspicion of 
Lewy Body disease in four patients), four early-onset patients were shown 10 have Oj-1-
Iinked parkinsonism S,21 and one had early-onset parkinsonism with additional 
neurological and dysmorphic syl11ptol11s suggestive of a different aetiology. In the 
remaining 41 patients, the clinical features were compatible with idiopathic PO, 
Figure 1. Ascertainment of 41 idiopathic-PD patients in the genetically isolated population 
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In the study population at large, the ave rage age at onset of idiopathic PO was 63.3 
years. When plotting ages at omet (Figure 2), the distribution was found to be bimodal. 
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Assuming a log-normal distribution with equal variances, the hypothesis of a unimodal 
distribution was rejected in favour of the bimodal distribution (p = 0.0001). Based on 
peaks in this bimodal distribution, the geometrical mean in the age-at-onset distribution 
was 44.3 years in early-onset PO, and 66.8 year~; in late-onset PO. Using a cut-off point 
of 55 years, as in the Rotterdam Study'5, seven patients (17 percent) had a disease 
onset below age 55 years (early-onset PO), and 34 patients (83 percent) an onset at or 
over age 55 years (Iate-onset PO). 
FigUire 2. lJistribution of age at onset of idiopathic PIJ in the genetically isolated population 
0.0 
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Clinical features of the seven early-onset and 34 late-onset patients with PO are 
comparecl in Table 1. The duration of illness was similar in both groups (7.0 years in 
the eariy-·onset group compared to 5.6 years in the late-onset group). Levodopa 
treatment had been administered in 37 patients, whereas four patients had received 
amantadine or dopamine agonists only. Orug-incluced dystonia and/or dyskinesias 
were reported in 43 percent of early-onset and in 21 percent of late-onset PO patients, 
but this difference was not statistically significant. All patients with early-onset PO had 
resting tremor and an asymmetric pattern as presenting symptoms at disease onset. 
These symptoms were less frequent, although not significantly so, in the late-onset 
patients (74 percent for resting tremor, and 73 percent for asymmetry). At neurological 
examination, the early-onset and late-onset patients did not differ significantly with 
134 
PARKINSON'S DISEASE IN A GEr'-JETIC ISOLATE 
respect to rigidity, bradykinesia or resting tremor. The UPORS score of the early-onset 
patients (17 ± 5), however, was significantly better than that of the late-onset patients 
(29 ± 11 ,p = 0.012). Furthermore, patients with early-onset PO had significantly better 
MMSE scores than those with late-onset PO (p=0.025). Neuroimaging, available in 26 
out of 41 patients, showed age-conc:ordant cerebral atrophy in seven patients and a 
lacunar infarct in three patients. In the remaining patients, neuroimaging was 
unremarkable. 
Figure 3. Pedigree of 41 idiopathic-PD patients hom the genetically isolated population 
. " 
* 
* * * 
* 
The filled symbols denote PO patients, and those marked with an asterisk earl)l-onset PO patients. 
The arrow indicates the common ancestor. 
Genea/ogy 
Few patients had a positive iamily history for PO, essential tremor and dementia in 
first-degree relatives (see Tablel ). Although only three patients reported a positive 
family history for PO in first-degree relatives, a large pedigree could be constructed 
(Figure 3) in which the seven early-onset patients (filled symbols with asterisks) and the 
34 late-onset PO patients (iilled symbols) were all connected to one common ancestor. 
The entire pedigree contains 601 individuals spanning 14 generations. The pedigree 
depic:ted in Figure 3 is constructed in such a way that the largest possible number of 
patiel1ts could be linked to the closest common ancestor. Multiple links between 
patiel1ts exist, but are not shown in this figure. Some patients could not be linked to 
another patient in a shorter way than through c:ommon ancestors up to 14 generations 
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ago. E ighty·-th ree percent (34/41) of patients, however, cou Id be connected to another 
patient within at most eight generations. When comparing separate pedigrees of the 
late-onset and early-onset groups of PO patients,. patients with early-onset PO were not 
more closely related to one another than patients with late-onset PO. The pedigrees of 
early-onset and late-onset PO patients could thus be merged to make one large 
pedigree. 
Genetics 
None of the 41 PO patients in this study c:arried mutations in the 0)-1 gene. No parkin 
mutation" were detected in the tested early-onset patients. Other known PO genes and 
loci (studied in 3 out of 7 early-onset patients and in 17 out of 34 late-onset PO 
patients) showed no common haplotype for markers flanking candidate genes. 
Furthermore there was no evidence for association to the disease with any of the 
markers surrounding the genes and loci on chrolTIosomes 4q22, 6q25.2-q27, 2p13, 
4p14-16.3, 4p14, 1 p35-36, 1 p36, 12p11.2-q13. 1 and 1 p32. 
Discussiol1l 
In this study, we show that out of 109 patienis with parkinsonism, a group of 41 PO 
patients could be linked to one common anc:estor 14 generations ago. Between early-
onset anel late onset PO, few features differed significantly. Involvement of all known 
PO genes could be excluded. 
In genetically isolated populations, di"orders may present with a different 
phenotype compared to the general population. The size of the group of patients we 
studied was limited by the fact that they were derived trom a small community and 
therefore warrants caution in the interpretatioll of differences between sub-groups. 
Howevel', in terms of presenting and subsequent symptoms, PO patients in our study 
resembied PIJ patients from the Rotterdam Stud)!.1s 
The earl ier onset of PO in our study was nevertheless remarkable. In our study 
population overall, the ave rage age at onset of idiopathic PO was 63.3 years, which is 
lower than the ave rage age at onset observed in prevalent PO-patients included at 
baseline in the Rotterdam Study (71 years),'" and than that observed in a large 
European stuely (72 years).22 This coulel partly be explained by a high proportion of 
early-ollset idiopathic PO in the genetically isolated population (17 percent), which 
was higher than that observed in PO patients at baseline in the Rotterdam Stuely (five 
perc:ent).IS The Rotterdam Study, however, only included in its follow-up those subjects 
surviving to be 55 years anel oleler. Excluding from our study group all early-onset 
patients, the mean age at onset in the ieliopathic-PO patients from the genetically 
isolated population increased to 67.1 years, whic:h is still significantly lower than the 
mean age at onset in the Rotterdam 5tudy (p<O.OOl). 
Olle explanation for the early age at onset of disease in our patients may be 
selection bias in favour of patients with early onset of disease. Our patients we re, 
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however, ascertained through general practitioners based on the diagnosis of PO and 
use of dopamine and dopaminergic medication. Previously was shown that in The 
Netherlands, over 88 percent of PO patients can be ascertained in this way" and health-
care facilities in the GRIP population closely resembie those elsewhere in the 
country.15 Moreover, the overall participation rate in our study was high (109 out of 
113 patients). Participation bias in early-onset patients (due to a greater disease 
awareness in individuals affected at a younger-than-average age) was therefore less 
likely to occur. The proportion of women in the late-onset PO sample from the 
genetically isolated population (71 percent) approximates the 65 percent female PO-
patients observed in the Rotterdam Study,15 which suggests that our ascertainment 
procedure led to a series of patients similar to that obtained in a door-to-door survey 
such as performed in the Rotterdam Study. In the early-onset PO patients in our study, 
the proportion of women is 43 percent, which ag rees with the approximately equal sex 
ratio reported in another study of early-onset PO patientsY These findings make a high 
percentage of early-onset PO by biased ascertainment less likely. FUlthermore, the 
geile implicated in early-onset parkinsonism in the local population 5 may represent a 
locally larger genetic burden in PO, resulting in more early-onset disease, 12 
Bimodality in idiopathic-PO onset-age distribution was present in PI) patients in 
our population (p<O.OOOl), but also in the Rotterdam Study, albeit of lesser 
significance (p = 0.03). Both geometrical means of the peaks in the Rotterdam Study 
were, however, positioned in the late-onset range of onset over 55 years (57 and 76 
years).15 This phenomenon could therefore be an artefact caused b)' a population-
dynamic bottleneck in the general population (with a subsequent 'baby-boom'). From 
general demographic and genealogical data in the GRIP population anel the Rotterdam 
Study, however, no such bimodality in age distribution could be noted (unpublished 
material). This suggests lhat the bimodal pattern is a PO-specific entity in our genetic 
isolate. The earlier-positioned age peak for PO in the GRIP population cornpareel to the 
Rotterdam Study along with the finding of a larger genetic contribution in early-onset 
P012 points to another genetic factor 1'or PO in our genetically isolated population. 
As also appears from other neurodegenerative diseases such as Alzheimer's 
disease, neurological signs anel syrnptoms show few differences between early-onset 
and late-onset PO. 15,23 Motor anel cognitive performance scores were significantly 
worse in late-onset PO compared to early-onset PO, while the duration of disease was 
similar in patients with late and early onset of PD. Furthermore, PO-related cognitive 
decline occurred nearly exclusively in the late-onset patients. These are significant 
differences between early-onset and late-onset PO, but may not necessarily represent 
distinct clinical phenotypes or genetic causes. 
The genealogical studies linking 41 patients with idiopathic PD to a common 
ancestor show that familial aggregation of PO may become evident b')' availability of 
extensive genealogical information. '3 The possibility cannot be exclucled that the 
familial aggregation of PD patients is a chance finding. Unfortunately, no control 
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population was available from the same community to test for excess familial 
aggregation amongst PO patients. Even without a reference population, however, the 
common ancestor in these patients may indicate that PO patients in our genetic isolate 
can share a genetic risk factor. This risk factor is likely to only have low penetl'ance, 
since no consistent inheritance pattern for PD could be deduced from pedigree or 
family-hi5tory information on patients in our study. 
The candidate-gene study did not show association of PO with presently known 
genes. lVIutations in OJ-1, a gene for early-onset, autosomal recessive parkinsonism 
recently identified within the framework of Dur study, are frequent in the GRIP 
population, having a carrier frequency of almost one percent. 5 On the contraly, no 
mutation:; in DJ-1 were found in 380 control samples from the directly surrounding 
area anc! from elsewhere in The Netherland5. Although this finding supports the 
presence of astrong degree of genetic isolation of the GRIP population, none of the 
other, mostly late-onset, PO patients in th is stucly carried mutations in DJ-1. Mutations 
in another gene, parkin, being the most impoliant cause of disease in patients with 
early-onset parkinsonism,23,24 did not account either for the excess of early-onset PO in 
the genetic isolate. In this population, yet another genetic factor may therefore be 
involvecl in PD. 
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ClHAPTER 3.3 
Parkinson's disease in a genetically isolated poplUllatiion: 
results from a genomic screen 
Abstract 
Apart from some rare mendelian forms, the genet ic basis of Parkinson's disease (PO) 
is not imown. In contrast to PO in the general populatnon, genetically isolated 
populations with a limited number of founders are expected to harbour a genetically 
more homogeneous variant of PD. We performec:l a genomic screen in PD patients 
from a gem~tic iso~ate, results of which are givero here. A second genomic screen in a 
larger series of patients is ongoing. lwo peaks were identified on chromosomes 19 
andl 10. Upon follow-up analysis of thle posi~ive findings, the association for 
chromosome 19 appeared to be false positive. Tli1e association for chromosome 10 
was furlther examined by saturating the l'egiol1 with a denser set of markers. 
Unforhmately, haplotype construction was not possible d1ue to an ambiguous marker 
order. Furthermore, more than one alle~e was fmmd to be associated. Analysis using 
the CLUMP program me, which merges aUeles to gÎve the highest chi-square statistic, 
yielded significant results for two markers in the fine-typed region on chromosome 
10. lhe firs! concerned the originally associated marker on chromosome 10, of 
which tvvo ,alleles gave a significant result. On,e of these was the originally associated 
allele in the first genomic screen. A second marker on duomosome 10 had a single 
associated aIleie. The marker order now needs Ito he determined, and the finding 
replicated in aro independent data set. 
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Intmdluction 
Parkinson's disease (PO) [MI/V\ 1613600] is a late-onset neurodegenerative disorder 
characterised by bradykinesia, resting tremor and rigidity. The cerebral pathology 
includes 1055 of dopaminergic neumns, particularly in the substantia nigra, and 
cytoplasmatic eosinophilic inclusions called Lewy bodies. In the majority of patients 
the cause of PO is unknown, anel currently available therapy neither halts nor cures the 
disease. The role of genetic factors in the origin of PO with mendelian inheritance is 
being rapidly elucidated, now that 10 recessive and dominant forn-\s have been 
identified.1-10 The genetic basis of the, usually late-onset, form of PO with a complex 
inheritance pattern, however, is less evident. Although twin studies showeel the genetic 
component of late-onset PO to be much smaller than that of early-onset PO,ll the risk 
in 1st-degree relatives of PO patients to develop the disorder is still 2-14 times the risk 
in 1't_ degree relatives of unaffected family members, arguing in favour of a genetic 
component. 12 In Icelandic PO patients who were at first sight unrelated, familial 
aggregation of the disorder was demonstrated by a genealogical search upon which a 
locus for late-onset PO, PARK10, could be mapped to chromosome 1 p32. 1 :,14 
Linkage disequilibrium (LD) mapping of disease loci is based on the 
identification of marker allel es or haplotypes, which are more frequent in patients than 
in controls. The general population is assumed to be too genetically heterogeneous for 
such an approach. In such populations, genome-wide association studies using LD 
mapping would require very dense maps of polymorphic markers or Single i'-Iucleotide 
Polymorphisms (SNPs) in large case-control series, which is currently not vet feasible. 
On the contrary, genetically isolated populations may be more homogeneous 
due to a small number of founders. Furthermore, LO might be maintained over 
sizeable regions around disease genes in recently isolated populations. C:oarser marker 
maps of highly informative single tandem repeat (STR) markers might therefore be 
sufficient to successfully map disease genes in isolated populations,15 as was illustrated 
by the recent discovery of the PA,I~KI 0 IOCUS. 14 Kruglyak has shown that factors of 
importance for successful LD mapping in isolated populations are a small founder 
population and subsequent exponential population growth with only limited inward 
migration. 16 
We studied 42 PD patients with ancestry from a genetically isolated population 
in The Netherlands. The aim of this study was to find a gene involved in the late-onset 
form of PD. An analysis of the positive findings in a genomic screen with 21 PO 
patients in this genetically isolated population is reported here. A second genomic 
screen of all 42 patients and in-deptn analysis of the data is ongoing. 
Methods 
Patients 
This study is part of a research program named Genetic Research in Isolated 
Populations (GRIP).7,17-19 The scientific pmtocol of GRIP has obtained approval of the 
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Medical Ethics Committee of the Erasmus Me. The GRIP population is a genetically 
isolated community in the Southwest of The Netherlands. Around 1750, this 
population counted approximately 150 indivieluals, followed by minimal inward 
migration anel considerable population growth. 20 An estimated 20,000 descendants of 
this population are now scattered over eight adjacent villages. Church and municipal 
registers are readily available and date back to the 1800s. Genealogical history up to 
1600 ha~; been computerised to a large extent, holeling information on approximately 
60,000 individuals. 
Patients with parkinsonism were trac:ed through local general practitioners, 
neurologists anel nursing-home physic:ians as described in Chapter 3.2. All patients 
provieled informed consent to participate in the study. Parkinsonism was diagnosed 
when at least two out of three cardinal symptoms (braelykinesia; rigidity; resting 
trernor), as weil as clinical improvement on doparninergic therapy were present. The 
diagnosis of idiopathic PO was established after exclusion of other causes of 
parkinsonisrn anel was verified by two inelependent neurologists according to criteria of 
EUROPARKINSON.21 Data on presence of PO, essential tremor anel dementia in first-, 
second- and third-degree relatives were collecteel by rneans of a family-history 
questionnaire. In order to detect any subclinical or untreated parkinsonism, first-degree 
relatives of patients also underwent neurological exarnination. Finally, genealogical 
inforrnation obtained frorn partic:ipants and local municipal, church and computerised 
registers was extended up to 16 generations. 
The initially ascertained data set used for the first genomic screen contained 21 
PO patients and their relatives. In order to inc:rease sample size for the follow-up 
analysis of our positive findings, this initial group was extended with another 21 PO 
patients, their relatives and 88 control individuals, all from the GRIP population. The 
latter series were ascertained later on. Regarding clinical and genealogical (kinship) 
characteristics, there were no significant differenc:es between the first and the second 
group. The second, ongoing, genornic screen includes all 42 patients, their relatives 
and 88 contl"Ols. 
Genetics 
For all patients and available first-degree relatives,. genomic DNA was isolated from 
peripheral blood as described elsewhere. 22 For the systematic genome scan were used 
sholt tandem repeat polymorphisms (STRPs) trom the ABI PRISM® Linkage Mapping 
Set MD-IO IApplied Biosystems). Additional rnarkers for fine mapping were obtained 
from the Genethon and Marshfield genetic rnarker sets. Information about marker order 
and distances were obtained from the Marshfield integrated linkage rnap and Celera 
hurnan genome database. Genomic DNA (20 ng) was amplified in a 7,5 111 PCR 
reactions containing 1 X GeneAmp PCR Gold Buffer; 1..5 mM MgCf2; 10 pmol of each 
primer (forward primer labeled with FAM, TEl or HEX), 250 uM dNTPs and 0.4 units 
of AmpliTaq Gold DNA polymerase. Initial denaturation was 15' at 95°C followed by 
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32 cycles of 30" denaturation at 9:;oC, 30" annealing at 55°C and 90" extension at 72 
oe. Reactions were prepared lIsing a Beckman Biomek 2000 robot system and 
performed in 384-well plates covered with sealing lids (Costar 6557; 6555). 
Amplification was done using a dual 3B4-wells equipped Perkin Elmer CeneAmp PCR 
5ystem 9700. PCR products were pooled and loaded on an ABI377 (filterset 0; 6.25% 
denaturing FMC LongRanger acrylamide gel) or ABI3100 automated sequencer, data 
were analyzed using ABI Cene5can 3.1 and ABI Genotyper 2.5 or Cenemapper 
software from Applied Biosystems. !\s reported in Chapter 2.2 and 3.2, all patients in 
this study screened negative for mutations in the 0)-1 gene (which were identified in a 
family with early-onset autosomal recessive parkinsonism from the same community). 
Furthermore, 3 of 7 early-onset, and 18 of 35 late-onset PO patients were studied for 
genetic markers flanking PO genes, HO,14 but showed no association. 
For chromosome 10, saturation mapping with additional markers (01051651, 
0105217, 01051676, 01051439, 01051655, 010512413, 0105169, 01051770, 
0105555,01051675,0105590, Dl051711 and 01051700) was clone in all 42 
patients and in a control group of BB healthy individuals from several other studies in 
the GRIP population. For chromosome 19, marker 01954113 was typed in additional 
sets of healthy controls (n = 92), Alzheimer's disease (AO) patients (n =" 19), diabetes 
mellitus (OM) patients (n = 60) from the GRIP population, as weil as in a group of 
randomly selected individuals from the Rotterdam 5tudy, a population-based cohort 
study23 (n = 352). 
Statistica! ana!ysis 
Marker data from the genomic screen were analysed using a test for combined linkage 
and association. This test is a family-based adaptation of the method described by 
Terwilliger and assumes that, when many of these chromosomes descend hom a single 
ancestor carrying the disease mutation, marker alleles will be over-represented on 
chromosomes with the clisease mutation. 24,25 The proportion of increase of the 
ancestral allele in disease chromosomes is represented by the parameter lambda ("-), 
which is estimated by maximizing the log-likelihood function. Here, the likelihood is 
the weighted sum over potential founder-alleles of conditional likelihoods given an 
ancestral aileie. The weights are equal to the a priori probability of an 3ncestral aileie, 
which are estimated from the allele frequencies in controls (in this situation the 
spouses of the 21 patients). For the linkage component of the analy:,is, a dominant 
genetic model with a penetrance of 40 % was assumed. The disease-gene frequency 
was kept constant at 0,1 % and the recombination frequency at 0.01. 
For the saturation-mapping analysis, phases were set using CENEHUNTER26, 
vet haplotype construction was not possible due to an ambiguous order of markers on 
the physical map. Moreover, with the assumption of a single allele being associated, 
no haplotypes extending bevond two markers were possible. We then decided to 
perform single-point analysis of each marker separately, and allowing for more than 
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one associated allele per locus. To this end, the CLUMP pragramme was used. This 
method dumps alleles together into a 2-by-2 table in such a way that the highest chi-
square statistic is obtained. 27 lts corresponding p-value is obtained by means of Monte 
Carlo simulations. 8y doing 50, more than one ancestral haplotype in patients is 
allowed for because of marker mutations, earlv recombinations or multiple ancestors 
introducing different alleles. For the associated markers, lambdas are estimated for risk 
alleles. 
ReslJlts 
Forty-one patients with idiopathic PO could be connected to a common ancestor 14 
generations ago. A simplified version of the pedigree of 41 patients is depicted in 
Figure 3 of Chapter 3.2, leaving out the multiple links amongst individual patients to 
obtain better visibility. A forty-second patient with ancestry fram the GRIP population 
was added to this series in a later stage. The first genomic screen, which comprised the 
series of 21 PO patients and their 37 first-degree relatives who were ascertained 
initially, yielded significant evidence for combined linkage and association for a 
marker on chromosome 10qter, the 211-base pair (bp) allele of 01051651 (À = 0.47, 
P = 0.009). A second positive finding concerned the 96-bp allele of marker 0195418 
(1..=0.99, p"=0.02). 
The lambda value for the associated allele of 0195418 was exceptionally high 
because all patients carried at least one 96-bp allele and 7 patients were homozygous. 
5ince the method used for this analysis 24,2) derived allele frequencies from the contra I 
graup, we extended our original sample to rnore groups in order to obtain better 
estimates of the contra I allele frequency for this marker. Therefore, 0195418 was also 
typed in series of individuals from GRIP (92 healthy contrais, 19 AO patients, 60 OM 
patients) and fram the Rotterdam 5tudy (352 randomly selected individuals), and 
inforrnation on CEPH families was obtained. Upon extension to larger control groups, 
it appeared that the 96-bp allele is not only by far the most frequent allele am angst PO 
patients, but also amongst all other graups. The peak for this marker was therefore 
assumed to be false positive, prabably due to the srnall sample size of control alleles 
used in the genomic screen, or to a minimally informative marker. 
The lambda value for marker 01051651 was also high (1..=0.47) and was 
therefore te~;ted in a larger contral graup in order to obtain a better estimate of the 
allele frequency. Moreover, the marker flanki ng 01051651, 0105217, was weakly 
positive in the first genomic screen, which raised the question whether there could be 
a haplotype of two adjacent markers. Twelve additional rnarkers on chramosome 10 
araund 01051651 (0105217, 01051676, 01051439, 01051655, 01051248, 
0105169, D1051770, 0105555, 01051675, 0105590, 01051711 and 01051700) 
were subsequently tested in the case-contra I series of 42 patients and 88 contrals from 
the GRIP region. Attempts were made to construct haplotypes by using the originally 
associated 211-bp allele as a starting point, but only by assuming early recombinations 
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or mutations could any haplotype be extended beyond two markers. Moreover, the 
order of the markers in this telomeric region of chromosome 10q proved to be 
unreliable: publically available maps through the NCBI showed conti icting positions, 
which could not be omitted by consuiting the existing physical maps at NCBI or Celera 
as large parts of this region consist of draft and unfinished sequence. Thel'efore, the 
CLUMP method was used. 27 
By using CLUMP, two of 13 markers appeared to be significant. All other 
markers had p-values > 0.30. In Table 1, the risk alleles of the two associated markers 
are given. One of these markers was the original marker Dl OS 1651, for which two risk 
alleles were identified (p=0.049l, The original 211-bp allele has a lambda of 0.12, and 
the other aIleie, the 229-bp aIleie, a lambda of 0.08, The other marker was 
Dl OS1711 with only one risk aileie, the 1 77-bp allele (p = 0.006, 11.= 0.21 l. 
Table 1. Association of marker Dl OS 1651 and Dl OS 1711 with PD (42 patients; 8H controls) 
Marker Frequency cases Frequency contra/s À, p-va/ue 
01051651' 0.049' 
21 ! -bp alle/eb 0.17 0.10 0.12 
229-bp alle/e 0.27 0.17 0.08 
01051711 0.OO6c 
177-bp alle/e 0.32 0.14 0.21 
, Origina/ peak from genome scan; b original/v associated al/e/e; C two-sided p-va/ue obtained bI' 
simu/ation (n ~ 10,000), ta/dng into account that 2-by-2 tab/e is formed in order to obtain the 
highest chi-square statistic 
Discussion 
We here report significant evidellce for linkage and association for a marker on 
chromosome 10q26.3-qter in a group of 21 patients with typical PD from a genetically 
isolated population in The Nethel"lands who share an ancestor 14 generations ago. 
Upon saturating this region with a den ser set of markers in an augmented patient 
sample (42 patients as weil as 88 contrals from the GRIP populationl, the control allele 
frequencies could be estimated more accurately and the significance of the association 
with the original marker was maintained. Haplotype analysis was nol: possible, firstly 
because the assumption of association of a single allele did not hold and secondly 
because of an unknown marker order. Our initial approach, used for analysis of the 
genomic screen,24,2S assumes a single ancestral allele and hence lacks power in 
situations such as reported here. 
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Wh en more than one risk allele can be expected (due to early recombinations 
dispersed throughout the population or multiple founders) clustering alleles into one 
group would increase the power to detect these variant alleles. The CLUMP 
programme allows for multiple alleles to be mergee! into one virtual risk-alieleY Using 
CLUMP, two alleles of 01OS1651 together gave a significant over-representation by 
patients compared to controls. 
When identified risk alleles only slightly differ in length (2-4 bp), early marker 
mutations may have occurred. The two alleles of [)lOS1651 identified by CLUMP in 
our study, however, differed by 18 bp. The explanation of marker mutations is 
therefore biologically implausible, leaving multiple founders or early recombinations 
as a possible reason. Although the originally associated risk allele maintained a 
significant association in the follow-up analysis in êi larger series of patients, a marker 
order cOllie! not be determined with sufficient certainty to construct haplotypes. This 
currently limits the interpretation of the findings reported here. To enable haplotype 
analysis, the marker order will hopefully be ascertained on a physical map or on a 
newly constructed genetic map. Finally, independent and larger patient series must be 
tested to confjrm these findings. 
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CHAPTER 3.4 
Mutations in tlle Ilaemochromatosis gene (t-IFIE)p 
Parkinson's disease and parkinsonism 
Abs1tract 
Iron overioad increases oxidative stress andl Glln lead io neurodegenerative diseases 
like PD. We therefore studied the role of Mut.ations in the haemochromatosis gene 
HFE in PD and parkinsonism. Two popn.llation-based case series were studiedl- the 
first counting B7 patients with PO and 184 wil:h parkinsonism, and the second of 60 
patients with PO and 85 with parkinsonism" In the first series, PO patients we re 
significantly More often homozygous for the C282Y mutation than controls 
(p = 0.03), and in the second, parkinsonism patients were more often homozygous for 
the C2:B2Y mutation than controls. Although hampered by small numbers, our data 
suggest that homozygosity for the C282Y mutation in the HFE gene increases risk of 
PO, and possilbly of parkinsonism overall. Given the rarity of this genotype, large 
series of patients are required to prove this hypothesis. 
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In as early as the nineteen twenties, iron was suggested to be involved in the 
pathogenesis of Parkinson's disease (PD).l Increased iran concentrations in the 
substantia nigra are seen in brains of PD patients on magnetic resonance imaging and 
at postmortem examination. 2,3 It has been postulated that excessive iron deposition in 
the brain causes overproduction of free radicals, giving rise to parkinsonism,4 The 
recent implication of D)-l in autosoillai-recessive parkinsonism, a gene involved in the 
response to oxidative stress,5 raises the question which is the contriblltion of iron-
related oxidative stress to PD and parkinsonism in the general population. 
Haemochramatosis is an irall overload disorder with increased ab~;orption and 
pragressive storage of iron in several tissues of the body, Two mutations in the HFE 
gene account for most cases of hereclitary haemochromatosis,6,7 The C2B2Y mutation is 
highi)' penetrant, leading to intracellular sequestration of iran,8 The H63D mutation is 
mllch less penetrant and is, althollgh biological evidence for abnormal iron processing 
is not conclusive, a sllsceptibility factor for haemochromatosis.9 In haemochromatosis, 
iran deposits were observecl in the basal ganglia, causing clinical parkinsonism. lO lts 
rale in iran metabolism makes HFE a potential candidate gene for PD. 
Results of studies on the role of HFE mutations in PD have not been consistent 
and vary from an unexpected protective effect of C282Y heterazygosity,11 to no effect 
of either mutation. 12 Prablems in the interpretation of the previolIs studies are the 
highi)' selected patient series (with a likely mendelian origin of disease) the studies 
were based upon, as weil as the various sources from which the conlrol series were 
derived. We therefore stlldiecl mutations in the HFE gene in two serie~, of PD patients 
and in contrais, all derived from population-based samples. 
HFE mutations may not necessarily lead to classical, idiopathic PD, but rather 
to parkinsonism which does not entirely meet criteria for PO (bradykinesia, rigidity and 
tremor, and improvement on dopaminergic substitution).l0 We therefore also assessed 
presence of HFE mutations in all patients with parkinsonism (consisting of PO plus all 
other syndromes, regardless of pathogenesis, of which clinical signs resembie PO) in 
the two population-based series. 
The first series of 137 patients with PO, 47 patients with parkinsonism by other 
causes and 2914 controls was derivecl from the Rotterdam Study, a large cohort study 
in an elderly poplilation (aged 55 years and over) in suburban Rotterdam, The 
Netherlands. A detailed description of this cohort of 7,983 individuals is given 
elsewhere. 13 The second series compriseel another 60 patients with PD anel 25 patients 
with parkinsonism by other causes anel was derived from the SOlIthwest of The 
Netherlands. The control group hom the Rotterdam Study was also usecl for the second 
series. The protocols of both studies have obtained appraval of the Medical Ethics 
Committee of the Erasmus Me. Befon: being entered into the study, all participants 
provided their informed consent Information on past and present health status was 
obtained by means of a standardised questionnaire. Participants were screened for and 
eventually diagnosed with PD or parkinsonism according to the EUROPARKINSON 
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protocol. I·j Control individuals with a history of PD, parkinsonism or other 
neurodegenerative disease were excluded. Li DNA was isolated from whole blood 
using the salting-out procedure,16 and the samples were genotyped for the HFE 
mutations C282Y and H63D as described previously.7 Chi-square tests, Fisher exact 
tests and regression analysis were performed with two-sided significance thresholds of 
0.05. 
In the two series of cases and in the controls, there were no significant 
deviations from Hardy-Weinberg equilibrium proportions. The first series of PD 
patients derived from the Rotterdam Study consisted of 13 7 individuals (41 percent 
males and S9 percent females) with an ave rage age of 75.8 ± 8.1 years. The second 
series of PD patients from the Southwest of The Netherlands consisted of 60 
individuals (37 percent males and 63 percent females) with an ave rage age of 68.2 ± 
10.0 years. The control group of 2914 individuals from the Rotterdam Study (50 
percent mal es and 50 percent females) was on ave rage significantly younger (66.8 ± 
7.5 years) than the case series from the Rotterdam Study, but not from the series from 
the Southwestern Netherlands. Genotype and allele frequencies in PD and 
parkinsonism cases and controls are given in Table 1. For the C282Y mutation, the 
proportion of C282Y homozygotes amongst PD patients from the Rotterdam Study was 
higher than in controls (OR 5.4; Cl 1.1-25.6, P = 0.03). A C282Y allele-dosage effect 
(an increase in frequency of C282Y heterozygotes) was not observed. Of PD patients 
frorn the Southwest of The Netherlands, none were hornozygous for the C282Y 
mutation. In patients with parkinsonisrn from the Rotterdarn Study, the C282Y-
homozygosity excess was accounted for by the aforementioned typical-PD patients. 
Frorn the smaller series from the Southwest of The ~Ietherlands, one patient with 
parkinsonism proved to be homozygous for the C282Y mutation, but the excess of 
C2B2Y homozygotes did not reach significanee. There was no evidence for a 
difference in frequency of any of the other genotypes in the two series. In particular, 
the frequency of heterozygosity for C282Y was not significantly reduced in patients 
with patienh with PD or parkinsonism." 
Our study showed an increased prevalence of C282Y homozygotes amongst 
PD patients in the Rotterdam Study. Two more case-control studies on the relation 
between C282Y and PD have been conducted. ll ,12 One study reported a protective 
effect for CZ82Y carriers." These findings are, however, difficult to interpret as the 
control group was cornposed of, amongst others, siblings of patients, thereby possibly 
diluting the effect of genetic risk factors such as the C282Y mutation. The other study 12 
reported no association of HFE rnutations with PD. In the patient series in this study, 
the proportion with a positive family history for the disease was high (52.3 percent12). 
In comparison, the proportion of patients with a positive family history for PD was 4.9 
percent in the Rotterdam Study17 and 7 percent in the Southwest of The Netherlands 
(data not shown). Possibly, genes other than HFE play a predominant role in PD 
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Table 1. Distribution of the HFE genotypes and alleles in Parkinson's disease (PD) and parkinsonism (PS) patients from the Rotterdam Study and from the 
Souihwesi ern i'>leiherlands, and in controls 
Rotterdam Study Southwestern Netherlands Contrals (%) 
All PS (%) PO (%) other PS (%) All PS (%) PO (%) other PS (%) 
n= 184 n=137 n=47 n=85 n=60 n=25 n=2914 
Genotype 
vv'tdj-'Nt 'I'" ï Ir'""} r\ I I1 ~O.).O} 89 (ó5.û) 28 (59.6) 51 (60.0) 38 (63.3) Î 3 (52.0) Î838 (63.Î) 
wtlH63D 38 (20.7) 31 (22.6) 7 (14.9) 20 (23.5) 16 (26.7) 4 (16.0) 661 (22.7) 
H63D/H63D 2 (1.1) 2 (1.5) o (0) o (0) 0(0) 0(0) 68 (2.3) 
wt/C282Y 20 (10.9) 10 (7.3) 10 (21.3) 12 (14.1) 6 (10.0) 6 (24.0) 290 (10.0) 
H63D/C282Y 5 (2.7) 3 (2.2) 2 (4.2) 1 (1.2) o (0) 1 (4.0) 49 (1.7) 
C282Y/C282Y 2 (1.1) 2 (1.5) b o (0) 1 (1.2) o (0) 1 (4.0) 8 (0.3) 
Allele frequencies 
wt 79.7 % 80.6 % 77.2 % 77.5 % 79.6 % 72.1 % 79.4 % 
H63D 12.7 % 13.8 % 9.1 % 13.9 % 15.3 % 10.4 % 14.5 % 
C282Y 7.6 % 5.6 % 13.7 % 8.6 % 5.1 % 17.5 % 6.1 0/0 
, wt = wild-type aIleie; b p = 0.03 
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patients with a positive family history for the elisease. 12 Furthermore, the mean age at 
onset of PD in the latter study was comparaiively low (52.3 years), which mayalso 
indicate a, different, genetic contribution to F'D in this particular study population. 
Here we analysed two separate groups of PD cases with respect to a large 
control group. The first series of patients anc! the controls were derived from the same 
strictly defined source of the Rotterdam Study, II reducing a potential selection bias. In 
order to minimise any underestimation of the effect of the HFE mutations on PD or 
parkinsonism, we excluded patients with neurodegenerative disease in the selection of 
control "ubjects. The genotypes in the PD patients anel controls from the Rotterdam 
Study and the PD patients from the Southwest of The Netherlands were in Hardy-
Weinberg equilibrium proportions, suggesting no major selection against C282Y 
homozygotes. A question arising when studying a gene such as HFE in a late-onset 
disorder such as PD, is whether C282Y homozygotes live long enough to develop PD. 
They are at increased risk of liver pathology, diabetes and vascular disease. 18 
Interestingly, both C282Y-homozygous PD patients in our study were female (data not 
shown), and women are known to have an increased survival in haemochromatosis. 19 
Probably due to regular blood loss during menstruation, female C282Y homozygotes 
are at lower risk for clinical symptoms of iron overload than male C282Y 
homozygotes. 
Our study shows an increase in frequency of PD in individuals homozygous for 
the C282Y mutation, and is in line with the hypothesis that, through iron deposition, 
C282Y hOlTIozygosity increases the risk af PD anel passibly af parkinsonism overall. An 
important implicatian af our findings is that the protective effect af the C282Y 
mutatian 11 is not supported by our data. Thenumber of C282Y homazygates in our 
study, however, was smal I, and our findings remain to be confirmed. Further study in 
larger populatians is needed to assess the role of C282Y hamazygotes in PD. 
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CHAPTER 4 
GENERAt DISCUSSION 

GENERAL DISCUSSION 
4.1 Introduction 
Parkinson's disease (PD), one of the most frequent movement disorders of old age, has 
raised many a debate about its cause. The first known descriptions of PO come from 
ancient India and date back approximately 4,000 years. 1 Lead by the cardinal 
symptoms bradykinesia, rigidity ancl tremor, it was probably the Greek physician 
Galen (175 A.D.) who introduced the descriptive term 'shaking palsy', which was in 
use up to the 19th century. Vet it was )ames Parkinson, an English physician, 
paleontologist and politician, who in 11317 provided a modern and detailed account of 
the disorder.2 His name has been associated with the condition since. 
After these two centuries, treatment of PD is still based on sylllptom relief. As 
dopamine deficiency is largely re!iponsible for the motor disturbances in PO, the 
therapeutic regimen is primarily formed by dopamine substitution. Medicinal extracts 
of cowage or velvet bean (Mucuna pruriens), the seeds of which contain large amounts 
of levodopa,3 have been used to alleviate symptoms of PD for thousallcls of years. In 
1961, a synthetic analog of levodopa was manufactured, which formeel a milestone in 
the c1evelopment of PD therapy. The American Food and Drug Agency (FOA) 
registered synthetic levodopa for clinical applications nine years later, upon which it 
became the mainstay of PO treatment. 4 Dopamine suppletion can, however, neither 
cure Ilor halt the disease process. 1 Furthermore, although not confirmed in vivo, some 
experimental evidence suggests that therapeutic dosages of levodopa accelerate nigral 
decline in vitro by the procluction of tree radicals. s 
Prevention or cure of PD will become feasible only when causal mechallisms in 
PO are clear. In recent years, rare mendelian forms of PD have been unraveled (see 
Chapter 2 on familial parkinsonism).6.15 The bulk of PD, however, is the common, 
sporadic form; mendelian variants form the tip of the iceberg. Chapter 1.7 has already 
reviewed general aspects of the genetics of PD. This chapter will address 
methodological aspects, implications and forthcoming lines of research of the studies 
conducted within the framework of this thesis. 
4.2 Familial parkinsonnsm 
4.2. 1 MethodoJogical aspects 
Mapping and significance of PO genes 
However rare single-gene variants of PD may be (see Chapter 1.1), they have lifted a 
tip of the veil covering the causal rnechanism(s) in PD. Ten rnendelian forrns identified 
to date represent the growing body of eviclence for genetic heterogeneily in PO.G.1S 
Three of five PD gen es, alpha-synuclein, parkin and 0)-1, were identified by 
positional cloning. 6,7,12 Their biological properties have provided thE' first important 
clues about pathways leading to PO, Alpha-synuclein and parkinG,? were the first two 
genes discovered and are, in terrns of biology and neuropathology, characterised 
extensively, leaving little if any doubt about their causal role in the corresponding 
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forms of PD. 16.19 About D1-1,12 no details about function or neuropathology are known 
yet. 
The remaining two PD genes UCH-L 1 anel NR4A2 were candidate genes for a 
role in F'D based on their function, anel large series of familial-PD patients were 
screened fOI' mutations in these genes, 10, 15 UCH-L 1 is an enzyme in the ubiquitin-
mecliated protein degradation pathway and t-.JR4A2 plays a role in the genesis and 
maintenance of mesencephalic dopaminergic neurons. IO ,20 One mutation in the UCH-
L 1 gene in a single family, and two mutations in a non-coding exon of the NR4A2 gene 
in 10 families were thus identified. 1O,15 In UCH-Ll, the mutation was associated with a 
decreased ellzymatic activity in vitro, and in NR4A2, the two exonic mutations were 
associated with decreased mRNA transcription (by an unknown mechanism).10,15 In 
both cases il concerned, in terms of PD neuropathology, biologically plausible genes. 
Also, the mutations had functional consequences. Nevertheless, regarding the fact that 
the latter two gen es were studied based on an a priori hypothesis on their role in the 
pathogenesis in PD, they raised the question wh ether the observed mutations could be 
chance findings due to large-scale screening, and in fact be rare polymorphic 
variants. 21 ,2:! Extensive efforts have been made to confirm the role of UCH-L 1 mutations 
in familial PD, yet in the five years since the original report, no confirmation in other 
families has become available. 1O,23,24 The possibility remains, however, that the 
originally reported mutation 10 is a valid fincling but mutations in UCH-L 1 are simply 
excessively rare. Preliminary confirmation studies on the role of NR4A2 in other 
families have been negative,22,25 but due to its only recent discovery, more studies can 
be expecleel. 
Research in genetic iso/ates 
Genetically isolated populations represent an important and powerful tooi in 
genetically mapping inherited disorders. Populations call develop into genetic isolates 
due to a variety of reasons (Tabie 1).26'33 As a result of a limited number of founders 
anel genetic drift, such isolated populations are less genetically heterogeneous than the 
general population. Within a genetically isolateel population, one can assess genetic 
traits on a family basis, but also on a population basis. F'atients from an isolate who 
have a COITlfnOn ancestor are expected to share stretches of DNA flanking a disease 
gene and thus exhibit a larger extent of linkage di:;equilibrium than individuals from 
the general population. This property may facilitate detection of disease genes. 
Homozygosity mapping, the method used in Chapter 2.1, enables localisation of 
homozygous chromosomal regions that are identical by descent (lBD). In 
consanguineous families showing a pattern of disease inheritance compatible with a 
recessively acting gene defect, this is a suitable approach to map a disease gene. 
Although homozygosity mapping can be useful to examine a distinct trait in a 
consanguineous pedigree, caution is warrallted when several traits co-exist in one 
family. The exact segregation pattern should be determined for each trait 
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independently, since one would be inclined to analyse these in terms of a syndrome 
(with the underlying assumption of a single genetic or genomic cause). Even in an 
inbred family with a rare disease, the degree of consanguinity can be larger than 
anticipated, such that coexistence of genetically independent phenotypes (caused by 
other genes elsewhere, and/or in associated homozygosity reglons) must be 
considered, an issue al50 addres5ed in Chapter 2.4. Furthermore, the assumption of 
recessive inheritance does not necessarily apply to all of the observed traits, since 
some may in fact be inherited in a dominant or other fashion. 
Table 1. Genetically isolated populations worldwide 
Nature of the iso/ation 
Popu/ation Religious Geographica/ Sociocultura/ Reference 
Amish X Kelley et al.,2002 26 
(N.-America) 
Costa Rica X Freimer et al., 1996 27 
Iceland X Gulcher e·: al.,2001 28 
Finland X Kallinen et al.,2001 29 
GRIP population X This thesi, 
(Netherlands) 
Hutterites X Robertson et 
al.,19993O 
Mennonites X Morton et al.,2002 31 
(America)" 
Palau X Kruglyak,l 999 32 
(Micronesia) 
Sardinia X Parratt et al.,2002 33 
" Groups of the Mennonite People (originally Swiss/Cerman Dutch immigrants to the Eastern US) 
are found from Canada to Argentina 
Three of the four recessive PO genes and loci, PARK6, 0)-1 and PARK9, could 
be mapped to chromosome 1 p36 by means of homozygosity mapping in 
consanguineous families. ll ,14,34 In families with many consanguineous loops, 
homozygosity can be ample, leading to false-positive association with disease for a 
certain locus. 35 Furthermore, telomeric regions (such as chromosome 1 p36) possibly 
have higher recombination rates, requiring a den ser map of markers to cletect linkage 
disequilibrium. A chance finding becomes unlikely when mutations (or linkage to the 
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same region) are found in independent families, suggesting independent mutational 
events. Ta date, mutations in the DH gene have been found in families of several 
ethnic ongins across the world (Bonifati perscmal communication). Although support 
for linkage to PARK6 11 was obtained in eight families in different European countries,36 
this must be interpreted with caution, since ie concerns linkage results from small 
families not showing statistically significant linkage by themselves, and largely based 
on the presence of compound heterozygotes. The causative gene within PARK6 
remains to be identified. Finally, PARK9, the thircllocus on chromosome 1p36,14 was 
identified in a single consanguineous Jordanian family. Linkage to PARK9 has not been 
confimled elsewhere, but the locus is tentatively close to the DJ-l gene and the PARK6 
locus. This vicinity suggests some genomic rean'angement (e.g., inversions) or overlap 
for the PARI<6- and PARK9-linked families. DJ-I mutation analysis in the PARK9 and 
PARK6 families is necessary to ru Ie-out involvement of DJ-1 in these closely adjacent 
PD-related loci. 
GenealogiGl/ 10015 
The usefulness of community-derived patient series from a genetic isolate primarily 
comes with the availability of genealogical information. Nowaclays, databases can 
contain genealogical relationships of an entire community over several generations. 
Since the early days of clinical genetics, cletailed genealogical records have been 
indispensable for the assessment of family structures such as in the genetically isolated 
Amish and Mennonite demes of the United States of America. The availability of 
extended pedigrees facilitated the systematic clinical-genetic descriptions by McKusick, 
whose pioneering work in the Amish formed the basis of Mendelian Inheritance in 
Man (URL: http://www.ncbi.nlm.nih.gov/omim/l. Furthermore, the IceI élildie 
population recently passed a bill allowing their inclusion into a nationwide database 
used for genetic research in the deCODE project. 2!! Similarly, the GRIP project, the 
framework within which research for this thesis was conducted, has a community-wide 
genealogical database, reaching back unti I the end of the sixteenth century and 
containing information about 60,000 individuals. Results of high-capacity genealogical 
searches can be impressive, linking all patients with a certain trait to a common 
ancestor rnany generations ago. Vet originating trom a genetically isolated population 
per se is lIn:ipecific: finding a gene reqllires familial aggregation of a certain trait. 
Familial aggregation of a disease must always be viewed relative to a, preferably 
disease-free, control group from the same population. If this reference group is not 
available, the assumption that the selection of patients may have inherited a common 
sllsceptibility factor for a disease can then onl;; be made with the greatest caution. A 
better approach is comparing a family history for F'D amongst PD patients versus a 
family hislory for PD amongst controls. 37 If there are more observed than expected PD 
cases among patients' relatives than among the controls' relatives, there is familial 
aggregation. Information can still be unbalanced, however, as there is likely to be some 
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degree of recollection bias arnongst patients (more inclined to rernel11ber having 
relatives with PO). Furthermore, the possibility that shared environmental factors also 
playa role in the clustering of traits within particular families cannot be excluded, such 
that exposure to putative risk factors should also be registered. 
4 . .2.2 Imp/ications and suggestions for further research 
We ascertained aconsanguineous family with early-onset parkinsonisl11 suggesting an 
autosomal recessive pattern of inheritance in a genetically isolated community in the 
Southwest of The Netherlands. By mean5 of homozygosity mapping and linkage 
analysis, a new locus for familial PO was identified on chromosome 1 p36: PARK7 
(OMIM 606324) (Chapter 2.1). Since the identification of mutations in the alpha-
synuclein gene in 1997,6 this was the 7'h monogenic form of parkinsoni:,m identified 
worldwide. After an extensive search 1'01' the responsible gene in the 16-cM wide 
candidate-gene interval, all parkinsonism patients were shown to have a homozygous 
deletion of the 0j-1 gene (Chapter 2.2). In the other (Italian) family with significant 
linkage to PARK7, a point mutation in the 0)-1 gene was identified. 
The function of the 0)-1 gene is unknown. /n vitro studies on the 0)-1 protein 
and exposure to e.g., hydrogen peroxide or the neurotoxic pesticide component 
paraquat suggested involvement in the response against oxidative 5tre5s. 38,\9 Another, 
more recent, study suggested the 5. cerevisiae 0)-1 ortholog to assume chaperone-like 
properties in response to the presel1Ce of misfolded proteins,40 This property, albeit 
observed in yeast, could be a tentative link to the postulated mechanisms of 
neurodegeneration in alpha-synuclein and parkin-linked parkinsonism. 'b·") 
The identification of mutations in 0j-1 in familial parkinsonism will have 
impact on views of the pathogenesis of PO and according research. Interactions of 
parkin and alpha-synuclein are l11ultiple,'8,'9,41 but the common feature in all three 
previously identified PO genes alpha-synuclein, parkin and UCH-L 1 is their 
involvement in ubiquitin metabolism. Anti-oxidant properties and/or chaperone-like 
properties of 0j-1 could all make 0)-1 a suitable candidate rol' a role in 
neurodegeneration. 
The hypothesis of oxidative damage in PO has been long-standing but also 
much debated. Conclusive evidence for a role of oxidative damage in col11mon PO is 
sti 11 lacking (see Paragraph 4.3.7) The discovery of 0)-1 therefore sheds new light 
upon an old hypothesis, nourishing further research. Since its identification in 2002, 
othel' mutations have been identified worldwide, making 0)-1 mutations the second-
most common genetic cause of PO after parkin (Bonifati, personal communication). Vet 
it raises more questions than can be currently answered. 
Cenetics and mo/ecu/ar bi%gy 
By the time of the identification of 0)-1 mutations in parkinsonism, the available 
functional studies suggested it to be an mRNA transcription factor,42 and to have 
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oncogenic pmperties. 43 Furthermore, OJ-1 was shown to be involved in male infertil ity 
in the rat, and, finally, in the response to oxidative stress. 38,39,44,45 The variety of 
suggestecl functions along with the ubiquitous presence and the strong conservation 
across species46 suggest that OJ-1 has an important function. Which exactly, remains to 
be c1arified i n studies elaborating upon the association to neurodegeneration. 
Computer simulations have predicted the OH protein configuration to be changed by 
the L 166f' point mutation (identified in an Italian family, Chapter 2.2). The properties 
of the mutant OJ-1 protein and the neurodegenerative potential resulting from that 
abnormal protein configuration will have to be studied in more detail. With the 
identificalion of more mutations it will also be interesting to assess the similarities and 
differences of the impact upon protein configuration and function. In parkinsonism 
associatecl with mutations in alpha-synuclein, the severity of the clinical phenotype 
was correlatecl with the degree of disruption of the normal protein and its subsequent 
tendency to form aggregates.46 Of the two parkinsonism kindreds with OH mutations 
in Chapter 2.2,46 the Italian patients (in whom mutant OJ-1 protein was co-Iocalised 
with m itochondrial structures in the cell) appear to be more severely affected than the 
Outch patients (in whom the OH protein is absent) (Bonifati, personal 
communication). In order to obtain an accurate impression of the genotype/phenotype 
relation, more families with OJ-1 mutations are needed. 
The function of the OH protein could be intertwined with other PO-gene 
proclucts (e.g., parkin and alpha-synuclein) via a common pathway or mechanism. 
Therefore" any interactions between the OJ-1, parkin and alpha-synuclein proteins will 
yielel a more complete picture of pathways to PO. Furthermore the co-Iocalisation of 
the L 166F' mutant OH to mitochondria in an immunofluorescence study (Chapter 2.2) 
is intriguing anel still unexplained. Firstly, the exact position of the precipitated protein 
will have to be determined, since it is not c1ear whether the immunofluorescent layer 
(containing the L 166P mutant OJ-1 protein) coats the outer mitochondrial membrane, 
or in fa ct sits inside the mitochondrial organel Ie. Secondly, a routine screen for 
metabolic disease in one parkinsonism patient with OH deletions in the Outch 
kind red revealed abnormal but not c1assifiable results for some aspects of ATP 
metabolisrn (Horstink, unpublished data). A systematic evaluation of the possible 
influence of the OJ-1 mutation on basal energy metabolism would be helpful to 
identify the pathogenic effe cts of mutant OJ-1 , 
Variations in a gene implicated in familial PO mayalso play a role in idiopathic 
PO. PolymOl'phisms in the OJ-1 gene were recently identified (Bonifati, personal 
communication). If these polymorphisms prove to be suHiciently informative, the 
involvement of OJ-1 polymorphisms on a population level could be assessed in series 
of PO patients and controls (e.g., population-based series such as the Rotterdam Study). 
Finally, as long as autopsy material of patients (and c1inically unaffected 
carriers) with OJ-1 mutations is not available for study, animal models homozygous or 
heterozygoLis for OJ-1 mutations may provide c1ues about the exact patterns of 
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degeneration in the brain and, if any, pleiotropic expression of the gene elsewhere in 
the body. An important issue to be addressed in this respect is the presence of Lewy 
bodies, a neuropathological key feature in PO,47 which are usually absent in some 
mendelian forms of parkinsonism. 13 ,48 Furthermore, if other protein inclusions or 
aggregates reminiscent of other neurodegenerative disorders are observed, they could 
provide more clues about the mechanism of neurodegeneration. It will th en be 
important to find out whether any such neurodegenerative features preferentially affect 
the substantia nigra or also other regions of the brain, such as the cerebellum and 
cortical areas (Chapters 2.3 and 2.51. 
C1inica/-genetic studies 
In Chapters 2.3, 2.4 and 2.5, various aspects of the phenotype of the patients with 
early-onset parkinsonism associated with deletions in the 0)-1 gene are described. Oue 
to the small number of patients and relatives in this original kindred, conclusions are 
drawn with caution. The clinical presentation of parkinsonism and their neuroimaging 
features are similar to other recE'ssive farms (parkin and PARK6-linked parkinsonism 7",) 
(Chapters 2.3 and 2.5). Oistinctive clinical features in parkinsonism associated with 0)-
1 mutations are psychiatric symptoms, which were not only present in all three 
patients of the first branch of the kindred, but also in one patient in the Italian family 
with a mutations in the 0)-1 gene. Furthermore, apart from a dopaminergic deficit 
typical for PO, functional neuroimaging as performed in one of the patients revealed 
cerebellar hypometabolism of glucose. Although this was also observed in parkin-
associated parkinsonism, the hypometabolism could as weil represent another, 
independent, familial trait (Chapter 2.5). Contrary to parkin- and PARK6-associated 
parkinsonism, heterozygotes for the 0)-1 mutation had norm al presynaptic 
dopaminergic function on F-OOPI\ PET imaging (Chapter 2.5).49,50 Oue to the small 
number studied here, however, dopaminergic function will have to be assessed in 
larger series of patients and carriers. A detailed description ofthe original parkinsonism 
kindred with 0)-1 mutations wa!; important to provide a first de:iineation of the 
associated phenotype. The more families are described in terms of clinical 
presentation, the sharper the delineation of the associated phenotype can become. The 
question whether, for instance, psychiatrie features form a part of the parkinsonism 
phenotype or are a private trait in the Outch and in the Italian patients (Chapter 2.3), 
can then be addressed. If compound heterozygous patients can be identified in wh om 
psychiatrie features do not or only I'arely occur, this may indicate that these features are 
in fact caused by another gene in the PARK7 homozygosity region. 
When examining the patients from the Outch kindred, a striking short stature 
and brachydactyly was noted, which formed a rather unusual combination with 
parkinsonism (Chapter 2.4). In order to assess segregation patterns of these traits we 
studied body height and hand-bone length in all patients and relatives in the kindred as 
weil as in acontrol group from the same community. 1\ significant association of the 
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DJ-1 deletion with body height was found, but for the brachydactyly segregation with 
the DJ-l deletion was incomplete. This suggests that short stature is possibly caused by 
a gene or regulatory element within the region :,urrounding the DJ-1 gene, or even by 
DJ-1 itself. Brachydactyly, on the other hand, may be caused by vet another gene, 
and/or modil'ied by a gene present in the PARK7 homozygosity region. As mentioned 
in Paragraph 4.2.1, in families with a high clegree of consanguinity with more 
conspicuous traits such as this kindred, disentangling the influence of Dj-1 gene 
mutations trom the influence of other genes can be difficult, more so since the function 
of DJ-1 is unknown. In order to obtain a valicl impression of the effect of the respective 
gene(s) involved, however, more families segregating this DJ-1 deletion, but also those 
segregating other DJ-1 mutations will have to be studied. Equally important in this 
respect are any relatives of DJ-1 deletion carriers who clo not have DJ-1 deletions (wild-
type genotype). In the kindred studied in this thesis, except for one sibling with the 
wild-type genotype, no other relatives with the wild-type genotype were available. This 
makes neither confirmation nor exclusion of arelation between the body-height and 
hand tl"aits with the DH deletion possible (Iet alone a valid impression of the 
penetrane:e of the genotype). 
The repOit on DJ-1 mutations in parkinsonism is the first to implicate DJ-1 in 
human disease. In animal studies, however, DI-l was shown to be associated with 
infertility in male rats. 45 Of the patients in the Dutch kindred homozygous for the 
deletion in DJ-1, three are male and one is female. The female patient has had one 
child, but none of the male patients have chilclren. Any infertility, however, cannot be 
viewed independently of the psychiatric symptoms (present in all but one patient). In a 
genealogical assessment of all known heterozygous deletion carriers and generation-
matched controls in the GRIP population (unpublishecl data), however, the number of 
offspring in male or female heterozygotes for the cleletion was not smaller than that in 
the controls, which argues against fertility problems in at least the heterozygous 
deletion carriers. In this respect, in a work-up of novel families with DJ-1 mutations, 
the issue of fertility should be kept in mind. 
Genetic counseling 
When attempting to qualify a genetic study, implications for the patients involved are 
regularly :;pe<:ulated upon but often do not have to be dealt with all at once. When 
pathogenie: mutations are indeed identified, communie:ating the findings to patients 
and their clo:;e relatives is very important. Depencling on whether and how much the 
patient wishes to know about the genetic origin of his disorder, genetic counseling can 
be offered to patients and their relatives. In the case of early-onset disease (such as 
applies here), the choice whether or not to have children could depend on the 
outcome of genetic counseling. In rare recessive conditions occurring in the general 
populatioll, this usually means that the aftected parent may have physical and 
emotional limitations due to his disease, but that the a priori risk of the disease in 
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offspring is low, since the partner only has a small chance to also carry a mutation in 
the same gene. In genetically isolatecl populations, however, a priori probabilities can 
be quite different, aptly demonstrated by the fact that the carrier frequency of the OJ-1 
deletion in the GRIP population estimated from a sample of village controls was almost 
one percent (Chapter 2.2). This frequency is higher than the frequency of 0.004 
assumed in the linkage model described in Chapter 2.1. This might mean lh at genetic 
counseling and testing for this mutation in patients and partners from the GRIP 
population who (plan tol have children has certain 'high-risk' aspects, since that 
partner would also have the risk of almost one percent to carry a DJ-1 deletion. In this 
respect, the GRIP population would be comparable to e.g., Ashkenazi Jew, Amish and 
Mennonite populations with considerable degrees of consanguinity anel high carrier 
frequencies for certain mutations. Ethically, counseling anel testing must in this case 
only concern those inelividuals affected by parkinsonism and their relatives. Offering 
gel1etic counseling to asymptomatic heterozygotes from the community would be 
rather questionable, as it may generate more anxiety than it provides reassurance. 
Moreover, problems are the variabie penetrance of the mutation in DJ-l (Chapter 2.3) 
anel the current lack of any effective long-term treatment for parkinsonisllI. Vet in this 
community with a high degree of consanguinity, based on allele-frequency 
calculations more homozygotes for the OJ-1 deletion are expected than the four 
individuals with parkinsonism detected in our survey (Tabie 2). 
Table 2. Expected number of individuals'or the DJ-1 deletion in the GRIP population. 
Care papulatian GRIP area 
Allele frequency in community control group 
Probability of couples of heterozygous carriers 
Probability of homozygous offspring 
Expected number of homozygous offspring" 
a p=O.0008 versus observed number (4 homozygotes) 
Population-genetic aspects af OJ-7 
- 8,000 inhabitants 
0.009 
(0.009)2 = 0.0081 
0.0081 *0.25 = 0.002025 
0.002025*8,000 -,16 
The GRIP population (which the originally described family originates from) provides a 
unique opportunity to study some population-genetic aspects of the OJ-l deletion anel 
its phenotype. By means of a genealogical study (Figure 1), all presently identified 
homozygous and heterozygous deletion carriers could be connected to a common 
ancestral couple seven generations ago (second half of the 18 th century). The pedigree 
contained various consanguineous loops running between carriers, but these were left 
out of the Figure for better visibility. Furthermore, individuals in the pedigree have 
been masked for gender to protect confidential ity. The wife from the ancestral couple 
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(marked by the arrow) had children from two different men. The fact that deletion 
carriers are observed in the lineages from offspring of both her husbands suggests that 
she has introduced the mutation into the pecligree. 
Calculations based on the allele frequency of 0.009 (Tabie 2) indicate that the 
statistically expectecl number of homozygotes for the D)-1 deletion is fourfold the 
observecl number (16 versus 4 individuals, respectively, p = 0.0008). Furthermore, the 
estimated number of expected homozygotes may be even higher due to considerable 
inbreecling in some sub-groups of the GRIP population. Several explanations for this 
discrepancy are possible. 
FigUire L Pedigree of D)-l deletion carriers in the GRIP population 
0--[-_-0-
> -t 
l l 
1 
<r 
(~ 
1 
Thc likcl)! founder is marked with an arrow. For reasons of confidentiality, carrier gender has been 
masked. Filled diamonds indicate individuals homozygolfs for the OJ-7 deletion, and semi-filled 
diamonds heterozygotes. 
Firstly, the assumed allele frequency of 0.009 (4 heterozygotes / 440) may not 
be representative of the true frequency due to a biasecl selection of contrais. The 
control individuals, however, consisted of patients as weil as healthy individuals 
derived from various other population-based stuclies in the GRIP population, and, to 
our knowiedge, had no overrepresentation of patticular diseases, family history for 
diseases or other features (unpublished data). Secondly, if the statistically expected 
number holcls true, then the question arises what has become of the other 12 
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homozygotes. Any (combination) of the following explanations could account for these 
'missing cases'. Since even arnongst the four known parkinsonism patients in this 
iso late the severity of the observed phenotype is extremely variabie (supported by the 
mild phenotype in two of the homozygotes who were newly diagnosed with 
parkinsonism in the framework of our research, Chapter 2.3), the other homozygotes 
may simply go unnoticed because their mild symptoms do not require medical 
attention. Furthermore, psychiatrie features are a common feature of this and the Italian 
kindred, suggesting an association with mutations in 0)-1. In some homozygotes for 
the 0)-1 deletion, prominent psychiatric symptoms may thus be masking the motor 
symptoms of parkinsonism. If the psychiatric pathology in these individuals also 
requires admission to a psychiatric hospital, they reside outside the catch ment area of 
the isolate and may not easily be asc:ertained. A survey for 0)-1 deletion mutations 
amongst psychiatric patients who originate from the genetically isolated population 
would darify this, vet is hard to justify. 
Finally, as mentioned in the section on dinical-genetic studies of OH, male 
homozygotes for the deletion might be infertile and thus would not transmit the 
mutation due to 'reduced fitness'. One could further hypothesise that the 0)-1 protein, 
highly conserved during evolution (Chapter 2.2), is important during embryogenesis, 
such that offspring homozygous for the deletion are less viabie and die more frequently 
in utero. In the parents of the Outc:h parkinsonism patients, however, no history of 
(frequent) miscarriage or stillbirth was reported. 
Therapeutic intervention ? 
As stated in the introductory section of this chapter, developing a causal therapy for PO 
is within reach when at least some of the pathogenic mechanisms are dear. If the 
mechanism for 0)-1 associated parkinsonism concerns an impaired response to 
oxidative stress, three approaches are theoretically possible. The first to mention but 
the last in terms of (short-term) feasibility is gene therapy. Since in patients in this 
kindred the 0)-1 gene is not expressed, vi ral-vector mediated 0)-1 incorporated in the 
patient genome may (partially) reverse symptoms. Unfortunately, currenl developments 
in gene therapy have not vet reached a level of practical applicability. A second 
approach and within the range of feasibility is putting patients on a sirnple regimen of 
dietary compounds, which can 'buffer' reac:tive oxygen species. Examples are vitamin 
E (tocopherol, a component of vitamin E, traps free radicals), vitamin C (asc:orbic acid, 
an electron buffer) and coenzyme QlO (or ubiquinone, a key enzyrne in oxidative 
phosphorylation and electron buffer). All three compounds have been studied with 
respect to PO before. 51 .53 
Ascorbic acid has interactions with levodopa. It has been shown to protect 
against levodopa-induced toxicity in vitro, suggesting a means of slowing progression 
in PO. 51 A trial on vitamin E in PO showed no effect on symptorn severity or 
progression, but coenzyme QlO was recently shown to significantly arneliol'ate PO 
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symptoms. i2 ,5J The latter study, however, was conducted in a small sample (80 
patients), and will need confirmation in larger patient series, Since parkinsonism 
associated with defects in DH may pathophysiologically differ from PO, and be 
targeted along a (presently unknown) pharmacological route, some of the compounds 
may be beneficial in this rare variant. Although the efficacy of this simple 
interventional approach is unknown, conventional dosages probably have no harmful 
adverse effects. Furthermore, they could easily be combined with any existing 
therapeutic regimen. Regarding the long preclinical period of parkinsonism,S4 and the 
long-standing disease in most of the currently known patients with OJ-1 associated 
parkinsonism, however, any interventions airning to reduce oxidative stress in a 
progressed stage of neurodegeneration (in the case of the studied kindred disease 
durations up to 20 years) probably have little to no irnpact anyrnore, Therefore, thirdly 
and equally feasible, patients (or prospectively: DJ-1 deletion homozygotes at risk 
of/with early-stage parkinsonism) can be instructed to adapt a lifestyle and professional 
choice rninimising environmental exposure to possible oxidative agents, such as heavy 
metals and pesticides. Smoking, although shown to be protective for common PO 
through an unknown mechanism,5S,S6 should also be avoided due to the damage it may 
inflict upon these patients who are possibly more susceptible to oxidative stress. 
4.3 Sporadic Parkinson's disease 
The majority of patients with PO have the sporadic, 'typical' variant without a familial 
inheritance pattern. Sporadic PO is assumed to be a complex condition in which genes 
and environment interact. The traditional focus of causal research in PO lies upon 
either environmental or genetic risk factors. Yet risk of PO by environmental factors 
may depend on a genetic background, and a genetically determined risk of PD is often 
realistic only when adequate information on environmental exposure is available. To 
date, neilher the environmental nor genetic approaches have provided conclusive 
evidence for any toxin or gene that may raise the risk of the 'typical', common form of 
PO, The failure to identify the cause of PD is better understandable when 
acknowledging that PO is a nosological, but not a biological entity. It is most Iikely the 
clinical end point of several overlapping synclromes with common features and 
resulting trom multiple events and interactions, which may be variably important in 
certain genetically susceptible individuals. 
4.3.1 M,ethodoiogical aspects 
In the general population (e.g., urbanised areas with a history of inward migration), the 
genetic make-up is assumed to be heterogeneoLis. As was addressed in Chapter 3,1, a 
search ior shared segments in the genome, as is suitable in genetically homogeneous 
popl.llations, lacks statistical power in this setting, and the sample sizes required to 
detect any effect are astronomically large, An approach joining family-based and 
populatioll-based methods is the assessment of siblings with PO, derived from the 
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general population. Series of sibling pairs with PD (in whom a stronger genetic 
contribution is expected) together with their unaffected relatives can be ~;tudied in a 
genomic screen for susceptibility factors. Practically, only when combining efforts of 
various research groups, sufficiently large numbers of sib pairs can be collected to 
obtain enough power to detect susceptibility regions for PD. 36,57.59 
Diagnostic pitfafls 
The common, sporadic variant of PIJ as found in the general populatlon has several 
characteristics hampering ascertainment. First of all, unlike the early-onset 
parkinsonism associated with D)-1 deletions (Chapter 2.2), sporadic PD is generally of 
late onset. Younger and healthy relatives cannot be defined as definitively unaffected 
as they may still develop PD in the course of their lives. Hence their phenotype must 
be regarded as unknown, which reduces power in linkage studies. Secondly, a crucial 
diagnostic criterion for PD is progression of symptoms. If disease (in partiClilar early-
stage disease) is assessed at one point in time only, the feature of progression cannot 
be judged accurately. Therefore, (long-term) follow-up of PD patients to assess 
progression is necessary to obtain a valid impression of the rate of decline. Thirclly, the 
penetrance of PD (the extent to which a certain genotype is clinically observable) is 
reduced. This assumption, one of the features defining complex disease, can be 
illustrated by certain mendelian forrns of PD (PARK3 8, PARK49, PARl<8 U ). Recluced 
penetl'ance can thus give rise to false-negative results (exclusion of cases vvith the risk 
genotype who lack the according phenotype). Lastly, another feature of complex 
disease is the presence of phenocopies (phenotypes mimicking the trait under study 
without the underlying genetic rnutation), which can give rise to false-positive results. 
In common PD, examples of phenocopies are parkinsonism due to neuroleptic 
medication, drug abuse or vascular disease (although these secondary parkinsonisms 
usually do not respond as weil to levoclopa treatment). In families with monogenic 
parkinsonism, phenocopies may be PD patients in which PD has a completely different 
cause and who lack the mutation(s) segregating with PD in other relatives. Due to a 
high baseline risk of PD,60 the latter remains a possibility, even in families segregating 
other PD-associated mutations. 
Cenetic association studies 
An approach for genetic research in the general population that is less sensitive to 
sample size is the study of genetic association in candidate genes. Basecl on their 
function in a certain (hypothetical) pathway, polymorphisms or mutations in candidate 
genes can be assessed in PD patients and compared to controls. By means of the case-
control design, various groups of genes have been studied as suitable cancliclates for a 
role in the pathogenesis of PD. In Table 3, examples of commonly studied candidate 
genes are grouped by candidate pathway. Candidate genes markecl by an asterisk 
maintained a significant association with PD in a large meta-analysis. 61 
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Cl inical and neuropathological similarities between sporadic and mendelian 
forms of F'D form a plausible link between the PD genes and the common, sporadic 
form of PD. Polymorphisms in the first three PO genes (alpha-synuclein, parkin and 
UCH-L 1) and markers in the PARK3 locus have been studied extensively, but results 
are inconclu:,ive. 62.70 Other groups of candidate genes for the common form of PO are 
classified by the hypothetical disease pathway (Tabie 3), and may overlap one another 
in terms of function or possible pathways. The main groups are dopaminergic 
metabolism (led by the predominantly dopaminergic deficiency which gives the 
clinical sign~, of parkinsonism); protein degradation (Lewy bodies, the proteinaceous 
inclusion bodies seen in PO brains, suggest a cascade of events giving rise to abnormal 
protein aggregates, which are lethal to the normal neuronal architecture); xenobiotic 
metabolism (slow-breakdown variants of detoxification enzymes could impair the 
ability of PIJ patients to handle neurotoxic substances); mitochondrial function 
(metaboliles of MPTP, a neurotoxin extensively studied as the model for an exogenous 
cause of PO, cause mitochondrial damage in the substantia nigra) and, as studied in 
Chapter 3.4, iron metabolism and oxidative stress (considering the identification of the 
0)-1 gene in parkinsonism and its putative role in the response to oxidative stress). 
Table 3. Most frequently studied candidate genes in Parkinson's disease 
Dopamin~c metabolism 
Monoamine oxidase A, B (MAO-A, MAO-B) 
Catechol-O··rnethyltransferase (COMT) 
Tyrosine hydroxyl ase (TH) 
Dopamine transporter (DAT) 
Dopamine receptor 2-4 (DRD2-4) 
Protein ag~·gation 
a-synuclein (pARKl) 
Parkin (PARIG) 
UCH-Ll (PARK5) 
MAPT (Tau) 
Apolipopmtein E (APOE) 
Xenobiotic metabolism 
Debrisoquine-4-hydroxylase (CYP2D6) 
N-Acetyltl'an:;ferase 2 (NA T2) * 
Glutath ione transferases (GSTT1 *;GSTM 1 ;GSTP1 ;CSTZ1) 
Mitochondria! metabo!ism 
tRNA C'u " 
ND2 
* Significant association in a meta-analysis6J 
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Validity and future of polymorphism studies 
In recent years, the contribution of genetic association studies within genetic research 
has surged. PO represents disorclers in which polymorphisms in biologically plausible 
genes have yielded few, if any, conclusive results. Inconsistencies in diagnostic criteria 
for PO, ethnic origin of the study population and composition of the control group all 
contribute to this. 61 ,69 Pooling samples and applying meta-analysis could <;ubstantially 
increase the statistical power to detect an effect of a particular polyrnorphism. The 
possibility of publication bias (a tendency of researchers to report, anel publishers to 
publish, mostly the positive associations, or significant associations) distorting meta-
analyses cannot be excludecl. In a recent overview of genetic association studies, 
Hirschhorn et al. 71 collected over 600 polymorphism studies (various polymorphisms 
and various disorders) with positive I·esults. They found that only six of the 166 
associations studied repeatedly (about four percent) could be replicated in 75 percent 
of subsequent studies. Of these six robust and consistent associatiolls, nOlle was 
implicated in PD. 71 After Nature Genetics, The Lancet recently issued an editorial 
stating it no longer considered genetic association studies for publicatioll, unless a 
causal gene had definitively been identified. 72 Their policy can be justifiecl in terms of 
the limited space to place articles, but in the future. the precedent created by The 
Lancet may be adopted by more prominent scientific journais. Consequently, genetic 
association studies will be more diffjcult to publish, and a new form of publication bias 
against genetic association studies emerges. If other journals react on this clevelopment 
by encouraging submission and publication of negative and positive genetic 
association studies, this coulel result in a more balanceel impression of all performeel 
studies on a particular association anel a minimisation of the skewedness towards 
positive associations, which is likely to be present in the currently available literature. 
Furthermore, the Internet, not hampereel by the space restrictions of ten referrecl to by 
journals when rejecting manuscripts, creates ways to accommodate positive as weil as 
negative studies. A centrally managecl Internet database for genetic association studies, 
with results cast in a simple fOl'mat rather than in article format woulcl he a reaclily 
accessible and possibly more reliable source ior meta-analysis. The requil'ement of 
compulsory yet brief descriptions of objectives and the characteristics of patient and 
control populations (age; ethnicity; co-morbidity; possible confounding factors; family 
history for disease) and tests for e.g., deviations from the Hardy-Weinberg equilibrium 
might lower the threshold to publish (negative) results and improve the valiclity and 
uniformity ofthe data. Such a database, however, would become successful only wh en 
there is continuous and critical qual ity monitoring of the data input and output. 
Paradoxically, the present ban on polymorphism studies by some joumals can thus 
improve the validity and success of genetic association studies in the future. 
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4.3.2 Maïl11 findings and limitations 
From the genetically isolated population (the CRIP population), we ascertained a series 
of 41 PO patients who could be connected to a common ancestor within 14 
generations (Chapter 3.2). Mean age at onset in the patients with late-onset PO was 
significantly lower, and the proportion of early-onset patients was higher than in a 
group of PI) patients from the Rotterdam Study, a population-based cohort. The age-at-
onset distribution in the patients from the isolate was significantly bimodal with peaks 
in the ear-ly-onset and late-onset range. Although these characteristics suggest a genetic 
origin in at least the early-onset patients, a role of the known PI) genes and loci could 
be excluded. Most importantly, although four other parkinsonism patients from the 
same cornrnunity were homozygous for a 01-1 deletion anel the carrier frequency was 
almost one percent, no OJ-1 mutations were observed amongst these patients with 
'typical PD'. The question whether heterozygosity for the OH deletion would 
predispose to parkinsonism at later age can, ba~;ed on the absence of carriers amongst 
the typical-PD patients, thus provisionally be answered negatively. In conclusion, even 
though all patients originate from the same genetic isolate and a limited number of 
founders, yet another gene may be involved and thus genetic heterogeneity in PO is 
present in the genetic isolate. 
In th is study, 41 PD patients could be connected to a common ancestor. As 
mentioned in Paragraph 4.2.1, familial aggl'egation must be viewed relative to a 
reference group. The true degree of familial aggregation of the PO patients in the 
absence of a valid reference group is difficult to estimate. At the time of this study, a 
control gmup of healthy individuals was lacking. All important criterion is the sampling 
frame of a control group, which ought to be identical to that of the patients. Therefore, 
the patients' spouses would have constituted a most suitable control group. 
In a genomic screen (Chapter 3.3) performed in 21 of the 41 PD patients from 
the genetically isolated population described in Chapter 3.2, significant linkage and 
association was found for a locus on chromosome 10q. After saturating the flanking 
region with 12 additional markers, confirmation was sought in a sample including all 
aforementioned PD patients and 88 control individuals from the GRIP population. Due 
to an unreliable marker order, haplotype construction proved to be impossible. Since 
not one but several alleles seemed to be associated, the CLUMP programme was used. 
Upon this analysis, two alleles of the original marker (amongst which the originally 
associatecl aIleie) and a single allele of another marker showed significant association, 
but combining those into haplotypes was not feasible. 
This newly identified association on chromosome 10 is promising but requires 
further analysis. Since the CLUMP programme searches a maximal chi-square statistic 
in alleles or groups of alleles, as soon as alleles are clumped together, it is not possible 
to pinpoint the allele(s) truly associated with disease. When clumped alleles differ 
slightly in size, there are several explanations. Founders of the population may have 
introducecl different alleles of the same gene, or many generations ago mutations may 
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have occurred. Furthermore, !;ince the used markers have a mutator! rate of 
approximately 10-3, there is a possibility that marker alleles have changeel in length, 
which could cause more than one allele to be associated. However, wh en the 
associated alleles vary strongly in length, as was the case for the associated alleles 
identified by CLUMP in our study, the question arises what is the finding's biological 
plausibility. The region of interest was saturated with 12 interpolating markers, but the 
order of the markers in the, recombination-prone, telomeric area remains uncertain. 
Apart from further study of the marker order, still larger case series are needeel for 
confirmation of this association. 
In Chapter 3.4 we assessed the role of mutations in the HFE gene, a pivotal gene in 
iron metabolism and the commonly rnutateel gene in hereditary haernochromatosis, in 
patients with PO and patients with parkinsonism overall. Two independent patient 
series were studied, one frorn the Rotterdarn Study and one from the Southwest of The 
Netherlands. In the PO patients from the Rotterdam Study, a significant excess of 
C282Y homozygotes was observed, whereas in the series from the Southwest, an 
excess was observed in parkinsonism patients overall. Although hampered by the rarity 
of the C282Y mutation, these filldings suggest that C282Y homozygosity occurs more 
frequently among PO patients and possibly parkinsonism patients overall. lf true, PO 
and/or parkinsonism may be a rare expression within the clinical spectrum of 
haemochromatosis. Alternatively, the abnormal iron metabolism associated with 
C282Y homozygosity may be considered to predispose to 'typical' PD. Hereditary 
haemochromatosis is a treatable disorder, and lessening the iron load of the body by 
regular phlebotomy lowers the risk of long-term complications such as diabetes and 
cardiovascular disease. 74 If PO were part of a C282Y-related elisease spectrum, 
phlebotomy could lower an excess risk of PO amongst those individuals. 111 the current 
sample, the rarity of C282Y homozygosity severely limits the power 10 study anel 
statistically test other variables, such as the phenotypic expression of the mutations 
(clinical presentation; transferrin, ferritin and total iron values; rnagnetic resonance 
imaging to assess brain-iroll contents) in homozygotes and heterozygotes. Therefore, 
our observation requires confirrnation in still larger samples. 
Condusion 
This thesis aimed to dissect the genetic basis underlying PD. We were successful at 
identifying a new gene, 0)-1, illvolved in early-onset PD. Putative properties of 0)-1 
yield clues for a novel aetiological ll1echanisll1 in PD. At present, half a year after its 
identification, seven different ll1utations in 0)-1 have been identified worlelwide and 
more may be added to this list in the future. Hopefully, it will soon be feasible to 
eletermine whether the recently identified polymorphisms in the DH gene play a role 
in common PD. Patients from the Rotterdam Stuely6° would constitute a suitable 
population to assess this. 
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The results of our studies conducted in patients with 'sporadic' PD were less 
unequivocal, Problems we encountered were very similar to those in studies on other 
complex diseases. Future study would therefore benefit from improvement of statistical 
methods anel study design to successfully identify genes involved in the common, late-
onset form of PD. 
Looking back, the setting for most studies in this thesis, the GRIP community, 
harboured an entire clinical spectrum, ranging hom genetically complex late-onset PD 
to monogenic early-onset parkinsonism: PD genetics in a nutshell. 
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SUMMARY 
Parkinson's disease (PO) is a common movement disorder, estimated to affect 1/1,000 
of the world's population aged 65 years and over. Although evidence for rare genetic 
subtypes is mounting, the vast majority of PO is of unknown cause. In Chapter 1.1, 
advances in the genetics of PO are reviewed focusing on monogenie fonm of PO, their 
clinical presentation and the extent to which they attribute to the risk of PO in the 
general population. 
Individuals from geneticallv isolated populations are expected to be more 
genetically homogeneous than individuals from the general population. Chapter 2 
describes studies on familial pal'kinsonism, conducted in a genetically isolated 
population in the Southwest of The Netherlands. A consanguineous kindred 
segregating autosomal recessive early-onset PO was ascertained (Chapter 2.1). In a 
genomic screen, homozygosity mapping yielded significant evidence for linkage to a 
haplotype of 16 cM on chromosome 1 p36. This haplotype could be clearly separated 
from the more centromeric PARK6 locus on chromosome 1 p35-36 by 25 cM. This 
newly discovered PO locus was named PARK7. We identified the responsible gene 
contained in the PARK7 locus: 0)-1 (Chapter 2.2). In the kindred from the isolated 
population a deletion of the gene was found. Another parkinsonism family from Italy 
segregated a point mutation in the gene. OH codes for a smal I, highly conserved 
protein. The function of the OJ-1 protein is unknown, but there is evidence that the 
gene is involved in the response to oxidative stress. Our findings suggest that 1055 of 
0)-1 function leads to neurodegeneration. The Outch patients with OH mutations 
exhibited typical early-onset parkinsonism. In addition, however, other psychiatric and 
neurological traits were observed, as outlined in Chapter 2.3. The severity spectrum 
ranged from mild hypokinesia and rigidity, to early-onset parkinsonism with levodopa-
induced dyskinesias anel motor fluctuation. Three of four patients in this PARK7-linked 
kindred exhibited psychiatric elisturbances. Structural neuroimaging was umemarkable, 
but functional imaging of the brain as peJformed in three patients showed significant 
dopaminergic dysfunction. Assessment of cerebral glucose metabolism performed in 
one patient showed possible involvement of the cerebellum. Furthermore, the 
phenotype observed in this parkinsonism kindred also comprised 50me remarkable 
physical traits (Chaptel' 2.4). At clinical examination of the parkinsonism patients, we 
also observed short stature and brachydactyly. This prompted us to further investigate 
body height and hand structure in patients and their relatives, as weil as in a control 
group from the same genetically isolated population. Using the OJ-1 deletion as a 
marker for the homozygosity region on chromosome 1 p36 (PARIO), we found a 
significant association of the deletion with body height, adjusting for age and gender 
(p = 0.005). This association suggests that either 0)-1 itself or a gene or regulatory 
element elsewhere in linkage disequilibrium with 0)-1, is implicated in short stature. 
Analysis of hand-bone length showecl incomplete segregation of the deletion with 
brachydactyly, rendering it unlikely that the brachydactyly is fully explained by a gene 
in the OH region. The, homozygous, patients had a more pronounced overall bone-
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length reduction than their heterozygous unaffected relatives. Given these differences 
within the kindred, a modifier gene for brachydactyly may be present in the region 
containing the 0j-1 gene. Finally, we assessed whether (neurologically unaffected) 
heterozygotes for a OJ-l mutation may have signs of preclinical disease at functional 
neuroimaging. Subclinical dopaminergic dysfunction in heterozygotes has been 
observed two other recessive forms of parkinsonism associated with mutations in 
parkin anel with linkage to the PARK6 locus. In order to assess cerebral dopamine and 
glucose rnetabolism, PET neuroimaging was performed in homozygotes (patients) and 
heterozygotes (c1inically unaffected) for the OJ-1 deletion, as weil as in a non-carrier 
relative (Chapter 2.5). The homozygous patients had, regardless of the degree of 
clinical severity, significantly reduced F-OOPA uptake concordant with typical PO, and 
putaminal FOG hypermetabolism. In the heterozygotes for the 0)-1 mutation and a 
relative not carrying a deletion, F-OOPA metabolism was unremarkable: an effect of 
the OJ-1 gene deletion was not observed. Oue to the small number of participants in 
this study, however, dopaminergic function must be assessed in more individuals with 
OJ-1 mutc,tions when they become available. 
Chapiter 3 describes genetic studies of sporadic PO (in which the mode of 
inheritance is difficult to pinpoint). How to assess the genetic basis of PO and other 
neurological diseases is reviewed in Chapter 3.1. The genetically isolated community 
described in Chapter 2 was the setting for a stud)' on PO patients who were at first sight 
unrelated. Clinical characteristics of a series of PO patients, the extent of relationship 
and results of a candidate-gene stud)' are discussed in Chapter 3.2. We studied 109 
patients with parkinsonism from an area comprising the genetically isolated 
population. Of these 109 patients, 41 patients with typical PO could be linked to a 
common founder 14 generations ago. The distl'ibution of ages at onset of these PO 
patients was significantly bimodal (one peak with a mean at age 67 years and another 
peak with a mean at 44 years), the latter being significantly larger than that in a 
population-based study, the Rotterdam Stud)'. In other clinical features, the only 
statistically significant difference between early-onset and late-onset PO was a 
decreased motor and cognitive function in patients with late-onset PO. Association to 
other PO genes and loci, most importantly OJ--1, could be excluded in these other 
studied PI) patients from the same community_ The finding of a common ancestor in 
the 41 PD patients along with the exclusion of known PO genes and loci suggests the 
presence of at least one other susceptibility gene involved in PO in this population. In 
Chapter 3;.3, the results of a genomic screen performed in 21 of these 41 patients are 
outlined. Upon analysis for linkage and association, two peaks were identified, on 
chromosomes 19 and 10. The association for chromosome 19 appeared to be false 
positive. The association for chromosome 1 Cl was further examined by saturating the 
region with a denser set of markers. Unfortunately, haplotype construction was not 
possible clue to an ambiguous marker order on the physical map. More than one allele 
appearecl to oe associated (the 211- and 229-bp alleles of o lOS 1651 and the 177-bp 
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allele of Dl OS 1711). Chapter 3.4 presents findings of a genetic association study. 
Mutations in the HFE gene, which are the major cause of the iron-storage disorder 
haemochromatosis, may result in excessive oxidative stress, as possibly do mutations 
in DJ-l. Two series of patients with common, sporadic PD, anel, sincE' it possibly 
concerning atypical neurological features, parkinsonism overall were therefore studied 
for mutations in the HFE gene. In one series, PD patients were significanti)' more often 
homozygous for the C282Y mutation than controls (p = 0.03), anel in the other, 
pal'kinsonism patients were more often homozygous for this mutation than controls. 
Although hampered by the sm all numbers of patients, our data are s'Jggestive of an 
increased risk of PD, and possibly of parkinsonism overall, in homozygotes for the 
C282Y mutation. Given the rarity of this genotype, large series of patients are required 
to prove this hypothesis. 
Finally, Chapter 4 provicles a eliscussion of the results, limitalions anel 
implications of the studies in this thesis. 
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De ziekte van Parkinson (ZvP) is een bewegingsstoornis waar ongeveer één op de 
duizend wereldbewoners van 65 jaar en ouder aan lijdt. Hoewel het bewijs voor 
zeldzame erfelijke subvormen gestaag toeneemt heeft is de oorzaak in het overgrote 
deel van de ZvP onbekend. In Hoofdstuk 1.1 passeren ontwikkelingen in de genetica 
van de ZvP de revue met een nadruk op monogene vormen, hun klinische presentatie 
en de bijdrage aan het risico van de Zvi=' in de algemene bevolking. 
Mensen uit genetisch ge'lsoleerde bevolkingsgroepen zijn waarschijnlijk 
genetisch homogener dan mensen uit de algemene bevolking. Hoofdstuk 2 beschrijft 
onderzoeken naar familiair parkinsonisme, uitgevoerd in een genetisch geïsoleerde 
gemeenschap in Zuid-West Nederland. Daar werd een consanguiene familie met 
autosomaal-recessief parkinsonisme onderzocht (Hoofdstuk 2.1) waarin een 
genomische zoektocht met homozygotie-mapping een significant bewijs voor linkage 
opleverde voor een haplotype van 16 cM op chromosoom 1 p36. Dit haplotype lag op 
een afstand van 25 cM van het dichterbij de centromeer gelegen PARK6 locus 
(chromosoom 1 p35-36). Dit nieuw ontdekte ZvP-locus kreeg de naam PARK7. 
Vervolgens werd het verantwoordelijke gen in het PARK7-locus geïdentificeerd: DJ-1 
(Hoofdstuk 2.2). De familie uit het genetisch isolaat had een deletie en een andere 
familie met parkinsonisme uit Italië een puntmutatie in het DJ-1 gen. DJ-1 codeert voor 
een klein en sterk geconserveerd eiwit. De functie van het DJ-1 eiwit is onbekend, 
maar er zijn aanwijzingen dat het gen betrokken is bij de reactie op oxidatieve stress. 
Onze bevindingen doen vermoeden dat verl ies van DJ-1 functie tot neurodegeneratie 
leidt. De Nederlandse patiënten met DJ-1 mutaties hadden een typisch, jong 
beginnend parkinsonisme. Ook werden echter andere psychiatrische en neurologische 
kenmerken waargenomen, zoals wordt uiteengezet in Hoofdstuk 2.3. De ernst van de 
aandoening liep uiteen van milde hypokinesie en rigiditeit, tot jong beginnend 
parkinson isme met levodopa-geïnduceerde dyskinesieën en schommelingen van 
motore activiteit. Drie van de vier patiënten in de familie met PARK7· parkinson isme 
hadden psychiatrische symptomen. Structurele beeldvorming van de hersenen liet 
geen bijzonderheden zien, maar funktionele beeldvorming (verricht in drie patiënten) 
toonde een significante dopaminerge dysfunctie aan in het striatum. Beeldvorming van 
de glucosestofwisseling (verricht in één patiënt) wees op een mogelijke betrokkenheid 
van de kleine hersenen. Verder betrof het fenotype in deze familie met parkinsonisme 
betrof ook enkele opvallende lichamelijke kenmerken (Hoofdstuk VIl). Tijdens het 
klinisch onderzoek van de patiënten met parkinsonisme bemerkten we ook een korte 
gestalte en brachydactylie. Dit vonnde aanleiding tot nader onderzoek van de 
lichaamslengte en handstructuur in de patiënten, hun familieleden en een 
controlegroep uit dezelfde gemeenschap. Met de DJ-1 deletie als marker voor het 
homozygotiegebied op chromosoom 1 p36 (PARK7) vonden we een significant 
verband van de deletie met I ichaamslengte, na correctie voor leeftijd en geslacht 
(p = 0.005). Dit verband doet vermoeden dat ofwel DJ-1 zelf, of een genIregelelement 
elders in linkage disequilibrium met DJ-1, betrokken is bij een beperkte 
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lichaamslengte. Daarentegen toonde analyse van de handbeenderlengte een 
onvolledige segregatie van de deletie met brachydactylie aan, die het onwaarschijnlijk 
maakt dat de brachydactylie volledig kan worden verklaard door een gen in het OJ-1 
gebied. De verkorting van handbeenderen was meer uitgesproken bij de homozygote 
patiënten dan bij hun heterozygote gezonde familieleden. Gezien deze verschillen 
binnen de familie zou er een modificerend gen kunnen liggen in het gebied waar ook 
het DJ-I gen ligt. Tenslotte hebben we onderzocht of (neurologisch niet-aangedane) 
dragers van een DJ-1 mutatie op hersenscans wel aanwijzingen hebben voor een 
preklinisch ziekteproces van de hersenen. Subklinische dopaminerge dysfunctie bij 
heterozygoten werd ook gevonden in twee andere recessieve vormen van 
parkinsonisrne, geassocieerd met mutaties in het parkin-gen en met linkage met het 
PARK6-locus. Teneinde de dopamine- en glucosestofwisseling in de hersenen te 
bestuderen werden PET-scans gemaakt bij zowel homozygoten (patiënten) en 
heterozygoten (klinisch gezond) voor de deletie, alsook bij een familielid zonder 
deleties (normaal genotype) (Hoofdstuk 2.5). De homozygote patiënten hadden 
ongeacht de ernst van hun symptomen een significant verminderde F-OOPA opname 
zoals in de typische ZvP, en bovendien hypermetabolisme van glucose in het 
putamen. De heterozygoten en het familielid zonder de deletie hadden geen 
verminderde F-OOPA stofwisseling: een effect van de OJ-1 deletie werd niet 
waargenomen. Aangezien het aantal deelnemers aan dit onderzoek klein was is 
onderzoek van het dopaminerg systeem bij meer mensen met OJ-1 mutaties, zodra 
deze beschikbaar zijn, vereist. 
Hoofdstuk 3 beschrijft genetische studies over de sporadische ZvP (met een 
onduidelijk overervingspatroon). Op welke manier de genetische achtergrond van de 
ZvP en andere neurologische aandoeningen onderzocht kan worden, kan gelezen 
worden in Hoofdstuk 3.1. In de genetisch geïsoleerde gemeenschap die werd 
beschreven in Hoofdstuk 2 hebben wij Parkinsonpatiënten bestudeerd die op het 
eerste gezicht geen familie van elkaar waren. De klinische kenmerken van een reeks 
van deze patiënten, hun onderlinge verwantschap en de uitkomsten van een 
kandidaatgenstudie worden uiteengezet in Hoofdstuk 3.2. We onderzochten 109 
parkinsonismepatiënten die afkomstig waren uit een gebied dat het genetisch isolaat 
bevat. Van deze 109 patiënten konden 41 patiënten met de typische ZvP verbonden 
worden rnet een gemeenschappelijke voorouder 14 generaties terug. De verdeling van 
de beginleeftijden van deze Parkinsonpatiënten was significant bimodaal (één piek met 
een gemiddelde leeftijd van 67 jaar en één piek met een gemiddelde van 44 jaar). De 
laatstgenoemde piek was significant hoger dan die bij Parkinsonpatiënten uit het 
ERGO-ondel'zoek, een onderzoek in de algemene bevolking. In klinisch opzicht was 
het enig statistisch significante verschil tussen een vroeg en laat beginnende ZvP het 
verminderd motorisch en cognitief functioneren bij de patiënten met een laat 
beginnende ZvP. Bij de patiënten afkomstig uit hetzelfde isolaat in deze studie kon een 
verband met andere Parkinson-genen, met name OJ-1, kon worden uitgesloten. De 
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bevinding van een gemeenschappelijke voorouder in de 41 Parkinsonpatiënten, samen 
met de exclusie van bekende Parkinson-genen en -loci wijst op de aanwezigheid van 
tenminste één ander gevoeligheidsgen voor de ZvP in deze gemeenschap. Hoofdstuk 
3.3 bevat de uitkomsten van een genomische zoektocht in 21 van deze 41 patiënten. 
Met een analyse op linkage en associatie werden twee pieken gevonden, op 
chromosoom 10 en 19. De associatie op chromosoom 19 scheen vals-po~;itief te zijn. 
De associatie op chromosoom 10 is nader onderzocht door het gebied te verzadigen 
met een dichtere markerset. Haplotypevorming bleek helaas niet mogelijk vanwege 
een onduidelijke markervolgorde op de fysieke genenkaart. Meer dan één allel bleek 
te zijn geassocieerd (de 211 en 229 baseparen lange allelen van markel' DI OS 1651 en 
het 177 baseparen lange allel van marker Dl OS 1711), Hoofdstuk 3A bevat de 
bevindingen van een genetische associatiestudie. Mutaties in het HFE-gen, de 
voornaamste oorzaak van de ijzerstapelingsziekte hemochromatose, zouden 
overmatige oxidatieve stress kunnen veroorzaken zoals mogelijk ook mutaties in het 
DH gen dat doen. Twee reeksen patiënten met de 'gewone' sporadische ZvP, en -
aangezien het ziektebeeld mogelijk atypische neurologische kenmerken behelst-
parkinsonisme in het algemeen, werden daartoe onderzocht op mutaties in het HFE-
gen. In één reeks waren de Parkinsonpatiënten significant vaker homozygoot voor de 
C282Y-mutatie dan de controlepel'sonen (p = 0.03), en in de andere reeks waren 
parkinsonismepatiënten vaker homozygoot voor deze mutatie dan de 
controlepersonen. Hoewel belet door het kleine aantal patiënten, wijzen onze 
gegevens op een verhoogd risico van de ZvP, en mogelijk van parkinsonisme in het 
algemeen, bij homozygoten voor de C282Y-mutatie. De zeldzaamheid van dit 
genotype vergt echter grote groepen patiënten om deze hypothese te bewijzen. 
In Hoofdstuk 4, tenslotte; worden de uitkomsten, beperkingen en gevolgen van 
de studies in dit proefschrift besproken. 
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Stellingen 
behorend bij het proefschrift 'A genetic-epidemiologic study of Parkinson's disease' 
Marieke Dekker 
Mutaties in het D)-J gen (PARK?) veroorzaken een jong beginnend parkinson isme 
met autosomaal-recessieve overerving. (dit proefschrift) 
Parkinson isme als gevolg van een deletie in het D)-1 gen gaat gepaard rnet een 
verhoogd risico van psychiatrische symptomen. (dit proefschrift) 
Dragerschap van een deletie in het D)-1 gen is geassocieerd met een korte 
gestalte, hetgeen het meest uitgesproken is bij personen die homozygoot zijn 
voor de deletie. (dit proefschriftl 
De F-DOPA PET scans bij dragers van een enkele deletie in het D)-1 gen tonen 
een normaal presynaptisch dopaminerg neurotransmittersysteem. (dit proefschrift) 
De deletie in het DJ-1 gen speelt geen rol in patiënten met een laat beginnende 
ziekte van Parkinson afkomstig uit de onderzochte genetisch geïsoleerde 
gemeenschap. (dit proefschrift) 
Door de huidige ontwikkelingen in de genetica dient de ziekte van Parkinson te 
worden hernoemd tot de ziektes van Parkinson. 
Het vóórkomen van diabetes mellitus type 2 op de kinderleeftijd toont het belang 
van voorkómen. 
Eenieder die genetisch onderzoek verricht in een godsdienstige gemeenschap 
dient zich te verdiepen in -en te leren van- de heersende geboden en verboden. 
(naar McKusick, Medical Genetic Studies of the Amish, 1978) 
Wanneer het taboe op clinical trials bij jonge kinderen wijkt, wordt de 
kindergeneeskunde waarlijk 'evidence-based' 
Hoewel de media bijdragen aan de verwarring omtrent uitkomsten van 
epidemiologisch onderzoek (Breslow, Biometrics 2003;59:1-8) ligt de echte 
verantwoordelijkheid bij onderzoekers die hun resultaten onvoldoende duiden. 
Voordat loopbaan verwordt tot renbaan is het goed om even stil te staan. 
Rotterdam, 11 juni 2003 
